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ABSTRACT
Primary afferent neurons with perikarya in the dorsal root ganglia
(drg) mediate the transmission of sensory information from the periphery and
viscera to the spinal cord. A number of neuropeptides, including substance
P (SP), somatostatin (SS) and calcitonin gene related peptide (CGRP) have
been localised in discrete but often overlapping subpopulations of drg
neurons. These neuropeptides have been implicated in nociception and
neurogenic inflammation, both processes which can be influenced by
steroid hormones. Whilst steroid hormones have been shown to regulate
synthesis of a number of neuropeptides including SP, SS and CGRP in the
central nervous system, it is not known if they influence neuropeptides in the
drg . In this thesis I have investigated the regulation of SP, SS and CGRP
by steroids in vivo and in dissociated primary cultures of adult drg neurons.
The SP, SS and CGRP content of drg from C1 to L6 was determined
and a differential distribution of the three neuropeptides was found. Drg wet
weight and SP content were greatest in drg from the cervical (C6 - T1) and
lumbar (L4 - L6) enlargements. CGRP content tended to be greater in drg
from more caudal areas (T10 - L6) and SS content was uniform in most drg
but was notably lower in drg from area C5 - C7.
The regulation of neuropeptides in the drg by two classes of steroid,
adrenal steroids and androgens was investigated. Adrenalectomy (ADX) of
adult male Wistar rats increased SP and CGRP and decreased SS content
of cervical drg. The effects of ADX were reversed by subcutaneous
implantation of pellets containing corticosterone (B) or by daily
subcutaneous injection of dexamethasone (DEX). The neuropeptide
content of drg was not regulated by androgens; no significant change in the
SP, SS or CGRP contents of drg were found following castration or
administration of supraphysiological testosterone.
The regulation of neuropeptides in the drg by corticosteroids was also
examined in a rat model of inflammatory disease. Fifteen days following
unilateral inoculation of the carpal joint with a low dose of Freund's complete
adjuvant an inflammation of the joint resulted accompanied by a significant
increase in the CGRP content of C6/7 drg on the ipsilateral side of the
animal. SP content of ipsilateral C6/7 drg was also increased compared
with that of contralateral drg, although this did not reach significance: SS
content of ipsilateral C6/7 drg was not significantly different from that of the
contralateral drg. ADX of animals suffering from adjuvant induced disease
exacerbated and prolonged both the swelling of the ipsilateral forepaw and
increased the CGRP content of ipsilateral C6/7 and T1/2 drg at 20 days
following induction of inflammation.
The effects of corticosteroids on neuropeptides were probably due to
a direct action on the drg\ DEX or B significantly reduced the SP and CGRP
contents of cultures of dissociated drg grown in the presence of NGF .
The results presented in this thesis indicate that glucocorticoids
differentially regulate neuropeptides in the drg by a direct action. The
therapeutic actions of glucocorticoids may be mediated in part through
regulation of neuropeptides in the drg.
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1.1 THE DORSAL ROOT GANGLION
1.1.1 Introduction
The dorsal root ganglion (drg) comprises a collection of neurons and
satellite cells contained within a highly vascularised connective tissue
compartment. They lie in close proximity to the spinal cord within or near to
gaps in the vertebrae found below the transverse processes. The neurons
of drg develop from progenitor cells of the neural crest, a transient structure
overlying the neural tube of the vertebrate embryo which gives rise to a
variety of cell tissues and types. Other derivatives of the neural crest
include neurons of autonomic ganglia, glial cells, melanocytes and cells of
the adrenal medulla. Trunk neural crest cells which migrate ventromedially
develop into spinal drg, and evidence suggests that the cranial neural crest,
in conjunction with placode ectoderm develops into cranial sensory ganglia
(Yip 1986).
In their earliest stages of development the ganglionic rudiments
comprise a closely packed group of mitotically active cells devoid of blood
vessels and connective tissue elements, which appear later in development
(Pannese, 1968). The embryonic ganglia grow rapidly through cell
proliferation and incorporation of additional migrating neural crest cells
(Sobkowicz et al., 1973) and whilst initially, the ventrolateral portion
differentiates more rapidly than the dorsomedial, particularly in the avian
embryo (Gaik, 1973), this distinction does not persist. In rat, the final
division occurs between days 11 and 15 of gestation, with the majority of the
large light cells produced on day 12 and the small dark cells on day 13 (see
below 1.1.3; Lawson et al., 1974).
The drg next undergo a period of post-mitotic maturation during which
they extend processes and enlarge. Post-mitotic neuroblasts have several
small irregular processes, which are replaced by two neurites formed during
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the first stage of differentiation. This may occur through a process of axial
elongation and outgrowth from the two poles of the cell, or the peripherally
and centrally directed processes may arise, not as distinct neurites, but from
constriction and elongation of perikaryal cytoplasm at a single locus,
followed by subsequent peripherally and centrally directed elongation
(Tennyson, 1965; Sobkowicz et al., 1973). In any event, the peripherally
directed process is thicker than the centrally oriented and grows at a faster
rate (Pannese, 1974). Concomitant with this process of axon and dendrite
extension is a period of rapid increase in cell body volume (of nearly 25-fold,
Sobkowicz et al., 1973) and diameter antecedent to a slower expansion,
possibly throughout the lifetime of the animal (Hatai, 1902).
During this phase of cellular remodelling leading to the acquisition of
a pseudo-unipolar form, a concurrent change in cell ultrastructure and
organelle content occurs. The rough endoplasmic reticulum proliferates
and Nissl bodies appear, the number of mitochondria substantially
increases, the Golgi apparatus forms and microtubules and filaments
proliferate (Tennyson, 1965; Sobkowicz et al., 1973). RNA content also
increases in parallel with cell volume until adulthood, and the differentiation
of drg cells into chemically distinct phenotypes, which may begin as early as
after the final neuroblast division, continues (Tennyson & Brzin, 1970;
Sarratt, 1970; Pannese, 1974).
The satellite and Schwann ceils, derived from the neural crest (and
possibly neural tube), are initially stellate, appear in the drg rudiments after
the neuroblasts and elaborate processes to invest a number of neuroblasts
(Pannese, 1972). Subsequently, they assume a simpler form, and a more
intimate relationship is established in which each satellite cell invests only
one neuron. In the early post-natal period, during which considerable
enlargement of drg cell bodies occurs, the number of satellite cells
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undergoes a proportionate increase, and in adulthood, satellite cells retain
their mitotic capability (Friede & Johnstone, 1967).
1.1.2 Axons of Drg
Kolliker (1844; cited in Lieberman, 1976) first recognised the pseudo-
unipolar character of sensory ganglion cells in amphibia and in general,
ganglion cells of higher vertebrates are also pseudo-unipolar although in
fish, spinal ganglia are bipolar (Chase 1909). The cells give rise to a single
principal process, the main process or initial tract of the axon which splits at
a T or Y-shaped bifurcation a variable distance from the perikaryon. Whilst
the peripherally and centrally directed processes and the stem process that
connects them to the cell body are structurally axons and all three may be
myelinated, the peripheral process is often referred to as the dendrite and
the stem process as a dendro-axonal process (e.g. Warwick & Williams,
197). However, the term dendrite should be reserved for those regions of
neurons in which responses are generated and thus strictly applies only to
the receptor terminals, found in the periphery (Bodian, 1962).
Afferent fibres conveying impulses from peripheral receptors can be
classified as being either non-myelinated or myelinated (depending on the
composition of the surrounding Schwann cells). A more extensive
functional classification of afferent fibres is also possible based on analyses
of fibre diameter and conduction velocity. Originally, this work was
performed in frog sciatic nerve by Erlanger & Gasser (1937) who devised the
classification A, B and C. Group A comprises the largest fibres with the
fastest conduction velocity i.e., myelinated somatic afferent and efferent
fibres; group B contains myelinated preganglionic fibres of the autonomic
nervous system, and group C is composed of the smallest diameter, slowest-
conducting unmyelinated visceral and somatic afferents and post-ganglionic
autonomic efferents. Subsequently, Group A has been further subdivided
5
into Aa, A(3, Ay and A5 as a result of further combined histological and
electrophysiological studies. Table 1.1 gives a description of the
classification of afferent fibres from the drg, their diameter, and conduction
velocity, and the structures they innervate in the cat (Carpenter, 1990).
A number of well-established ultrastructural differences between
central and peripheral process of mature and developing neurons have
been found. The majority of these are thought to reflect differing transport
requirements of central and peripheral processes. Thus, in embryonic and
adult avian drg cells, a greater number of microtubules are found in
peripherally directed processes, and more filaments are present in centrally
directed processes of developing (Barasa et al., 1970) and mature neurons
(Zenker et al., 1973, 1975). However, some of the differences may not be
directly related to axoplasmic transport e.g., the embryonic peripheral
process has more granular endoplasmic reticulum and ribosomes than the
central (Tennyson, 1965; Zelena, 1972)
Interestingly, axoplasmic flow also differs centrally from peripherally.
The rate of fast transport is identical in both central and peripheral processes
and to that of a variety of neurons (16mm/h, Lasek, 1970; Ochs, 1972);
however, proteins synthesised in the perikarya are transported at a variety of
rates along both processes (Droz, 1965; Lasek, 1968) and the net
somatofugal flow along the central process is considerably less than in the
peripheral process (Lasek, 1968, 1970). Qualitative differences have also
been observed; thus, in cat sciatic nerve, electrophoretic analysis of 3H-
leucine labelled proteins following injection of tracer into L7 drg reveals two
peaks of 100Kd and 18Kq in sciatic axons, but in dorsal column axons, only
one of 65Kq is found (Anderson & McClure, 1973). It is not clear what these
differences in protein labelling reflect. However, it is likely that some
centrally transported proteins are concerned with transmitter release in the
spinal cord, and peripherally directed proteins may be involved in sensory
Table 1.1 Classification of primary afferent nerve fibres, and the
structures innervated by them (Carpenter, 1990)
I
TABLE 1.1















C < 1 < 2
(unmyelinated)
Motor nerve fibres are mostly A-a and A-y
Skin afferents are mostly A-J3, A-5 and C
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transduction, trophic interactions with the periphery or antidromic action
potentials.
Additional evidence of selective somatofugal transport comes from
observations of neurotransmitters in peripherally and centrally directed
processes. In dorsal roots, glutamate (a putative primary afferent
neurotransmitter) concentrations are higher (and equivalent to that of the
perikarya) than in peripheral nerve (Duggan & Johnston, 1970; Johnson &
Aprison, 1970); similarly, substance P (SP) is found in higher concentration
in peripheral than in central processes (Takahashi & Otsuka, 1975; Harmar
& Keen, 1982). Closer examination of the movement of intra-axonal
organelles of proximal and distal dorsal roots indicates that saltatory
movement of mitochondria and of large vesicles of smooth endoplasmic
reticulum occurs in both directions along definite intra-axonal 'tracks' (Smith,
1972, 1973; Cooper & Smith, 1974). Movement is, however, predominantly
somatopetal in both proximal and distal fibres, and most particles travelling
in both directions are transported at the 'fast' axoplasmic flow rate (see
above).
Although it is generally accepted that whilst there is no difference in
size between centrally and peripherally directed processes of myelinated
axons (Dale, 1900; Rexed & Sourander, 1949), a disparity in the diameters
of unmyelinated axons has been acknowledged (Ranson & Davenport,
1931; Ha, 1970). Ultrastructural studies of unmyelinated axons, central and
peripheral to drg, indicate the mean diameter and range of diameters is
considerably less on the central side (Gasser, 1950); this may explain the
reported slower conduction velocity of C-fibres on the central side of the drg
(Mei et al., 1971). It has been suggested, on the basis of ultrastructural
studies, that for some neurons, the peripheral process may be myelinated
and the central branch unmyelinated (Ha, 1970, 1969). However, only a
very small disparity between the numbers of myelinated axons central and
7
peripheral to drg is found (Dale, 1900; Rexed & Sourander, 1949) and it is
likely that this form of unequal branching, if it exists, is very rare in
mammalian drg.
1.1.3 Cell types in the Drg
Perikarya of drg neurons vary enormously in diameter both between
different drg and within individual drg of adult rat: 20-50p.m (Hatai, 1901),
10-80pm (Cavanaugh, 1951). The neurons are generally spheroidal
although some of the smaller cells may be ellipsoidal (Bunge et al., 1967)
and are thought to be randomly distributed within the drg. (It has been
suggested that small cells may be more numerous at the centre and large
cells at the periphery of developing human drg (McKinnis, 1936) and
differences between ventrolateral and dorsomedial cell groups do occur
early during development, but only transiently). Cell size is positively
correlated with axonal diameter (Cajal, 1909; Lee et al., 1986), the body
size of the animal (the largest perikarya are found in the drg of large
mammals; Levi, 1908), and the extent of the peripheral field innervated
(Ohta et al., 1974).
The number of neurons in individual drg also varies; thus, in rat,
cervical drg contain approximately 11,000 cells whereas thoracic ganglia
contain only 7,000 cells (Hatai, 1902). In cat, drg from C2-T1 contain 18-
33,000 cells, whereas those from T3-L3 contain 8-12,000 cells (Holmes &
Davenport, 1940). Drg from the cat have also been found to comprise cells
of different sizes depending on the site of origin of the drg (Larnicol et al.,
1988; Rose et al., 1990). Marked differences in cell number between
corresponding drg on opposite sides of the body have also been reported
(Delorenzi, 1937; Ygge et al., 1981).
When examined in the light microscope, the neurons of normal drg
are usually classified into two main categories: the large light or type A
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neuron and the small dark or type B. The small dark cells are more
intensely basophilic, argyrophilic and osmiphilic than the large light cells
(see Rambourg et al., 1983). A number of other criteria including perikaryal
size and morphology and distribution of Nissl bodies have been used to
further subdivide neurons (Clark, 1926) into a variety of classifications but
with only superficial correspondence one with another..." (Lieberman,
1976). Electron microscopic studies have confirmed the existence of two
groups of neurons on the basis of ultrastructural features (Dawson et al.,
1955; Jacobs et al., 1975) and histochemical properties (e.g., Tewari &
Bourne, 1962; Cauna & Naik, 1963; Kalina & Bubis, 1968; Kalina &
Wolman, 1970). Andres (1961) distinguished three subtypes for each of the
light (A1.A2.A3) and dark (B1,62,63) neurons from the appearance of the
Nissl bodies . Duce & Keen (1977) confirmed this configuration and further
demonstrated that prolonged nerve stimulation did not modify the relative
numbers of the various cell types, suggesting that ultrastructural differences
between cell types do not arise as a consequence of their history of activity.
Using improved techniques, Rambourg et al. (1983) further refined
and extended Andres' original classification. Compared with Type A2, Type
A1 cells have narrower strands of cytoplasm separating the Nissl bodies and
in addition, contain relatively few neurofilaments whereas A2 cells have
prominent bundles of neurofilaments. A3 cells are of intermediate size and
cytology between B and A type cells; in common with type A cells, they
contain Nissl bodies widely dispersed throughout the perikaryon and a
well-developed Golgi apparatus which, in combination with mitochondria
form a perinuclear ring characteristic of type B cells. Type B1 cells contain
prominent Golgi apparatus surrounding the nucleus forming a broad
perinuclear network extending to the nuclear surface and, less commonly, to
the cortex of the cell. Type B2 cells are the smaller of B type cells and
exhibit clear cut zonation of their perikaryal organelles. The juxtanuclear
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region contains Golgi apparatus and an abundance of mitochondria,
whereas the cortical area is occupied by an intricate mesh of rough
endoplasmic reticulum. Type Bi cells are more common than B2. The
Type A cells were the largest (40-75|im in diameter), B cells were of
intermediate size (20-50pm) and type C cells were the smallest (less than
20pm) of all ganglion cells with few and small Nissl bodies in the medial
zone of the perikaryon and a perinuclear Golgi apparatus. Rambourg's
classification is based on ultrastructure and cytology and bears no
consideration of a functional classification, however the dark/light distinction
(see above) may have some basis in a functional diversity. There is clinical
and histological evidence to support the contention that small dark cells are
specifically nociceptive (Knyihar, 1971; Gobel, 1974).
In addition, to neurons and satellite cells, drg have also been claimed
to contain 'atypical' ganglion cells; unipolar cells having, in addition, a
number of short dendrite-like processes originating from the cell body and
initial tract of the axon. It was initially proposed that 'atypical' cells were a
response to injury, but they are present in foetal and neonatal drg and it is
now generally accepted that they are fixation artefacts due to shrinkage
and/or distortion. In the rabbit nodose ganglion, ectopic autonomic neurons
can be distinguished in clusters close to the superior pole of the ganglion;
they are thought to occur through anomolous development of the vagus,
given its close relation to the cervical sympathetic system (see Lieberman,
1976).
Dogiel (1896) and others (see Lieberman, 1976) have described
pericellular nests similar to those found in association with autonomic
ganglion cells, which Dogiel interpreted as the receptor apparatus of other
(sensory) cells within the ganglion. His conclusions have since been
confirmed by a variety of workers (reviewed by Milokhin & Reshetnikov,
1972). Cajal (1928) took the view that these pericellular nests were the
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terminal arborizations of sympathetic fibres of extrinsic origin, and indeed
studies using fluorescence histochemistry do indicate the presence of
pericellular skeins of adrenergic fibres (Owman & Santini, 1966; Santini,
1966) around a few cells in cat cerebrospinal ganglia that are reduced
following sympathectomy. Despite strong anatomical evidence suggesting
a close affiliation of sensory and autonomic cells in the drg, they do not
appear functionally coupled; no synaptic contact between them can be
demonstrated except in dissociated cell culture (Miller et al., 1970; Lodin et
al., 1973) and thus, the autonomic ganglion cells in the drg may simply be
present as a consequence of anomalies during their development.
Electrophysiologically, the perikarya are thought to be of limited
functional significance in the intact animal; the perikaryon and initial axon of
the ganglion cell are devoid of synaptic contacts and do not normally
generate action potentials. Thus, the electrically active parts of the cell are
the terminal portion of the peripheral processes and the synaptic endings of
the central processes. However, perikarya do maintain a negative resting
potential of some 20-90mV and the soma is invaded by action potentials
passing along its processes (see Scott et al., 1969). Conduction along the
proximal region of the initial section is slow and often the central terminals of
large diameter axons are depolarised before the soma (Darian-Smith,
1973). Under experimental conditions drg cells can be demonstrated to
possess active properties; if cells are fatigued by repeated electrical
stimulation of the peripheral nerve, an antidromically directed action
potential is sometimes generated by, or close to, the cell body following the
electrically induced spike. This antidromic potential is never propagated
centrally (orthodromically; Tagini & Camino, 1973) and its significance, if it
exists under normal physiological conditions, is unclear. Spontaneously
arising impulses can also be detected in isolated drg one day or more after
isolation, but in this case the impulse was centrally directed (Kirk, 1974).
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Another important concern regards the passive delay experienced in the
propagation of the action potential as it passes through the drg, arising
almost certainly from the junction between peripheral and central processes
(Dun, 1955).
1.2 Neurochemistry of the drg
1.2.1 Peptide transmitter candidates of the drg
A number of chemically diverse compounds have been proposed to
act as neurotransmitters in neurons of the drg. Whilst some of the
candidates such as SP have been demonstrated within cell bodies by
immunohistochemical and other methods and also to be of some functional
significance centrally and peripherally, some of the more recently
discovered neuroendocrine peptides e.g., corticotrophin releasing factor,
localised in drg by immunohistochemical methods, have, as yet, no proven
function in sensory ganglia and may, in fact, be artefacts due to cross-
reactivity. The problem of cross-reactivity encountered using
immunohistochemical techniques should not be underestimated, and the
suffixes such as 'like immunoreactivity' or 'immunoreactivity' are commonly
used when describing peptide localisations. Whilst in this thesis I have
chosen, for expediency, to dispense with such terminology, the requirement
for caution implied in interpreting results obtained using immunological
techniques, including RIA, has not been ignored.
To date, the list of peptides so far discovered includes, SP (Hokfelt et
al., 1975; Nagy & Hunt, 1982; Ju et al., 1987), somatostatin (SS, Hokfelt et
al., 1975a, 1976; Johansson & Vaalasti, 1987; Ju et al., 1987), calcitonin
gene related peptide (CGRP, Rosenfeld et al., 1983; Gibson et al., 1984b;
Weisenfeld-Hallin et al., 1984), neurokinin A (NKA, Dalsgaard et al., 1985),
neurokinin B (NKB, Too et al., 1989) vasoactive intestinal peptide (VIP,
Lundberg et al., 1979; Gibson et al., 1984a), cholescystokinin (CCK,
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Lundberg et al., 1978; Ju et al., 1987), mammalian bombesin orgastrin-
releasing peptide (Panula et al., 1983; Fuxe et al., 1983), galanin (GAL,
Ch'ng et al., 1985; Skofitsch & Jacobowitz, 1985a), oxytocin (OXY), arginine
vasopressin (AVP, Kai-Kai et al., 1985, 1986), enkephalin (Senba et al.,
1982), dynorphin (Botticelli et al., 1981), endorphin (Itoga et al., 1980),
corticotrophin-releasing factor (CRF, Skofitsch et al., 1985), growth
hormone-releasing factor (GHRH, Jozsa et al., 1985), endothelin (Giaid et
al., 1990), and atrial naturetic factor (ANF, Nohr et al., 1989).
1.2.1.1 Tachykinins
SP, the most widely studied sensory neurotransmitter candidate, was
originally mooted by Lembeck (1953) as a transmitter candidate from the
finding that there was greater SP in the dorsal than ventral horn. Later,
Angelucci (1956) identified SP as one of a number of bioactive substances
released into perifused spinal cord on electrical stimulation of frog hind leg.
The suggestion that SP may mediate transmission of nociceptive information
to the spinal cord came from the observation that capsaicin, which is known
to cause a desensitisation to chemical noxious stimuli, depleted SP from
dorsal roots (Gasparovic et al., 1964). SP was also the first sensory
transmitter candidate to be localised histologically, to 20% of all cells in a
population of predominantly small sized neurons (Hokfelt, 1975a). More
recently, preprotachykinin (PPT) mRNA has been localised to the same
population of cells as those containing SP (Henken et al., 1988).
SP containing fibres and terminals have been demonstrated in
lamina I and II of the dorsal horn (Nilsson et al., 1974; Priestly et al., 1982),
and at the resolution of the electron microscope are found to form axo¬
dendritic contacts with dorsal horn neurons (Chan-Palay & Palay, 1977).
Following dorsal root transection or ligation,Takahashi & Otsuka (1975)
used bioassay to demonstrate a marked reduction of SP in the dorsal horn,
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and these studies have now been replicated by a number of authors using
immunohistochemistry or RIA (Hokfelt et al., 1975a; Barber et al., 1979;
Jessell et al., 1979).
SP has been demonstrated in a variety of peripheral nerves including
phrenic (Malthe-Sorensen & Oktedalon, 1982) and sciatic nerves (Brimijoin
et al., 1980; Lundberg et al., 1978; Lembeck et al., 1981), and, following
ligation or transection, SP accumulates in the proximal stump and is
depleted from the target area; the transport of SP is far greater in the
peripheral nerve than the dorsal root (Harmar & Keen, 1982). In the skin,
SP-containing fibres were first demonstrated in the hind paw of the cat
(Hokfelt et al., 1975); in human skin, they are found as free nerve endings in
some Meissner's corpuscles, and in association with blood vessels, sweat
glands and hair follicles (Dalsgaard et al., 1983a). SP containing fibres
have also been demonstrated in a variety of other tissues (see Dalsgaard,
1988) but of relevance to the role of SP in inflammation, a dense network of
SP-containing fibres around blood vessels has been demonstrated (Furness
et al., 1982) which is abolished by capsaicin pretreatment (Papka et al.,
1984).
Further evidence for a role of SP as a neurotransmitter comes from
electrophysiological studies. A peptide extracted from frog dorsal roots,
later identified as SP (Takahashi et al., 1974) is known to depolarise frog
motorneurons (Otsuka et al., 1972, 1972a). In mammals, a similar effect is
also found (Konishi & Otsuka, 1974, 1976) and can be mimicked by
capsaicin induced release of SP from the sensory nerve terminals (Theriault
et al., 1979; Bucsics & Lembeck, 1981). Furthermore, SP is excitatory on a
subpopulation of dorsal horn neurons which are excited by peripheral
noxious stimuli (Henry, 1976; Randic & Miletic, 1977).
Other tachykinins have also been found in the drg\ studies utilising
immunohistochemical and radioimmunoassay combined with high
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performance liquid chromatography (HPLC) have demonstrated the co¬
existence of SP, NKA and neuropeptide K (NPK, an N-terminally extended
form of NKA) in primary sensory neurons (Minamino et al., 1984a;
Dalsgaard et al., 1985; Hua et al., 1985; Ogawa et al., 1985). SP and NKA
have similar actions on effector cells (Hua et al., 1985; Nilsson et al., 1985)
and are co-released (Saria et al., 1984a). Recently, neurokinin B (NKB)
was reported in drg in substantially lower concentration than SP or NKA
(Too et al., 1989). Thus, from the evidence presented, it seems likely that
SP, and possibly NKA in primary sensory neurons, may mediate
transmission of nociceptive stimuli.
1.2.1.2 Somatostatin
SS exists in at least two forms (SS-14 and SS-28; see below) and
both have been found in primary sensory neurons (Ho & Berelowitz, 1984).
SS is present in approximately 10% of all cells, found primarily in small dark
neurons (Price, 1985) and SS mRNA has also been localised to these
neurons (Henken et al., 1988). In the spinal cord, SS-containing fibres are
found in greatest density in lamina II and to a lesser extent in lamina I
(Dalsgaard et al., 1981; Nagy et al., 1981); capsaicin pretreatment depletes
20% of SS in the spinal cord (Gamse et al., 1981; Jancso et al., 1981; Nagy
et al., 1981) but 90% of SS is depleted from the dorsal roots (Nagy et al.,
1981). The presence of numerous SS-containing small cell bodies in the
dorsal horn accounts for this difference (Dalsgaard et al., 1981; Ribeiro-da-
Silva & Cuello, 1990). SS is transported peripherally, is found in sciatic and
splanchnic nerves following ligation (Lundberg et al., 1978; Rasool et al.,
1981) and cell bodies retrogradely labelled from cutaneous and muscular
nerves are found to contain SS (Molander et al., 1987). In the human skin,
free nerve endings contain SS, suggesting a peripheral role for SS in
sensory perception (Johansson & Vaalasti, 1987); the presence of SS
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containing primary afferent fibres in the dorsal horn also indicates a central
role for SS, possibly in nociception (see below).
1.2.1.3 Calcitonin gene related peptide
CGRP has been localised using immunohistochemistry to a large
proportion of drg neurons of all sizes, and in a dense fibre network in the
dorsal laminae of the spinal cord and in nerve fibres of peripheral tissues
(Rosenfeld et al., 1983; Gibson et al., 1984b; Wiesenfeld-Hallin et al., 1984;
Gibbins et al., 1985, 1987; Skofitsch & Jacobowitz 1985; Uddman et al.,
1985; Lee et al., 1985; Lundberg et al., 1985; Wanaka et al., 1986; Kruger
et al., 1988). mRNAs encoding both a and (3 CGRP are found in perikarya
of drg and are present in overlapping but distinct cell populations (Noguchi
et al., 1990; Mulderry, 1988; Gibson et al., 1988). In peripheral tissues,
CGRP has been localised in axons of sensory neurons (Lundberg et al.,
1985), around blood vessels (Lundberg et al., 1985; Hanko et al., 1985;
Wanaka et al., 1985; Uddman et al., 1985; Wharton et al., 1986; Gibbins et
al., 1985) and in humans, in the skin as free nerve endings around blood
vessels, sweat glands, hair follicles and in a few Meissner's corpuscles (see
Dalsgaard 1988; Gibbins et al., 1987a; Dalsgaard et al., 1988) although not
all of this CGRP is of sensory origin (Landis & Fredieu, 1986; Lindh et al.,
1987). Molander et al. (1987) has shown that CGRP-containing sensory
neurons project to cutaneous, muscular and visceral neves. Thus, the
presence of sensory fibres containing CGRP in peripheral tissues and of a
dense innervation of CGRP in the dorsal horn suggests a possible role for
CGRP as a sensory neurotransmitter.
1.2.1.4 Cholecystokinin
Initial studies using antisera raised against CCK suggested that this
peptide accumulated in ligated peripheral nerves (Lundberg et al., 1978)
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and CCK was demonstrated in nerve fibres and drg (Larsson & Rehfeld,
1979). However, whilst the octapeptide (CCKs) is the dominant CCK-like
peptide in the CNS, the levels of CCKg in spinal ganglia were shown by
other methods to be extremely low or non-existent (Marley et al., 1982;
Schultzberg et al., 1982). Furthermore, capsaicin depletion of drg CCK
immunoreactivity was not paralleled by a reduction in CCKs content of drg
(Schultzberg et al., 1982). It has now been shown using
immunohistochemistry that CCK immunoreactivity in rat drg (Ju et al., 1986)
is abolished by preadsorption with CGRP, suggesting that these CCK
immunoreactive neurons in fact contain CGRP or CGRP-like peptide. This
finding has been confirmed by Hokfelt (1988) using more specific antisera to
CCK, which detected no CCK immunoreactivity in primary sensory neurons.
1.2.1.5 Vasoactive Intestinal Polypeptide
VIP was first described in primary sensory neurons of sacral drg and
in the proximal stump of splanchnic and sciatic nerves (Lundberg et al.
1978). In the spinal cord, VIP-containing fibres are found in Lissauer's tract
and in the most dorsal areas of lamina I; relatively higher levels of VIP are
present in the lumbosacral region of the spinal cord (Lundberg et al., 1979;
Annand et al., 1983, 1984; Basbaum & Glazer, 1983; Honda et al., 1983;
Kawatani et al., 1983) localised to areas where visceral afferents terminate
(Kawatani et al., 1983); but VIP has been identified in thoracic drg of
colchicine treated cats (Kuo et al., 1985). VIP, presumed to be of sensory
origin, is also present in peripheral tissues, in free nerve endings in the
dermis-epidermis region and around hair follicles in the human skin
(Bjorklund et al., 1986; Dalsgaard et al., 1988). In cat spinal cord, VIP is
released into the dorsal horn upon electrical stimulation of the sciatic nerve
at above C/A5 fibre threshold, and depolarises dorsal horn neurons to
increase their excitability (Jeftinija et al., 1982).
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1.2.1.6 Bombesin
Bombesin is a tetradecapeptide originally isolated from the skin of the
frog Bombina bombina (Anastasi et al., 1971). Whilst antisera raised
against bombesin recognise a mammalian form of this peptide in the spinal
cord (Moody et al., 1981) and sensory neurons (Fuxe et al., 1983; Massari
et al., 1983; Panula et al., 1983), the precise structure of mammalian
bombesin is not clear. It has been suggested that the 27 residue gastrin-
releasing peptide (GRP; McDonald et al., 1979) isolated from porcine
gastric tissue and Neuromedin B (NMB) characterised from porcine spinal
cord, which shows striking sequence homology with bombesin and elicit
effects similar to that of bombesin (Minamino et al., 1983; Nambaetal.,
1984), are the mammalian equivalents. In rat spinal cord, bombesin-like
immunoreactivity is found in nerve fibres, is in higher concentration in the
dorsal horn (laminae I and II) than in the ventral horn and is released by
veratridine and K+ in a Ca2+ dependent process. In lumbosacral segments
of spinal cord, bombesin immunoreactive fibres are found in greater
numbers than in cervical or thoracic segments (Moody et al., 1981; Namba
et al., 1985). O'Donohue et al. (1984) has found bombesin binding sites
localised to the outer laminae of the dorsal horn, which correlates with the
distribution of bombesin-containing fibres. Finally, it should be noted that
the tachykinins NKA and NKB share the two C terminal amino acids with the
bombesin/GRP family and the possibility that the bombesin-like
immunoreactivity is due to cross-reaction of the antisera cannot be
discounted (see Dalsgaard, 1988). Fortunately, the isolation of cDNA
clones for these peptides has allowed the unambiguous localisation of the
mRNA for both peptides using in situ hybridisation. It is found that only the
mRNA for NMB is present in a subset of drg cells (Wada et al., 1990).
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1.2.1.7 Opioid Peptides
A number of opioid peptides have been identified in drg in a variety
of species using immunohistochemistry and radioimmunoassay. Low levels
of dynorphin-i-13 have been found in extracts of rabbit drg (Botticelli et al.,
1981) but in the spinal cord levels of dynorphin-1.13 were unaltered following
dorsal rhizotomy; dynorphin has also been detected in cultures of drg
(Sweetnam et al., 1982). Prodynorphin has been localised to a population
of small somatosensory primary afferents of the guinea pig (Weihe et al.,
1985); cutaneous afferents and afferents projecting to the pelvic viscera and
airways also contain dynorphin (Gibbins et al., 1987). Senba et al. (1982)
has identified a small population of sensory neurons in drg containing leu-
enkephalin, although as dynorphin contains the leu-enkephalin sequence at
its N-terminus, it is not clear if the leu-enkephalin detected in this study was,
in fact, dynorphin cross reactivity. (3-endorphin has been identified in
cultured human drg (Kim et al., 1984).
1.2.1.8 Other peptides
In L5 drg of the rat, both OXY and AVP have been localised using
immunohistochemistry, and identified using reversed phase HPLC, but the
functional role of these two peptides remains unclear (Kai-Kai et al., 1985,
1986). GAL is a 29 residue peptide (Tatemoto, 1983) which has been
immunohistochemically localised to a subset of primary sensory neurons
(Ch'ng et al., 1985; Skofitsch & Jacobowitz 1985a; Ju et al., 1987). Whilst
the peripheral projection and function of GAL is unclear, in the substantia
gelatinosa, terminals containing GAL and a basal release of GAL have been
reported (Ch'ng et al., 1985; Morton & Hutchison, 1989). CRF containing
cell bodies have been reported in drg and capsaicin-sensitive fibres are
reported in the dorsal horn (Schipperet al., 1984; Skofitsch et al., 1984,
1985). However, it has been suggested that CRF immunoreactivity in
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primary sensory neurons is, in fact, due to cross-reaction with SP, despite
their structural dissimilarity (Berkenbosch et al., 1986). In support of this, in
preliminary studies for this thesis, I failed to detect any CRF in extracts of drg
using RIA (G. Smith, unpublished observations). GHRH-like
immunoreactivity has been reported in approximately 1% of all drg neurons;
however, no fibres containing GHRH are present in the spinal cord or
periphery and the possible role for GHRH remains obscure (Jozsa et al.,
1987). Recently, mRNA and immunoreactivity for endothelin 1 has been
localised to small and large neurons of drg, but immunoreactive fibres were
rarely found in the dorsal spinal cord (Giaid et al., 1989). Finally, fibres
containing ANF have been found in lamina I and II of the spinal cord and in
5% of the intermediate and large neuronal cell bodies in the guinea pig
(Nohr et al., 1989).
1.2.2 Non-peptide transmitter candidates
1.2.2.1 Excitatory amino acids
Both L-glutamate (Glu) and L-aspartate (Asp) have been proposed as
neurotransmitter candidates of drg neurons, and both have powerful
excitatory actions on spinal neurons (Curtis et al., 1959). However, the
available data tends to suggest that Glu is the endogenous transmitter acting
on the high density of binding sites in the superficial dorsal horn
(Greenamyre et al., 1984). Indeed, monosynaptic excitation of spinal dorsal
horn neurones in vivo by physiological and electrical stimulation of large
myelinated primary afferents is antagonised by iontophoretic application of
antagonists of kainate and quisqualate receptors but not by antagonists
specific for the NMDA receptor (Gerber & Randic, 1989; Yoshimura &
Jessell, 1990; Dickenson & Sullivan, 1990); although both these
compounds have been shown to be neurotoxic on the spinal cord (Urea &
Urea, 1990). In contrast, frequency-dependent potentiation of dorsal horn
neuronal responsiveness to repeated C-fibre stimulation ('wind-up';
Mendell, 1966) is abolished by NMDA receptor antagonists (Davies &
Lodge, 1987; Dickenson & Sullivan, 1990) which are also antinociceptive
(Dickenson & Aydar, 1991). These results do not, by themselves, imply that
Glu is released and acts postsynaptically, as these effects may be due to
presynaptic inhibition of release of another transmitter (see Salt & Hill,
1983). However, dorsal horn neurons maintained in dissociated cell culture
respond to application of Glu, but not Asp or NMDA (the specific agonist)
with a rapid depolarisation of similar time course to the excitatory post¬
synaptic potential (epsp) elicited by sensory neuron stimulation (Jahr &
Jessel, 1985).
Biochemical studies also suggest Glu may be the endogenous
transmitter. The ubiquity of Glu and Asp as components of cellular proteins
and metabolism make the interpretation of biochemical data more
complicated than for most other neurotransmitter candidates. However,
there is an excess of Glu in dorsal roots over ventral roots, which is not found
for other amino acids (Roberts et al., 1973). An uptake system for Glu (and
other amino acids) can be demonstrated in the spinal cord (see Salt & Hill,
1983) and [3H]D-aspartate, which is internalised only by neurons utilising
excitatory amino acid transmitters but not metabolised, is retrogradely
transported from the dorsal horn to exclusively label large perikarya of drg
(Cuenod et al., 1982). Antibodies raised against enzymes of amino acid
metabolism e.g., glutaminase (metabolising Glu) or aspartate
aminotransferase (metabolising Asp) have also proved useful.
Immunohistochemistry for these enzymes reveals that aspartate
aminotransferase is evenly distributed in drg cells but that a population of
small- to medium-sized drg cell bodies constituting approximately 30% of all
cells are selectively labelled by antibodies against glutaminase (Cangro et
al., 1985). More recently, Battaglia & Rustioni (1988) have used specific
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antisera raised against Glu to localise Glu in approximately 15-30% of drg
neurons. The transport inhibitor colchicine increased the proportion of cells
containing Glu to 70% but did not alter immunoreactivity for glutaminase.
Furthermore, it has been suggested that as the intensity of Glu
immunoreactivity does not correlate with cytochrome oxidase activity (a
marker for cell metabolic activity) Glu immunoreactivity is not concerned with
cell metabolism. Immunoreactivity for Glu has also been localised to
approximately 8.5% of unmyelinated and 2.5% of myelinated axons in
lumbar dorsal roots of the rat (Westlund et al., 1989). In studies using
antisera raised against Glu and Asp fixation products, immunoreactivity for
both was localised to the first three lamina of the dorsal horn, in a variety of
subcellular structures including vesicles and synaptic densities (Merighi et
al., 1991). Thus, whilst the evidence presented here does not rule out some
other transmitter substance such as Asp, or the acidic dipeptide N-acetyl-
aspartyl-glutamate (Westbrook et al., 1986) as the transmitter mediating the
monosynaptic epsp, there is considerable support for Glu as the transmitter.
1.2.2.2 Purines
Electrophysiological studies indicate that ATP selectively excites a
subpopulation of cultured dorsal horn neurons (Jahr & Jessel, 1983) and is
found to increase the firing rate of neurons receiving primary afferent input in
cuneate and caudal trigeminal nuclei (Galindo et al., 1967; Phillis & Wu,
1981). Earlier, it was found that antidromic stimulation of sensory nerves
induced release of ATP at sites of termination in the periphery (Holton,
1959). Unfortunately, the ubiquity of ATP as the energy currency of the cell
militates against immunohistochemical localisation of this candidate
transmitter to drg neuron subpopulations.
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1.2.3 Cytoplasmic markers for drg subpopulations
1.2.3.1 Fluoride resistant acid phosphatase (FRAP)
FRAP enzyme activity has been localised in a large subpopulation of
small diameter primary afferent neurons in the rat (Kniyhar, 1971). In the
spinal cord, FRAP activity is localised to lamina I and II and is completely
abolished by capsaicin pre-treatment (Kniyhar-Csillick & Csillick, 1981;
Nagy & Flunt, 1982; McDougal et al., 1985). FRAP activity has also been
demonstrated in peripheral tissues (Kniyhar-Csillick & Csillick, 1981) and
drg cells projecting in muscular, cutaneous and visceral nerves contain
FRAP (Dalsgaard et al., 1984; Molander et al., 1987). The function of this
non-lysosomal hydrolytic enzyme is unclear, but a number of substrates
including thiamine monophosphate and guanine 5'-monophosphate are
known; ATP, however, is not a substrate for FRAP (see Nagy & Daddona,
1985). FRAP activity labels approximately 75% of neurons with a dense
cytoplasmic reaction product, whereas the remaining 25% exhibit staining of
granules scattered throughout the cytoplasm.
1.2.3.2 Carbonic Anhydrase (CA)
CA catalyses the interconversion of CO2 (gas) and FI2CO3 and as
such, is thought to be a marker of metabolically active cells. Cytochemical
staining for CA in drg of a number of species is limited to larger diameter
cells; smaller diameter cells containing little or no CA activity (Riley et al.,
1984). In support of CA activity as a marker for metabolically active cells,
the intensity of cytochrome oxidase staining (another measure of cell
metabolic activity) is found to be correlated with CA staining (Carr et al.,
1989).
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1.2.3.3 Adenosine Deaminase (ADA)
ADA converts adenosine to inosine, and ADA activity is localised to a
subpopulation of primary afferent neurons (Nagy et al., 1984). Such
neurons are distinct from FRAP and 5' Nucleotidase (see below)
populations, and terminals containing ADA activity have been localised to
laminae I and II; capsaicin pre-treatment depletes ADA activity (Nagy &
Daddona, 1985).
1.2.3.4 5' Nucleotidase (5'N)
5'N is involved in the catabolism of nucleotides and is localised in a
distinct subpopulation of neurons in the drg\ some 80% of cells containing
5'N activity also show FRAP activity (see Nagy & Daddona, 1985).
1.2.3.5 Cytoskeleton
The large light and small dark cell populations of drg can be
distinguished using monoclonal antibodies raised against the 200kD
neurofilament protein (RT97) which selectively label the large light neurons
(Lawson et al., 1984). Another antibody, MAb ICII, which recognises a
filamentous antigen selectively labels small and intermediate-diameter drg
neurons and shows little or no overlap with those cells labelled by RT97
(Dodd & Jessel, 1986).
1.2.4 Cell Surface Markers
A number of cell surface antigens have now been shown to be
expressed in subsets of drg. The majority of the surface antigens are
oligosaccharides; globoseries carbohydrate sequences, recognised by
monoclonal antibodies such as stage-specific embryonic antigen (SSEA)-3
and SSEA-4, are expressed selectively in the cytoplasm and on the surface
of about 10-15% of adult drg neurons, of mainly intermediate and large size
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(Dodd et al., 1984). The central terminals for these neurons are localised to
laminae I, III and IV of the dorsal horn, suggesting they are indicative of
myelinated afferents of either high threshold mechanoreceptors or
low-threshold cutaneous receptors (Dodd & Jessell, 1985; Tajti et al., 1988).
Monoclonal antibodies directed against lactoseries carbohydrates
(A5, LD2, KH10, 2C5, LA4, FC10.2, Anti-Le) label a variety of
subpopulations and proportion of mainly small drg neurons (Dodd & Jessell,
1985; Mollicone et al., 1986). Terminals expressing lactoseries
carbohydrates are restricted to the superficial laminae of the dorsal horn,
and in the periphery, terminals of primary sensory neurons have been found
to express these same lactoseries carbohydrates (Dodd & Jessel, 1985).
Such cell surface markers appear early in the development of sensory
projections to the spinal cord, are conserved between species, and it may be
that these oligosaccharide epitopes are of importance in establishing the
proper connections between sensory neurons and receptive neurons in the
drg (Regan et al., 1986; Mollicone et al., 1986; Dodd & Jessell, 1986).
1.2.5 Peptide Co-existence
That neuropeptides co-exist in drg neurons is suggested from studies
in which the numbers of cells immunoreactive to each of a selection of
neuropeptides has been shown to exceed the total number of cells present.
However, whilst positive evidence regarding co-existence of neuropeptides
may, on first consideration, seem to be incontravertible, problems regarding
cross-reactivity must be considered when interpreting co-localisation
studies. Fortunately, consistent results, in a variety of species, now suggest
that widespread co-localisation of neuropeptides does occur, and that this is
not restricted to simply paired co-localisation, but cells containing a number
of peptides have been described; even co-localisation in the same
secretory granule has been reported (Merighi et al., 1988).
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Initial studies of co-localisation of SP and SS in rat drg indicated that
SP immunoreactivity was found in a population of small or intermediate
sized cells (10-20% of all neurons) distinct from those containing SS (10%
of all neurons; Hokfelt et al., 1976). Tuscherer & Seybold (1985) confirmed
the distribution of SP and the discrete populations of SP and SS containing
cell bodies, but found SS in small diameter neurons only. More recently in
the rat, Ju and colleagues (1987) have reported colocalisation of SP and SS
in 5-10% of SS-containing cells and colocalisation of SP and GAL; no co¬
existence of GAL and SS was reported. Co-localisation of SP and SS and
the absence of colocalisation of SS and GAL has also been reported for cat
(Garry et al., 1989) and Merighi et al. (1988) have reported colocalisation of
SP and SS in the same secretory granule. In cat, SS is also colocalised
with SP, VIP and 'CCK' (probably CGRP); and some cells may contain all
four peptide immunoreactivities (Leah et al., 1985). In situ hybridisation for
(3-PPT mRNA and preproSS mRNA in rat drg showed that peptide
immunoreactivity was found in the same cells expressing mRNA for the
respective peptide; although no data regarding colocalisation of mRNA was
reported in this study (Henken et al., 1988). Colocalisation of SS with
CGRP in rat, cat, horse and pig has also been reported to the extent that the
majority of SS immunoreactive cell bodies were also immunoreactive for
CGRP (Ju et al., 1987; Merighi et al., 1988; Merighi et al.,1990; Garry et al.,
1989). In the cat, colocalisation of SS with Leu-enkephalin has also been
reported (Garry et al., 1989).
SP has been reportedly colocalised with a large number of
neuropeptides. In the rat and cat, colocalisation with SS has been
discussed above; but in the rat, SP immunoreactivity was found in cells
containing CGRP and GAL (in fact, most SP cells contained CGRP; Ju et al.,
1987; Skofitsch & Jacobowitz, 1985b). In the cat, SP was found
colocalised with CGRP and Leu-enkephalin (Garry et al., 1989), and in
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lumbar and sacral drg , it has been reported that SP immunoreactive cells
can contain up to three other peptides; 'CCK' (probably CGRP), SS and VIP
(Leah et al., 1985). SP immunoreactivity in horse and pig has also been
colocalised with CGRP, GAL, enkephalin and combinations of SP, CGRP
and enkephalin and SP, CGRP and GAL were also noted (Merighi et al.,
1990). SP has also been colocalised with NKA (Dalsgaard et al., 1985),
AVP and OXY (Kai-Kai et al., 1986), Glu (Battaglia & Rustioni, 1988),
bombesin-like immunoreactivity (Dalsgaard et al., 1983; Fuxe et al., 1983)
dynorphin (Gibbins et al., 1987) and endothelin (Giaid et al., 1989), but not
ANF (Nohr et al., 1989). The mRNA for (3-PPT has been shown to colocalise
with SP-like immunoreactivity (Henken et al., 1988) and in all cells
containing endothelin 1 mRNA transcripts (Giaid et al., 1989).
CGRP, the most abundant of neuropeptides in the drg, is contained in
between 50% and 70% of drg neurons of diameter between 15pm and
65pm (Ju et al., 1987). Thus, it is not restricted to small dark neurons but is
also present in large light neurons. It is, therefore, of little surprise that
CGRP has been widely colocalised with a number of other neuropeptides in
drg. Colocalisation with SP and SS in rat, cat and other species has been
discussed above. In addition, in drg of rat, CGRP has been colocalised with
GAL and VIP and in some cells, with both GAL and SP (Ju et al., 1987); in
guinea pig colocalisation of CGRP with dynorphin and SP often in the same
cell has been reported (Gibbins et al., 1987); colocalisation with VIP in the
human has also been reported (Dalsgaard et al., 1988). Studies of the
localisation of mRNA encoding a and p CGRP showed that whilst small and
medium diameter neurons expressed both types of mRNA, larger neurons
expressed a predominance of a CGRP mRNA; the colocalisation of both a
and p CGRP mRNA was also noted (Mulderry et al., 1988; Noguchi et al.,
1990).
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1.3 ROLE OF SP, SS AND CGRP IN THE drg
1.3.1 Substance P (SP)
Whilst SP was first isolated by von Euler & Gaddum in 1931 (see
Nakanishi, 1987; Helke, 1990), it was only recently that the peptide was
purified and its structure elucidated as the undecapeptide Arg-Pro-Lys-Pro-
Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (Chang, 1971). SP is a member of the
tachykinin family of peptides (literally 'fast-acting'), characterised by the
common carboxy terminus Phe-X-Gly-Leu-Met-NH2 where X is a
hydrophobic or aromatic residue (Erspamer, 1971). Until recently, SP was
the only known mammalian tachykinin, the others in the family having been
isolated from octopod salivary glands or amphibian skin. However, a
number of other tachykinins have now been demonstrated in the
mammalian CNS (see Harmar, 1984; Maggio, 1988; Helke et al., 1990)
and the existence of a number of preprotachykinin (PPT) mRNAs and two
tachykinin genes has also been shown.
The PPT-A gene is approximately 8.4kbp long and consists of seven
exons separated by six introns (Fig. 1.1); exons 2-7 encode six protein
sequences as follows: signal peptide, SP, two spacer sequences, NKA
(substance K) and the carboxy terminal sequence respectively (Nawa et al.,
1983; Krause et al., 1987; Harmar et al., 1986). Alternative splicing of the
primary transcript of the tachykinin A gene yields a number of mature mRNA
species: a-PPT mRNA contains exons 2-5, but not 6, and exon 7, and thus
encodes SP only, (3-PPT mRNA consists of all exons 2-7 and thus, encodes
SP and NKA and y-PPT mRNA which does not contain exon 4 also encodes
SP and NKA (Nawa et al., 1984; Krause et al., 1987). Recently, a fourth
PPT mRNA, 8-PPT in which both exons 4 and 6 are absent has been
isolated and sequenced (Harmar et al., 1990). Translation of a, p and y
preprotachykinin mRNA gives rise to precursor peptides of 112, 130 and 115
amino acids, respectively. Post-translational processing of the a peptide
Figure 1.1 Schematic diagram of the transcription and splicing of
the rat preprotachykinin A gene. The rat tachykinin A is
depicted at the top with the boxes denoting exons;
transcription products of the genes are also shown.
The mRNAs are translated with concomitant signal
peptide cleavage, and the various peptides derived


















































































































































yields only SP. The p and y peptides can also yield SP, but in addition,
NKA and NKA (3-10) can also be produced through post translational
processing, p propeptide also gives rise to an NhVterminally extended
form of NKA (known as neuropeptide K) and the y peptide yields another
NH2-terminally extended form (neuropeptide y, see Helke et al., 1990). It
has been predicted that in addition to SP, 5-PPT may encode a novel C-
flanking peptide of 22 amino acids (Harmar et al., 1990).
NKB (neuromedin K), a further mammalian tachykinin, is encoded by
both of the two known transcripts of the PPT-B gene (Kotani et al., 1986). In
common with the PPT-A gene, the PPT-B gene consists of 7 exons
interspaced by 6 introns and gives rise to two PPT-B mRNAs, through use of
different promoter sites, both containing exons 1-7 (NKB is contained in
exon 5). The minor species of mRNA differs from the major in having two
extra 5' exon sequences and lacking the 5' terminus of the first exon
sequence of the major transcript. Translation of both mRNA species yields
a propeptide of 126 amino acids containing the NKB sequence. NKB is
thought to be the sole biologically active peptide product of the tachykinin B
gene (Kotani et al., 1986).
Cell bodies and nerve terminals containing immunoreactive SP have
been demonstrated in many regions of the CNS, most notably laminae I and
II of the dorsal horn of the spinal cord, the caudate nucleus, the substantia
nigra, the habenulointerpeduncular tract and intermediolateral cell column.
In the peripheral nervous system autonomic ganglia, sensory ganglia (see
above) and enteric neurons have also been found to contain
immunoreactive SP (Brownstein et al., 1976; Ljunghdahl et al., 1978; Nicoll
et al., 1980). Such studies employed radioiummunoassay of
microdissected tissue or immunohistochemisry of brain sections. However,
as SP is a member of a family of tachykinins, some only identified latterly,
and each with a homologous carboxy terminal region, antisera raised
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against one may (and often do) cross react with other peptides in the family.
Thus, immunochemical data must be interpreted with caution as
demonstrating the discrete distribution of one tachykinin peptide.
Combining radioimmunoassay with chromatographic techniques has
explicitly shown SP, NKA and neuropeptide K in spinal cord and drg
(Ogawa et al., 1985; Arai et al., 1986; Too et al., 1989). Antisera to SP,
shown not to cross-react with NKA and vice versa reveal a similar
distribution of SP and NKA immunoreactivity in the spinal cord (see Helke et
al., 1990), although the other mammalian tachykinins were not accounted for
in this study.
In situ hybridisation for PPT-A and PPT-B mRNA can give some
indication as to the likely distribution of NKB vs. NKA and SP. In the rat
CNS, distinct patterns of expression of the two genes are found. Thus, for
example, in spinal cord laminae I and II, PPT-A gene expression is
prominent, whereas the PPT-B gene is predominately expressed in lamina
III only. In the caudate nucleus numerous cell bodies containing PPT-A
mRNA are found, whereas PPT-B expressing cells are located in the
striatum (Warden et al., 1988). Interestingly, in the medial habenula, mRNA
of both genes are co-localised (Burgunder et al., 1989).
The distribution of the three mRNA encoded by the PPT-A gene, a, (3
and yhas also been examined, by Northern blot and in situ hybridisation. In
bovine tissues, tissue-specific distribution of PPT-A mRNAs has been
reported, with p-PPT predominating in nervous tissue and a-PPT
predominating in thyroid and gut (Nawa et al., 1984). In rat tissues, y-PPT is
the most abundant form and the splicing pattern of the PPT-A gene is
throught to be relatively constant in all tissues studied (see Harmar et al.,
1990). To date, 5-PPT mRNA has only been reported in rat drg (Harmar et
al., 1990).
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Mammalian tachykinins act through three tachykinin receptors
originally distinguished using the amphibian tachykinins, physalaemin
eiedoisin and kassinin in smooth muscle preparations and in ligand binding
studies (see Buck & Burcher, 1986; Mizrahi et al., 1985). More recently,
cDNAs encoding receptors binding SP (NK1), NKA (NK2) and NKB (NK3)
have been isolated and sequenced from rat cDNA libraries (Yokota et al.,
1989; Masu et al., 1987; Shigemoto et al., 1990). The three receptors
show sequence similarities with some divergence, but all conform to the so
called 7 transmembrane arrangement and belong to the family of G protein-
coupled receptors. More recently, a putative G-protein-coupled receptor
was isolated from a rat forebrain cDNA library using a probe for a particularly
well conserved sequence within the transmembrane region, TM6, of the G
protein coupled receptors. Sequence comparison showed that this clone
encoded a polypeptide containing seven transmembrane domains, showing
greatest homology with tachykinin receptor sequences (Eva et al., 1990). It
is possible, therefore, that a fourth tachykinin receptor may exist.
The distribution of tachykinin binding sites has been investigated
using Northern blot hybridisation of probes specific for each of the three
receptors, and autoradiography of a number of radiolabeled ligands with
some specificity for each of the three known subtypes. The distribution of
binding sites in the spinal cord is discussed below. In the CNS, NK-1
binding sites have been localised to neurons and glia, and are present in
high density in the caudate putamen, but in relatively low abundance in the
substantia nigra (Mantyh et al., 1989; Buck et al., 1986). NK-1 binding sites
are also present on neurons of the myenteric plexus, smooth muscle cells,
fibroblasts and a number of circulating inflammatory and immune cells
(Mantyh et al., 1989). The NK-2 receptor is present in highest concentration
in peripheral tissues, in a pattern distinct from that of NK-1 receptors, and
interestingly associated with smooth muscle of blood vessels (Mantyh et al.,
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1989). In the CNS, NK-2 binding sites are reported in highest density in the
external plexiform layer of the olfactory bulb, with lower densities in the
caudate nucleus, substantia nigra and the striatum (Dam et al., 1990).
However, some of these sites may have been NK-3, and some authors
suggest NK-2 binding sites may be exclusively in peripheral tissues (Mantyh
et al., 1989; Saffroy et al., 1988). The NK-3 receptor is found primarily in
the CNS, although neurons of the rat myenteric plexus and smooth muscle
cells of the rat portal vein reportedly contain NK-3 binding sites (Mantyh et
al., 1989; Buck et al., 1986; Saffroy et al., 1988). In the CNS, NK-3 binding
sites are concentrated in the deep cortical layers (Mantyh et al., 1989), and
in the nigrostriatal system, the distribution of NK-3 binding sites reflects that
of NK-2 sites (see above).
1.3.1.1 Central role of SP
Evidence supporting a role of SP in the drg as a sensory transmitter
was obtained from early studies indicating that dorsal roots contained
greater SP content than the ventral roots (Lembeck, 1953) and that SP was
released into the perifused frog spinal cord following electrical stimulation of
the hindlimb (Angelucci, 1956). Release of SP from sensory terminals has
now been demonstrated in the rat in vivo (Yaksh et al., 1980) and in vitro
(Otsuka & Konishi, 1976; Theriault et al., 1979) from peripheral sensory
fibres with conduction velocities in the A5 and C-fibre range (Yaksh et al.,
1980). Intracellular recording from dorsal horn neurons in the rat in vitro
has shown that the slow, synaptically-mediated depolarisation elicited by
high-frequency dorsal root stimulation is mimicked by application of SP
(Urban & Randic, 1984). Moreover, SP antagonists block this slow
depolarisation elicited either by SP or dorsal root stimulation. Further
support for SP as a sensory transmitter in the spinal cord comes from the
distribution of tachykinin binding sites. NK-) NK2 and NK3 type binding sites
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have been identified in the spinal cord. The density of NK-| binding sites in
the spinal cord is greatest in laminae I and II, the intermediolateral cell
column and lamina X. NK2 binding sites are associated with the dorsal
horn only, in lamina l-lll and NK3 binding sites are distributed similarly
(Helke et al., 1986; Charlton & Helke, 1985, 1985a; Buck et al., 1986).
lontophoretic application of SP onto the dorsal horn exerts a powerful
excitatory action on a subpopulation of dorsal horn neurons which are also
excited by a peripheral noxious stimulus (Henry, 1976; Randic & Miletic,
1977). Dorsal horn neurons responding to low threshold afferent inputs
also respond to SP (Henry, 1982) and Leah and collaborators (1985a)
found SP in afferents conveying both noxious and innocuous stimuli. More
recently, SP was found to be released following noxious mechanical or
noxious thermal stimulation (Kuraishi et al., 1985; Wiesenfeld-Hallin,
1986a) and noxious stimulation has also been found to lead to induction of
the PPT-A gene in rat drg (Noguchi et al., 1988). The distinct localisation of
SP immunoreactive fibres in laminae I and II (Henry, 1976), the area of
termination of fine myelinated (A8) and non-myelinated (C) fibres also
supports a role for SP in the transmission of nociceptive information
(Christensen & Perl, 1970). Behavioural studies have to be interpreted with
caution; however, lumbar intrathecal injection of SP in conscious rats elicits
caudally directed scratching, licking and biting behaviour consistent with
perception of a noxious stimulus (Piercy et al., 1981; Hylden & Wilcox, 1981;
Seybold et al., 1982; Wiesenfeld-Hallin et al., 1984). From the evidence
above, it appears that SP containing primary afferents, terminating in the
dorsal horn, may be involved in the transmission of noxious stimuli.
1.3.1.2 Peripheral role of SP
An important role for SP in peripheral tissues is implied from the
finding that the majority of SP synthesised in the drg is transported in
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peripheral compared with central nerve (Brimijoin et al., 1980; Harmar &
Keen, 1982). In addition, a number of nerves of the periphery are known to
contain SP, including the greater and lumbar splanchnic, phrenic and sciatic
(see Dalsgaard, 1988). SP immunoreactive fibres are also found in most
peripheral tissues; in the skin associated with blood vessels, sweat glands
and hair follicles (Dalsgaard et al., 1983a). SP immunoreactive fibres are
also present in dental pulp as free nerve endings and around blood vessels
(Olgarth et al., 1977, 1977a; Brodin et al., 1981); in the rat mammary nipple
(where it is associated with lactation; Traurig et al., 1984) and the cornea,
uvea, iris and retina of the eye (see Dalsgaard, 1988). In the cornea,
capsaicin pretreatment depletes 80% of the SP (Keen et al., 1982) and in
the iris, trigeminal nerve denervation completely removes SP innervation
(Butler et al., 1980; Tervo et al., 1982) suggesting in these tissues that SP is,
in part at least, of sensory origin.
Blood vessels are richly innervated by dense networks of SP
immunoreactive nerve fibres (Furness et al., 1982; Papka et al., 1984) which
are depleted following capsaicin pretreatment (Furness et al., 1982).
SP-containing fibres are also found in the nasal mucosa, respiratory tract,
epithelium of the lung and tongue, taste buds, gastrointestinal tract, parotid
gland, myocardium, endocardium, epicardium, bladder, kidneys, adrenal
gland and pia mater of the brain and spinal cord. However, it should be
noted that not all SP immunoreactive nerves are of sensory neuron origin
(see Dalsgaard, 1988).
In 1901, Bayliss noted that a variety of mechanical, chemical and
physical stimuli to the skin produced vasodilatation, and that this
phenomenon was dependent on the integrity of sensory neurons. Hinsey &
Gasser (1930) have shown that the nerve fibres mediating this increased
blood flow are the C fibres of sensory neurons; neurogenic inflammation is
prevented by capsaicin treatment or denervation (Jancso et al., 1967), which
34
also reduces SP in primary afferent neurons (Gamse et al.„ 1980). A
number of lines of evidence support a role for SP in vasodilatation (see
Pernow, 1985); the presence of SP in peripheral nerve terminals has been
discussed above. Release of SP from peripheral branches of primary
sensory neurons occurs in the cat tooth pulp following antidromic stimulation
of the inferior alveolar nerve (Olgarth et al., 1977), and results in a depletion
of 60% of the SP in this tissue. Similarly, in the skin, experimental blister
fluid is found to contain SP following antidromic stimulation of the sciatic
nerve (White & Helme, 1985). Antidromic stimulation of nerves innervating
skin also elicits a plasma extravasation and vasodilatation (Hallberg &
Pernow, 1975; Hagermark et al., 1978; Ferrell & Russell, 1985), similar to
that seen following close arterial infusion of SP (Lembeck & Holzer, 1979).
Both electrically and SP-induced hyperaemia is blocked by the SP
antagonist (D-Pro2 , D-Tryp7.8) SP (Rosell et al., 1981) and pretreatment
with capsaicin, which almost completely depletes SP in the skin, abolishes
antidromic vasodilatation and plasma extravasation (Lembeck & Holzer,
1979; Gamse et al., 1980).
Further evidence for SP as a mediator of plasma extravasation comes
from studies in the eye. Stimulation of the trigeminal nerve distal to the
gasserian ganglion causes depletion of SP immunoreactivity and increases
the SP content of venous effluent blood (Bill et al., 1979; Brodin et al.,
1981). Topical application of mustard oil or other irritants also releases SP;
and local administration of SP to the eye causes miosis, hyperaemia and
damages the blood aqueous barrier (Mandahl & Bill, 1981). This is a direct
action of SP as the responses are not significantly attenuated by nerve
conduction blockade by tetrodotoxin or trigeminal denervation. The effects
of noxious agents on the eye are attenuated by capsaicin pretreatment or
SP antagonists (Bynke, 1983). Thus, evidence from studies in skin and the
eye suggests SP may be involved in the process of neurogenic
inflammation.
The mechanism by which SP induces vasodilatation and hyperaemia
is unclear, however SP is found to induce degranulation of mast cells with
liberation of histamine and the leukotrienes LTB4, LTC4 and LTD4 (Erjavec
et al., 1981; Payan et al., 1984). Both histamine and LTB4 stimulate
release of SP from peripheral sensory nerve endings, and SP antagonists
inhibit oedema formation by compound 48/80, a histamine liberator (Saria et
al., 1984). Furthermore, histamine, LTC4 and LTD4 increase vascular
permeability and LTB4 stimulates influx and accumulation of endothelium
adherent polymorphonuclear leukocytes and monocytes. However, SP
may also have a direct action, as pretreatment with histamine receptor
antagonists or depletion of histamine with compound 48/80 reduces but
does not completely block plasma extravasation induced by SP or
antidromic nerve stimulation (Lembeck & Holzer, 1979; Couture & Cuello,
1984). SP also induces chemokinesis of polymorphonuclear leukocytes
and chemotaxis of monocytes and neutrophils (Wiedermann et al., 1989;
Helme et al., 1987).
1.3.2 Somatostatin
SS was first isolated and sequenced as a tetradecapeptide from
extracts of ovine hypothalami (Brazeau et al., 1973), and subsequently
identified in a variety of other tissues (see Reichlin, 1986). In addition to the
tetradecapeptide (SS-14), an amino-terminally extended form (SS-28) and
a variety of prohormonal forms and other fragments have been identified
(Esch et al., 1980; Pradyrol, 1980) . The gene encoding SS has been
isolated from a variety of species including anglerfish, catfish, and human
(see Andrews & Dixon, 1986); fish express two SS genes, which give rise to
distinct prepro SS I and II mRNA, encoding SS-14 and SS-28 respectively
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(Noe & Speiss, 1983). Mammalian tissues contain a single gene, yielding a
prepro SS encoding both SS-14 and SS-28 (Shen et al., 1982; Tavianini et
al., 1984).
The rat and human SS genes are similar and consist of two exons
separated by a 621 bp intron (see Fig. 1.2). The first exon contains a signal
peptide and the sequences for SS-14 and SS-28 are found in exon 2. A
prepro SS consisting of exon 1 and exon 2 results from transcription of the
SS gene and, in turn, yields a 116 amino acid proSS, containing the SS-14
and SS-28 sequences at the carboxy terminus. The SS-14 sequence is
preceded by two adjacent basic residues, whilst that of SS-28 is preceded
by a single arginine. It is thought that proteolytic cleavage occurs to release
either SS-28 or SS-14, although the enzymes involved and factors
regulating this process are not known . Tissue-specific processing to either
SS-14 or SS-28 has been shown in a number of tissues including drg and
side-chain modification occurs in fish (see Andrews & Dixon, 1986).
Since the identification of SS, the peptide has been ascribed a wide
variety of functions in both peripheral and central systems (see Reichlin,
1986). SS containing fibres form part of the complex that terminates in the
median eminence, and inhibits growth hormone secretion. Hypothalamic
SS is also one of a number of factors that regulate thyroid stimulating
hormone secretion. In the pancreatic islets, SS contained in D cells inhibits
release of insulin (B cells) and glucagon (A cells) in what is thought to be a
paracrine role, although a genuine endocrine role cannot be excluded. SS
also has a large number of effects on the gut, inhibiting exocrine secretions
and release of a number of gut peptides, including gastrin, CCK, VIP,
glucagon and secretin. In addition, it may also inhibit duodenal motility, gall
bladder contraction and gastric emptying (see Bethge et al., 1982). In the
nervous system outwith the hypothalamus, SS has been found in significant
concentration in the cortex, septum, preoptic area and the thalamus. Lower
Figure 1.2. Schematic illustration of the transcription and splicing
of the rat SS gene primary transcript. The gene is
depicted at the top with the numbered boxes, denoting
exons. The single transcription product is shown, this
is translated with concomitant signal peptide cleavage,
and the possible post-translational processing



















concentrations of SS are found in midbrain and brainstem nuclei, striatum,
cerebellum and olfactory bulb (Brownstein et al., 1975).
Somatostatin is thought to produce its biological effects by binding to
high affinity membrane receptors coupled to one or more pertussis toxin-
sensitive G proteins. It is not clear if different SS receptors exist for the
various forms of SS found in mammalian tissues; however, in rat anterior
pituitary, a number of proteins have been specifically labelled using
radiolabeled SS ligands and affinity cross linking methods (see Brown et
al., 1990). More recently, photoaffinity labelling studies have identified an
85kDa protein in GH4C1 pituitary cell line membranes as a SS receptor. In
a number of other cell lines, proteins of slightly different molecular weight
were labelled, although this was thought due to differences in
glycocosylation (Brown et al., 1990).
1.3.2.1 Role of SS in the drg
In the spinal dorsal horn, SS-containing fibres are present in laminae
I and II (Hokfelt et al., 1975, 1976; Dalsgaard et al., 1981; Nagy et al.,
1981); some, but not all (Ribeiro-da-Silva & Cuello, 1990), are of primary
afferent origin (see above), and it has been suggested SS may be involved
in sensory transmission. Using antibody microprobes, Morton et al. (1989)
have shown that the basal release of SS in the region of the substantia
gelatinosa is increased following noxious thermal stimulation, but not
innocuous thermal or mechanical stimuli or noxious mechanical stimuli.
Similarly, release of SS into rabbit dorsal horn was increased by noxious
thermal, but not mechanical, stimuli (Kuraishi et al., 1985). Furthermore, SS
binding sites have been localised to the spinal cord of rat and human using
radiolabeled SS-14 and SS-28. Binding site density is particularly
pronounced in the substantia gelatinosa and lamina X, supporting the
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suggestion that SS may be involved in sensory transmission (Reubi &
Maurer, 1985; Reubi et al., 1986; Leroux et al., 1985).
Intrathecal administration of SS into the lower lumbar spinal cord
produces a caudally directed behaviour consistent with perception of
irritation and possibly pain, and increases the excitability of a flexion reflex to
noxious thermal but not to mechanical stimuli (Seybold et al., 1982;
Wiesenfeld-Hallin, 1985; Cridland & Henry, 1988; Wiesenfeld-Hallin,
1986). Intrathecal administration of anti-SS antiserum significantly inhibits
the nociceptive response to thermal, but not mechanical stimulation (Ohno et
al., 1988). SS also influences the firing of dorsal horn neurons (Randic &
Miletic, 1978) and SS applied topically to the spinal cord is analgesic in
animals (Mollenholt et al., 1988) and human (Meynadier et al., 1985;
Chrubasik et al., 1984); this variation in the results of intrathecal
administration of SS may be due to the variety of doses used. However,
SS also causes hind limbs paralysis and neuronal damage, possibly
through an ischaemic neurotoxic action and thus analgesia may be due to a
pathological, rather than physiological, action of SS (Long, 1988;
Mollenholt et al., 1988; Gaumann & Yaksh, 1988). More recently, it has
been suggested that analgesia is elicited by non-neurotoxic intrathecal
doses of SS (Mollenholt, 1990).
Intradermal injection of SS elicits a wheal and flare reaction in the
skin of the human forearm, and the flare, but not the wheal, is dramatically
reduced by capsaicin pretreatment, suggesting part of the action of SS is
mediated by primary afferent C-fibres (Anand et al., 1983). Whilst SS
containing fibres are found surrounding cutaneous blood vessels
(O'Shaughnessy et al., 1983), SS is also found to release histamine from
mast cells (Theoharides et al., 1981) and it may be that this mechanism
underlies the action of SS in peripheral inflammation.
1.3.3 Calcitonin gene related peptide
CGRP is a 37 amino acid peptide encoded by the calcitonin gene and
produced as a result of alternate post transcriptional splicing of the calcitonin
gene primary transcript (see Zaidi et al., 1987). The peptide was discovered
when a spontaneous and permanent switching from high to low calcitonin
production in a rat medullary thyroid carcinoma cell line was found to be due
to a switching of production from a calcitonin associated mRNA to a
transcript approximately 200 nucleotides longer (Rosenfeld et al., 1981).
Subsequent investigation revealed that this new transcript encoded a 128
amino acid precursor peptide (Rosenfeld et al., 1983) and was due to
alternate post-translational processing of the primary transcript (Amara et al.,
1982). More recently, Amara et al. (1985) and other groups have identified a
second closely related sequence in rat and human and now two
calcitonin/CGRP genes are known; the a and (3 respectively (Steenbergh et
al., 1985; Alevizaki et al., 1986).
The a-calcitonin gene is found on the short arm of chromosome 11,
consists of six exons and is about 6.5kbp long. The first three exons are
common to both calcitonin and CGRP mRNA (although exon 1 is not
translated), whilst the 4th exon contains the sequences for katacalcin and
calcitonin, and an untranslated sequence at the end of which is a
polyadenylation signal. The a CGRP mRNA consists of the first three exons,
exon five containing the a CGRP sequence and exon six, which is not
translated and has the alternative polyadenylation signal (see Fig. 1.3).
Evidence that the different transcripts arise from alternative post-translational
splicing and are not due to differentially directed transcription from the gene
comes from the finding that nascent transcripts prepared from nuclei of
tumours producing either calcitonin or CGRP mRNA show no difference (see
Maclntyre et al., 1987).
Figure 1.3 Schematic illustration of the transcription and splicing
patterns of the human a CGRP gene is depicted at the
top with the numbered boxes, denoting exons;
transcription products of the genes, arising through
alternate splicing are also shown. The mRNAs are
translated with concomitant signal peptide cleavage,



















































































The p calcitonin/CGRP gene is also localised to the short arm of
chromosome 11 and is thought to have arisen due to exon duplication.
Whilst exons three and five share 92% homology, the non-coding regions
(exons 1 and 6) are divergent. Exon four (containing the calcitonin
sequence in the a calcitonin/CGRP gene) is only 65% homologous with the
a and is unlikely to be translated as the reading frame terminates after only
eight amino acids. Furthermore, the polyadenylation signal is found to be
significantly altered in exon four of the p gene further reducing the likelihood
of transcription. It may be that the p Calcitonin/CGRP gene is committed to
CGRP production alone. The rat a and p CGRP sequences differ by only
one, conservative, amino acid substitution (an Asp at position 25 in a is
replaced by a Asn in P), suggesting that functionally they may subserve
similar or identical functions (see Zaidi, 1987; Maclntyre et al., 1987).
Despite its relatively recent discovery, CGRP has been shown to exert
a wide variety of biological activities including inhibition of gastric acid
secretion, cardiac acceleration, vasodilatation, regulation of calcium
metabolism, modulation of blood pressure, and body temperature and
modulation of nociception (see Dennis et al., 1990). The peptide is widely
distributed throughout the body, found in many of the areas of the CNS, in
the spinal cord, thyroid gland, stomach, duodenum, pancreas and kidney
(Skofitsh & Jacobowitz, 1985; Okimura et al., 1987; Wimalawansa et al.,
1987). On the basis of the activity of a C-terminal fragment of CGRP,
CGRP8-37 in a number of in vitro bioassay systems at least two CGRP
receptors are thought to exist (Dennis et al., 1990), although these are not
thought to distinguish the a and p forms of CGRP (Zaidi et al., 1990; Foord &
Craig, 1987).
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1.3.3.1 Central role of CGRP
CGRP has been localised to drg and in a dense network of fibres in
the dorsal laminae of the spinal cord (Rosenfeld et al., 1983; Gibson et al.,
1984b; Wiesenfeld-Hallin et al., 1984; Gibbins et al., 1987; Skofitsch &
Jacowbowitz, 1985b; Lee et al., 1985; Krugeret al., 1988). Furthermore,
'CCK'-like immunoreactivity (probably CGRP, see above) is found in both
noxious and non-noxious primary afferents, and CGRP binding sites have
been localised to the spinal dorsal horn, suggesting it may play some role in
transmission of sensory information from the periphery to the spinal cord
(Leah et al., 1985a; Henke et al., 1985) Immunoreactivity in the dorsal horn
of the rat is increased following electrical stimulation of the sciatic nerve
(Klein et al., 1990).
Administered intrathecally, CGRP does not of itself elicit any
behavioural response, but the scratching, biting and licking behaviours
observed following intrathecal administration of SP, NKA or SS are
potentiated (Wiesenfeld-Hallin et al., 1984, 1986; Woolf and Wiesenfeld-
Hallin, 1986); similarly, intraplantar injection of CGRP sensitises, but does
not induce, hyperalgesia (Nakamura-Craig & Kaur-Gill, 1991). It is not clear
how CGRP produces this effect, but it may be, as has been suggested, that it
inhibits enzymatic breakdown of the other peptides (Le Greves et al., 1985;
Le Greves et al., 1989). Alternatively, it might directly affect the dorsal horn
neurons responding to these other peptides to lower their threshold to
respond. Another possible mechanism of action of CGRP proposed by Oku
et al. (1987), that CGRP potentiates release of SP in the dorsal horn, is
evidenced from studies of capsaicin-induced release.
1.3.3.2 Peripheral role of CGRP
In the periphery, CGRP is found in terminals of drg (Dalsgaard et al.,
1988; Lundberg et al., 1985; Wanaka et al, 1986; Uddman et al., 1985;
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Gibbins et al., 1985, 1987) and both a and p forms have been implicated in
the process of inflammation (Brain et al., 1985, 1986a,b; Gamse & Saria,
1985; Brain & Williams, 1985; Weihe et al., 1988). Following antidromic
nerve stimulation, CGRP, a potent vasodilator (Brain et al., 1985) is released
into the periphery (Saria et al., 1986) and whilst not inducing plasma
extravasation itself, enhances oedema induced by SP and other mediators
of increased microvascular permeability (Brain & Williams, 1985; Gamse &
Saria, 1985). It has been suggested that CGRP vasodilatation is mediated
by a release of relaxing factors as the vasodilatation appears endothelium-
dependent (Brain et al., 1985). However, in the bovine coronary artery,
vasodilatation in response to CGRP does not require the presence of an
intact endothelium (Greenberg et al., 1987). Further support for a direct
action of CGRP on endothelial-smooth muscle comes from the finding that a
receptor for CGRP is found in such tissue (Hirata et al., 1988). Interestingly,
in rat lung, CGRP inhibits biosynthesis of the inflammatory mediator LTD4
(Di Marzo et al., 1986) and in guinea pig ileum, LTD4-mediated contractions
are inhibited by CGRP (Tippins et al., 1986).
1.4 ADRENAL STEROIDS
Of the 50 or so different steroids isolated from adrenal sources, only a
small number are secreted into the venous blood and fewer still have
ascribed biological activity, the remainder being biosynthetic intermediates,
products of catabolism or with poorly understood activities. The two major
steroid groups secreted by the adrenal gland are the glucocorticoids and
mineralocorticoids synthesised in the zona fasciculata, and zona reticularis
of the adrenal gland respectively. Whilst it is an oversimplification,
glucocorticoids influence carbohydrate and protein metabolism and have
anti-inflammatory activity, whereas mineralocorticoids are concerned with
electrolyte balance, especially Na+ and K+. Other steroids produced by the
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adrenal gland include androgens, progestogens and oestrogens. In rat, but
not man, the major secreted corticosteroid is corticosterone, with large
amounts of 18-hydroxy-11 -deoxycorticosterone also present;
18-hydroxycorticosterone and aldosterone (a mineralocorticoid) are also
secreted, but in smaller amounts (see Wilson & Foster, 1985; Leung &
Munck, 1975).
1.4.1 Mechanism of action of steroid hormones
The first indication that steroid hormones may produce their effects by
acting at the level of the genome came from the observation that ecdysone
induced 'puffs' in the giant chromosome of insects. It has subsequently
been shown that corticosteroids bind with a cytosolic receptor which moves
to the nucleus where it binds with chromatin. Much effort has been devoted
to the characterisation and cloning of steroid receptors, the identification and
cloning of hormone regulated genes and the characterisation of sequences
in the vicinity of such genes that confer hormone responsiveness (see
Carson-Jurica et al., 1990).
The mineralocorticoid (Type I) and glucocorticoid (Type II) receptors
belong to a family of ligand-activated enhancer-binding factors (see
O'Malley, 1990), which also includes receptors for the sex steroids, thyroid
hormone, vitamin D3 and retinoic acid, in addition to a number of oncogenes
(e.g., v-erbA) and so-called orphan receptors, the ligands for which are
unknown (e.g. COUPTF- the chicken ovalbumin upstream promoter-
transcription factor). Cloning and sequencing of cDNAs for a number of the
receptors in this family suggests they share a similar structure and may
derive from a common ancestral origin.
The receptors are characterised as being composed of five structural
domains designated A-E. Domains C and E are conserved between
receptors; C, the DNA binding region, is particularly homologous, and
44
E forms the ligand binding domain. Domain D forms the hinge region
between C and E; domains A/B located at the N-terminus, are hypervariable
but their function is not fully understood. Closer analysis of domain C
reveals nine conserved cysteine residues, eight of which form two zinc finger
motifs, containing one zinc atom each. A series of experiments utilising
domain swapping between receptor subtypes and site directed mutagenesis
has shown that the first Zn finger is concerned with determining the
sequence specificity of DNA binding and the second finger interacts less
specifically and may stabilise dimer formation at steroid response elements.
The ligand binding domain (E) contains a large number of hydrophobic
amino acids and is particularly well conserved in two regions of 42 and 34
residues located in the middle of the domain. Whilst this high degree of
conservation suggests that these two regions are functionally important, their
role is not clear. The less well-conserved regions of this domain may confer
ligand specificity on the molecule, but domain E is also important in ligand
activated nuclear translocation. For the oestrogen receptor, which binds to
DNA as a dimer (as does the GR), domain E is also important in the process
of dimerisation (see Fig. 1.4; see Evans, 1988; Green & Chambon, 1988;
Beato, 1989).
DNA sequences mediating steroid induction of gene transcription
have been identified using gene transfer, site-directed mutagenesis and
DNase protection techniques. This work has led to construction of a 15mer
consensus sequence AGAACAnnnTGTTCT for the glucocorticoid response
element (GRE). Induction by mineralocorticoids, androgen and
progesterone is also possible through this sequence, although subtle
differences in the detailed contacts each receptor makes with the GRE are
found. That these differences are of functional importance, is suggested by
the finding that mutation of individual sequences has differential effects on












including oestrogen, thyroid hormone and retinoic acid show similar
birotational dyad symmetry (see Beato, 1989).
In addition to upregulating gene expression, glucocorticoids can also
repress gene transcription. Currently, only three examples of this process
are known; the pro-opiomelanocortin gene, the prolactin gene and the gene
for the a subunit of glycoprotein hormones. Analysis of the sequence
recognised by the GR (GRE(-))does not allow a clear consensus to be
derived, however features in common with and divergent from the activating
GRE can be identified. Whilst it may be that the binding of GR to GRE(-) may
directly inhibit transcription (as is proposed for glucocorticoid repression of
prolactin), such sequences are not common in glucocorticoid repressed
genes. This has led to the suggestion that repression may be mediated by
competition, between GR and other activators for binding sites on the 5'
regulatory sequence of such genes. In the case of the a subunit gene,
glucocorticoid inhibition is only apparent in constructs also containing cAMP
response elements and in cells able to respond to cAMP. In other cell
types, the same response elements can act as positive modulators of
adjacent promoters, thus it may not be the nucleotide sequence perse that
mediates repression, but rather its proximity to other regulatory elements that
may be important (see Beato, 1989).
1.4.2 Anti-inflammatory activity of glucocorticoids
Glucocorticoids are potent anti-inflammatory agents used in the
treatment of inflammatory disorders such as rheumatoid arthritis (McCarty,
1989). Despite their widespread clinical use, the mechanism of action of
glucocorticoids is not clear. One suggestion promulgated over the previous
decade or so, is that these steroids induce the biosynthesis of proteins which
inhibit phospholipase A2 (PLA2) (see Flower, 1985, 1988). Previously,
these proteins were referred to as macrocortin (Blackwell et al., 1980),
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venocortin (Hirata 1981) or lipomodulin (Cloix et al., 1983), but are currently
termed lipocortins (Flower, 1985). PLA2 is presumed to initiate release of
fatty acid substrates for synthesis of pro-inflammatory eicosanoids, and thus
lipocortin, by inhibiting PLA2, reduces the production of inflammatory
mediators and the consequent inflammation.
Synthesis and release of lipocortin is greatly stimulated by
glucocorticoids, such that following adrenalectomy (ADX), the concentration
of lipocortin in the body fluids of animals is reduced (Blackwell et al., 1982).
Furthermore, in a carrageenin-induced pleurisy model of inflammation in the
rat, following ADX, the magnitude and duration of inflammation was
approximately double, compared with that of sham operated animals
(Flower et al., 1986). The concentration of pro-inflammatory eicosanoids
such as 6-keto-prostaglandin F-ia, thromboxane B2, and leukotriene B4was
also enhanced (Flower et al., 1986). Glucocorticoid administration reversed
the effects of ADX. More recently, the inflammatory reaction resulting, from
subcutaneous injection of polyacrylamide suspension in the dorsal surface
of mice, was strongly inhibited in a dose-dependent fashion by a mouse
lipocortin (Errasfa & Russo-Marie, 1989).
Glucocorticoids are also immunosuppressive, causing a reduction in
the T and B cell population in the circulation (Axelrod et al., 1981). It is
thought that glucocorticoids suppress the immune response by inhibiting
cytokine production (Besedovsky et al, 1986). lnterleukin-2 production, is
suppressed by dexamethasone acting at the level of gene transcription
(Gillis et al., 1979; Ariya et al., 1984). Synthesis of the cytokine
interleukin-1 (IL-1) is also inhibited by glucocorticoids in vivo (Gander et al.,
1968) and in vitro (Cunha et al., 1985). IL-1 has been implicated in the
pathophysiology of arthritis (Bunning et al., 1986) and is found to release
collagenase (Golds et al., 1983), promote bone resorption (Gowen et al.,
1983), prostaglandin E2 production (Mizel et al., 1981), neutrophil
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degranulation (Kampschmidt et al., 1976) and release of oxygen-free
radicals (Klempner et al., 1979). Peritoneal macrophages collected from
rats following ADX, release more IL-1 than those from sham operated
animals (Perretti et al., 1989). It is likely that the anti-inflammatory and
immunosuppressive actions of glucocorticoids contribute to their efficacy in
the symptomatic relief of inflammatory disorders.
1.5 AIMS
In this Chapter, I have described the possible mechanisms by which
glucocorticoids may be useful in the treatment of painful and inflammatory
conditions. The neuropeptides SP, SS and cGRP are found in the drg , and
their putative role in the pathology of inflammatory pain has also been
discussed. It may be that part of the action of glucocorticoids as anti¬
inflammatory analgesics involves regulation of SP, SS and CGRP in the drg.
Consequently, in this thesis, I have investigated the effects of ADX and
corticosteroids on the SP, SS and CGRP content of drg in the rat, both in
vivo and in vitro using primary culture of adult rate drg enriched for neurons.
Furthermore, I have assessed the changes in SP, SS and CGRP content of
drg in a rat model of inflammatory disease, and determined the effects of
ADX and glucocorticoids on the inflammation and changes in SP and CGRP
content of drg in this model. Finally, I have investigated if another steroid,
testosterone, also regulates neuropeptide content of drg in the rat, and
described the distribution of the three neuropeptides under study in drg from






In all experiments, male Ham Wistar rats (Charles Rivers, UK) were
used. The animals were housed four to a cage in raised lid RP2 cages, and
given grade 6 sawdust bedding and paper wool nesting material. Cages
were cleaned daily and fresh food, water and bedding provided. Food (a
CRM cubed diet; Special Diet Services, UK) and tap water were provided
ad libitum and the temperature was thermostatically controlled between 68
and 72°F. Illumination was also automatically controlled, giving 14h of light
between 5 a.m. and 7 p.m.
2.1.2 Anaesthetic
For surgical procedures, animals were anaesthetised under
halothane (Fluothane, ICI) in oxygen (2.5l/min). For induction, 2%
halothane concentration was used and animals were subsequently
maintained in 1-1.5% halothane. Animals to be anaesthetised were placed
in a perspex box 4" x 5" x 9" with a close-fitting lid and the box connected in
series with a gas line from the anaesthetic machine (King Portable Boyles
BOC Ltd.) fitted with a fluotec vapouriser (BOC Ltd.). A controlled O2 flow
could be switched into the anaesthetic supply at will, from 2 x 45lb medical
oxygen cylinders carried on the apparatus. The exhaust gas from the
induction box was led through rubber tubing into a bottle containing liquid
paraffin through which it was bubbled, to remove most of the halothane
before venting it to the operating theatre extraction system. Once induced,
the animals were transferred to a 'small animal' face mask connected in
series with the box, and received a maintenance dose of anaesthetic under




Animals were anaesthetised under halothane as described, and the
fur removed from their flank using a small animal electric razor. The area
was sterilised with ethanol and a small incision of approximately 1cm was
made in the flank, 1.5cm from the spinal column, of the animal, the muscles
were separated and the kidney located. The adrenal gland, lying above the
kidney, was identified and excised with surrounding connective tissue.
Care was taken to ensure that no fragments of the adrenal gland remained.
The incision was sutured with running stitches and the animals placed in a
37°C incubator to recover. For the first ten post-operative days, the animals'
diet was supplemented with a mash consisting of milk and brown bread, but
subsequently they were fed on normal diet. Chlortetracycline (Aureomycin
10g/I; Cyanamid, UK) was included in the drinking water for the first ten
post-operative days. Seven days later, the procedure was repeated, and
the second adrenal gland removed. Bilateral adrenalectomised animals
were given a choice of drinking water containing 1% saline (NaCI; BDH),
5% glucose (BDH) and chlortetracycline or tap water containing
chlortetracycline. To verify successful adrenalectomy, plasma samples
were collected on the termination of experiments and assayed for
corticosterone and ACTH using RIA (see below). In addition, the cadaver
was inspected post-mortem for adrenal fragments.
2.1.3.2 One Step
Animals were anaesthetised in halothane and both adrenal glands
removed as described above. Following surgery, the animals' diet was
supplemented as above, and they were given a choice of tap water or 1%
saline, 5% glucose, supplemented with chlortetracycline.
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2.1.3.3 Sham Operation
For sham operation, the animals were prepared and anaesthetised
as for adrenalectomy. Incisions were made in the flanks, the muscle
separated and the adrenal glands located, but not manipulated. Post¬
operative treatment was as for adrenalectomised animals.
2.1.4 Castration
Animals were anaesthetised under halothane anaesthesia and the
scrotum swabbed with ethanol to sterilise the area prior to surgery. An
incision was made in the tip of the scrotum to permit extrusion of the testis
and a single ligature (2/0 silk) secured around the internal spermatic
vessels, the deferential vessels and the vas deferens to minimise bleeding
and facilitate excision of the testis. The testis, together with the caput, and
caudate epididymes were excised by cutting above the ligature and the
scrotum was sutured with one or two running stitches using 2/0 silk. The
procedure was then repeated for the other testicle. For sham operation,
animals were swabbed and the internal spermatic vessels, the deferential
vessels and the vas deferens clamped; no incision was made into the
testicle. For implantation of capsules, a small incision was made in the
shoulder and using a pair of forceps a space was formed below the skin of
the right upper forelimb. The capsule, either empty or containing
testosterone, was then eased in under the skin and the incision stitched with
two running sutures using 2/0 silk. Following surgery, animals were placed
in an 37°C incubator to recover, and their diet was supplemented with a
brown bread and milk mash. In addition, operated animals were given
chlortetracycline (1 Og/I) in their drinking water.
2.1.5 Induction of Adjuvant Arthritis
Animals were anaesthetised with halothane and injected subdermally
in the left forepaw with Freund's complete adjuvant (1mg/ml; Sigma, UK).
Two injections of 50|il each were made at two separate locations in the
forepaw. In some cases, control animals were given subdermal injections




Animals were decapitated through the brain stem using a small
animal guillotine and the dorsal surface of the spinal column exposed. The
drg were exposed by laminectomy. Briefly, the spinous processes were
removed from the dorsal surface of the spinal column using a large pair of
rongeurs and subsequently a pair of fine rongeurs were used to remove the
remainder of the dorsal surface of the vertebrae, the lamina (that part lying
above the transverse processes), from the severed end to approximately
level T3. The spinal cord thus exposed, was carefully excised using curved
watchmaker's forceps (No. 7) and curved microdissection scissors (Weiss)
to free the connective tissue attaching it to the ventral surface of the spinal
column. The dorsal and ventral roots were also severed. Once the spinal
cord was removed, the drg were visible lying on either side of the spinal
column and the drg from level C4-C7 were identified by counting down from
level C1. The drg were collected with the aid of a binocular dissecting
microscope by grasping them firmly with fine forceps and severing the
dorsal root and peripheral nerve with curved microdissection scissors.
They were collected in bilateral pairs in Eppendorf tubes, frozen on dry ice
and stored at -20°C until processed. With practice, this procedure could be
completed in 3-4 mins from the time of decapitation.
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2.1.6.2 C2/3-T5/6
The animals were decapitated and drg exposed by laminectomy as
described above, from the severed end to approximately level T8. Identified
drg were collected unilaterally in pairs C2/3, C4/5, C6/7, T1/2, T3/4 and T5/6
from the left and right sides. They were placed in Eppendorf tubes, frozen
on dry ice, and stored at -20°C until processed. This procedure typically
took around 10 mins from the time of decapitation.
2.1.6.3 C1-L6
Animals were killed by asphyxiation in a high CO2 atmosphere. This
was achieved by placing the animal in a dessicator with dry ice in the bottom
and replacing the lid, sleep and death typically ensued within 1 min. The
dorsal surface of the spinal column was exposed by making an incision from
the head to the base of the tail on either side of the spinous processes.
Skin, overlying flesh, and spinous processes were removed by using a large
pair of rongeurs and the bone was freed from above the cerebellum. The
dorsal surface of the spinal column was removed by laminectomy as
described above, from the atlas to below L6. Following removal of the
spinal cord, drg were removed bilaterally in pairs from C1 to L6, frozen on
dry ice and stored at -20°C until processed.
2.1.7 Collection of plasma samples
Trunk blood samples were collected following decapitation. Animals
were allowed to bleed through a filter funnel into plasma tubes held on ice.
Prior to collection, the funnel and tubes were washed in 0.9% saline
containing 100U/ml of Heparin (Evans Medical, UK) and 1000KIU/ml of
Trasylol (Bayer, UK). Immediately following collection, the tubes were
inverted a number of times and then centrifuged at 2300 x g for 30 min at
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4°C to pellet the cells. The supernatant was removed with a glass pipette
and stored in Eppendorf tubes at -40°C until assayed.
2.1.8 Preparation of drg samples for RIA
Drg were homogenised in 10Opil 2M acetic acid using 0.1 ml rod
formed glass mini homogenisers (Jencons, UK) and centrifuged at 16000g




Injections were administered subcutaneously into the scruff of the
neck.
Corticosterone (B; Sigma, UK)
Stock concentration of 2.5mg/ml in sesame oil was given daily in
volume of 200|il to a final dose of 2.5mg/kg.
Dexamethasone (DEX; Sigma, UK)
Stock concentration of 0.2mg/ml in sesame oil administered daily in
200pl volume giving a final dose of 0.2mg/kg.
RU38486 (Roussel UCLAF, France)
Stock concentration of 10mg/ml in sesame oil given daily in 200pl
injection at a dose of 10mg/kg.
Control Animals
Control animals received daily injections of 200pl sesame oil.
2.1.9.2 Oral Dosing




Stock concentration of 0.05mg/ml in 0.9%, saline, 0.2% ethanol
administered twice daily by gavage in 0.4ml/100g volume giving a final dose
of 0.2mg/kg.
RU38486 (Sigma, UK)
Stock concentration of 2.5mg/ml in 0.9% saline, 0.2% ethanol
administered twice daily by gavage in 0.4ml/100g volume giving a final dose
of 10mg/kg.
Control Animals
Controls received 0.4ml/100g of 0.9% saline, 0.2% ethanol.
2.1.9.3 Pellets
Reagents: Corticosterone (Sigma, UK)
Cholesterol (Sigma, UK)
50% w/w of B/cholesterol was mixed and heated rapidly in an oil bath
at 260°C until melted. The molten mixture was then poured into the moulds
used for mounting samples for electron microscopy until full, which gave
pellets of 200mg. They were allowed to cool, at which time the pellets could
be easily removed. For control animals, pellets of the same shape and size
were cut out of bone wax. Pellets were implanted subcutaneously in the
scruff of the neck and replaced after 15 days.
2.1.9.4 Silastic Capsules
Silastic capsules were used to administer testosterone to castrated
animals. A 30mm length of silastic tubing (Dow Corning Corp., Michigan,
USA) of internal diameter 1.57mm and external diameter 3.18mm was filled
with crystalline testosterone propionate (Sigma, UK) and sealed with wax.
Prior to implantation, they were soaked in 0.9% saline at room temperature
to ensure they contained no leaks.
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2.2 PRIMARY CULTURE
2.2.1 Tissue Culture Plastic
Tissue culture plates used in these experiments were:
35mm x 15mm - Falcon 3001F
60mm x 15mm - Falcon 1007
140mm x 17mm - Sterilin 501V
35mm x 15mm, 4 raised ring dishes - CelCult
2.2.1.1 Poly-Ornithine Coating (Collins, 1978)
Reagent: Poly-DL-Ornithine Hydrobromide (Sigma, UK).
Polyornithine was dissolved in 0.15M Na2 B4 O7 10H2O/O.15M H2
BO4, pH 8.3 to final concentration of 500pg/ml and filter sterilised through a
0.2pm filter. To coat 60mm plates, 6ml of this solution was placed in each
plate and left at room temperature for between 6 and 18 hrs. The solution
was aspirated from the plate and it was washed twice in sterile distilled
water. For four-well plates 80pl per well of polyornithine was used; after
incubation, the solution was aspirated and the plates washed twice in sterile
distilled water.
2.2.1.2 Laminin Coating (Edgar et al., 1984)
Reagent: Laminin (1.15mg/ml; NBL, USA)
Laminin was dissolved in sterile Dulbecco's phosphate buffered
saline to concentration 5pg/ml. To each of the four wells of previously
polyornithine-coated plates 80pl of the laminin solution was applied and
incubated at room temperature for at least two hours. The solution was
aspirated and the wells washed twice in phosphate buffered saline.
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2.2.2 Incubator
Cells were incubated at 37°C in 3% CO2 atmosphere at 100%
humidity. The incubator was a water jacketed Forma-Scientific model 3157
(Forma Scientific, Marietta, Ohio USA).
2.2.3 Culture Medium
Reagents: Hams Nutrient Mixture F14 - Imperial Laboratories (see
Appendix A for composition)
L-Glutamine (200mM) - Flow Laboratories
Penicillin (100IU/ml)/Streptomycin (100|ig/ml) - Gibco
Na HCO3-BDH
Hams Nutrient Mixture F14 was dissolved in Millipore filtered water
(12.11 g/l) and Na HCO3 (1.176g/l) and L-glutamine added (5ml). The
solution was sterilised through a 0.22(im bottle top filter (Falcon, 1705),
attached to a water pump and penicillin and streptomycin added (1:100
dilution); the solution was referred to as F14 basic medium. Medium was
stored at 4°C but was incubated for 1 h at 37°C prior to use in order to
reduce the cold shock for cells. Medium was never used over one month
old due to loss of NaHCC>3 and L-glutamine from the medium.
2.2.4 Drugs and Supplements
Ultra Ser 'G' (Gibco, UK)
Ultra Ser 'G', a synthetic serum, was purchased as a lyophilised
powder in sealed sterile glass bottles. The powder was reconstituted under
aseptic conditions in 20ml F14 basic medium and the dissolved product was
added to 500ml basic medium, giving a final concentration of 4% v/v.
Cis-4-OH Proline (Sigma, UK):
Cis-4-OH proline was dissolved in F14 basic medium and filter
sterilised to give a final stock concentration of 20mg/ml. The stock was
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stored at 4°C, and 25pl added to each 35mm plate (containing 2.5ml
medium) to give a final concentration of 200(ig/ml.
Nerve Growth Factor (NGF; kind gift of R.M. Lindsay):
NGF was received at a concentration of 100mg/ml and diluted further
in F14 basic medium giving a stock concentration of 2.5pg/ml. It was stored
at 4°C and 10pil was added to each 35mm plate giving a final plate
concentration of 25ng/ml.
B (Sigma, UK)
The powder was dissolved in ethanol to a stock concentration of
10mg/ml which was stored in a foil-wrapped tube at 4°C. 25pl was added
to each plate, giving a final concentration of 100pg/ml.
DEX (Sigma, UK)
Dexamethasone was dissolved in ethanol to give a stock
concentration of 1 mM. This was stored in a foil-wrapped tube at 4°C and
25pl added to each plate giving a final concentration of 10pM.
Forskolin (Sigma, UK)
Forskolin was dissolved in tissue culture grade dimethylsulfoxide
(Sigma, UK) to stock concentration 800pM and stored at 4°C. 25pl of this
stock was added to each plate, giving a plate concentration of 8pM.
ITS+ (Collaborative Research Ltd., UK)
ITS+ was received as a concentrated aqueous solution containing
insulin (12.5mg), transferrin (12.5mg), selenic acid (12.5mg), bovine serum
albumin (2.5g) and linoleic acid (10.7mg) in a volume of 20ml. The stock






Bovine serum albumin 1.25mg/ml
Linoleic acid 5.35|ig/ml
2.2.5 Dissection
All dissection instruments were placed in 70% ethanol in water for at
least 15 minutes prior to commencing dissection, which was performed on
the open bench. Periodically throughout the dissection, the instruments
were resterilised in 70% ethanol. The animals (Ham Wistar rats, male,
200g) were decapitated and the cadaver sprayed with 70% ethanol to
sterilise the outer surface. The dorsal surface of the animal was exposed
using a sterile scalpel blade and tissue overlying the spinal cord removed
with a large pair of dissection scissors. Starting at the severed end, the
spinal column was excised from the carcass by cutting the muscle free from
either side of the column and freeing the outer ventral surface from the
underlying connective tissue. Once free, the cord was transferred to a
sterile 140 x 17mm tissue culture dish, and using a small pair of scissors, an
incision made down the length of the dorsal surface of the column on either
side of the spinous processes. The resulting strip of bone was removed
and the two halves of the column split by cutting along the midline on the
ventral surface. Treating each side separately, the overlying spinal cord
was removed with the aid of a binocular microscope and drg teased free by
grasping the dorsal root firmly between watchmaker's forceps (No. 7) and
cutting this root and the peripheral root as near to the drg as possible. Drg
were collected in F14 basic medium containing 4% USG, and freed of
connective tissue and remnants of dorsal roots. Typically, 40-45 drg were




10 x stock solutions: 5% Collagenase (Worthington, UK) in F14
medium containing 4% USG: 2.5% Trypsin (Worthington, UK) in F14
medium.
Stock solutions were stored in 400|il aliquots at -70°C.
Procedure
Cleaned drg were transferred to a laminar flow hood in a 35 x 15mm
dish and the medium removed with a sterile glass pipette. An aliquot of the
10 x stock collagenase was thawed, diluted 1:10 in F14 containing 4% USG
and filter sterilised. The drg were then placed in this solution and incubated
for 3h at 37°C. Following incubation, the drg and medium were removed
from the dish using a 10ml sterile disposable pipette and placed in a sterile
10ml tube. The drg quickly settled to the bottom of the tube and were
washed twice in 10ml F14 basic medium. An aliquot of 10 x stock trypsin
was diluted 1:10 in F14 basic medium and the drg incubated in this solution
for 30 min at 37°C. Following incubation, the drg were washed twice in
10ml F14 containing 4% USG and resuspended in 2ml of F14 containing
4% USG.
2.2.6.2 Trituration
The tip of a Pasteur pipette was fire-polished in a bunsen flame until
the orifice was typically between 0.5mm and 1mm in diameter (Lindsay,
1988). Digested drg contained in 2ml of F14 containing 4% USG were
taken up into the pipette and gently passed out. This procedure was
repeated until the majority of drg were dissociated, and a milky solution was
obtained.
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2.2.6.3 Neuronal enrichment and plating
The solution containing dissociated drg was diluted such that it was
contained in 4mls F14/4% USG for each rat that was dissected. Following
mixing in a pipette to produce a homogenous solution, 2ml of this solution
was added to an appropriate number of 60mm culture dishes precoated with
poly-ornithine. The solution was agitated to cover the whole plate and a
further 2ml F14 containing 4% USG added, before they were placed in the
incubator for between 15 and 20h (typically 18h).
Following incubation, the medium was removed, using a fire-polished
pipette attached to a Buchner vacuum pump, and the plates were washed
twice with 3ml F14/4% USG. The neurons which adhered loosely to the
plate were detached by a gentle stream of medium from a fire-polished
pipette and collected from each plate in 2ml F14 4% USG leaving the more
strongly adherent non-neuronal cells on the plate. Further purification was
achieved, due to the differential sedimentation of neurons and non-neuronal
cells, by centrifugation for 5 min at 680 x g. The supernatant was removed
and the pellet, containing the neurons, resuspended in 1ml of F14/4% USG.
Cells were counted in a haemocytometer and resuspended in F14/4% USG
to give a final concentration of between 3000 and 5000 cells per 80pl
medium. The solution was gently mixed to ensure the cells were evenly
distributed and the cells plated onto laminin-coated 35mm 4 well dishes.
80|il was added to each well, and the plates transferred to the incubator for
3-4h to allow the cells to adhere. Following this settling period, the plates
were flooded with medium to a final volume of 2.5ml. Medium was
supplemented with cis 4-OH proline (25p.l, stock solution to final
concentration 200|ig/ml) to inhibit non-neuronal cell proliferation, and was
changed every two days.
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2.2.7 Sample extraction
The samples were removed from the wells in 2M acetic acid. The
medium was aspirated from the plates, 60p.l 2M acetic acid added to each
well, the bottom of the well scraped with a pipette tip and the plates
incubated for 30 min at 37°C. The solution was removed, collected in
Eppendorf tubes and centrifuged for 5 min at 16000g in an Eppendorf bench




Radioimmunoassay (RIA) is a well-established technique used in
many laboratories throughout the world to measure the concentrations in
blood, tissues and other fluids of peptide and non-peptide hormones, steroid
hormones, drugs and other substances of biological interest. The method
can be expeditious, highly sensitive and relatively specific. RIA is based on
a concept developed in the late 1950s by Yalow & Berson to measure
insulin in the plasma of patients (Yalow & Berson, 1960). Independently,
around the same period, Ekins (1960) developed a method for measuring
serum thyroxine levels based on the same principles as RIA, but relying on
the naturally occurring binding protein thyroxine binding globulin rather than
an antibody as the specific reagent in this 'saturation assay method'.
The principles underlying RIA are relatively simple, based on the law
of Mass Action. The concentration of an unknown sample is obtained by
comparing its inhibitory effect on the binding of radioactively labelled
antigen or tracer to a specific antibody with that of a series of known,
standard concentrations of antigen (see Ekins, 1974; Yalow, 1980).
In order that the binding characteristics of both standards and
unknown are the same, the solutions should be identical in all respects,
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excepting the concentration of ligand. In practice, this is not always
achieved, as it is not possible to produce, synthetically, the environment of
tissue extract, and consequently non-specific effects must be considered. If
the standard curve is parallel to a dilution curve of sample extract, this is
usually considered sufficient indication that the binding characteristics of
both standard and sample solutions are similar under the assay conditions.
Non-specific binding of the antibody may also produce specious
results. Clearly a tissue extract contains a large number of proteins and
peptides and it is possible the antibody may have low affinity for one or more
of these non-specific ligands. This non-specific binding is detectable by a
departure from parallelism between the standard curve and a dilution curve
of sample. Figs.2, 2 and 2.5 show the parallelism between standard
dilution curves and sample dilution curves for the SS, SP and CGRP RIAs
used. In addition, the cross-reactivity of each assay for the other two
ligands was determined.
2.3.1.2 Preparation of Antisera
Antibodies are produced in an animal when the cells of the immune
system encounter a foreign compound, be it protein, polysaccharide or DNA.
Generally, a molecule only stimulates an immune response if it is over
10,000 daltons in molecular weight. However, many compounds of interest,
including SS, CGRP and SP, are less than this minimum weight. In order to
raise antisera to smaller molecules, they first have to be coupled to a larger
molecule known as a carrier protein.
2.3.1.3 Antisera
The anti-SS and anti-SP antisera were raised by Dr. A.J. Harmar and
Dr. P. Keen in Bristol (Harmar & Keen, 1976), using a method based on that
described by Carraway & Leeman (1976) for raising antisera against
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neurotensin. SP and SS both have molecular weight below 10,000 daltons
and thus were conjugated to succinylated thyroglobulin. Forty milligrams of
bovine thyroglobulin (Sigma, UK) was dissolved in 8ml 0.15M NaCI, and the
pH adjusted to 7 with Na2CC>3. Over the space of 1 h, 80mg of solid succinic
anhydride was added to this solution with the pH being maintained at 7 by
further addition of Na2C03. The solutions reacted for a further 30 min and
were then dialysed against distilled water and lyophilised. For conjugation
of peptides, 20mg of the succinylated thyroglobulin was dissolved in 1ml of
0.1 M phosphate buffer pH 7.4 and 10mg SP or 10mg SS-14 (UCB
Bioproducts, Belgium) was added. The reaction was achieved by the
dropwise addition of 10mg 1-ethyl-3-(3-dimethylamino-propyl)
carbodiimide-HCI (Sigma, UK: 20mg/ml in phosphate buffer, pH 7.4). This
mixture was kept in the dark and stirred for 20h, dialysed for 48h against
distilled water, and lyophilised.
To raise antisera using the resultant conjugates, the lyophilisate was
suspended in 4.5ml 0.15M NaCI and emulsified with a further 4.5ml
Freund's complete adjuvant supplemented with heat-killed tubercle bacilli
(5mg/ml, Difco, USA). Two millilitres of the immunogen was administered
by multiple intradermal injections to each of four New Zealand white rabbits
together with a single s.c. injection of pertussis vaccine (Difco; 0.5ml).
Following a booster injection 6 weeks later of a further 2ml immunogen, the
animals were bled from the ear vein at 10-14 day intervals. The anti-SS
antiserum and the anti-SP antiserum used in this thesis were obtained from
single animals respectively seven and eight weeks after the booster dose.
2.3.1.3 lodination
A number of methods are available for the radioiodination of peptides
and proteins, which can be divided into direct methods in which 125l is
incorporated directly into tyrosine and/or histidine residues, and conjugation
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methods in which a radioiodinated moiety is conjugated to a specific side
chain usually £-NH2 groups of lysine residues or at the N-terminus. Whilst
conjugation is more complex, it has the advantage that it can be used to
label peptides that do not contain tyrosine residues.
The most widely used method of iodination is the chloramine-T
oxidation of Na125l in the presence of the protein or peptide to be labelled
(Greenwood & Hunter, 1962). This results in incorporation of125 I into the
tyrosine residues in high yield but, unfortunately, the presence of oxidising
agents can also damage the peptide. Whilst peptide damage can be
reduced by addition of a reducing agent such as sodium metabisulphite to
remove excess chloramine-T, the use of a solid phase oxidising agent is
more satisfactory. 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoturil (lodogen,
Fraker & Speck, 1978) is coated onto the surface of the reaction vessel and
iodination affected by the addition of Na125l and peptide solution. A further,
more gentle, method was first described by Marchalonais (1969) in which
iodination of peptide is catalysed by lactoperoxidase in the presence of
small amounts of hydrogen peroxide.
2.3.2 Radioimmunoassay for Somatostatin
2.3.2.1 Buffers
The standard assay buffer consisted of 0.1 M sodium phosphate pH
7.4 with 0.15% w/v BSA. Antiserum buffer comprised 0.1 M sodium
phosphate, pH 7.0, 0.1% w/v BSA, 0.1% w/v Triton X-100, 250KIU/ml
Trasylol (Bayer).
2.3.2.2 Standard Curve
A stock solution of SS-14 (Peninsula) of 10jig/ml in 0.1M acetic acid,
0.1 % w/v BSA was prepared and stored at -40°C. Aliquots of the stock
solution were evaporated to dryness, resuspended in assay buffer and a
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series of dilutions in assay buffer, prepared in duplicate, of 10, 20, 35, 50,
70, 100, 140 and 200pg/ml in 100pl volume. The standard curve was
constructed by an on-line computer using a best fitting linear regression
programme and a log-logit transformation. Unknowns were compared
automatically by the computer (see Fig. 2.1).
2.3.2.3 Primary Antibody
The antibody was raised in rabbit against SS-14 conjugated to
succinylated bovine thyroglobulin (Harmar & Keen, 1976). Stock antiserum
was kept at -40°C and diluted to 1/200000th strength in antiserum buffer and
10Opil added to all assay tubes except total counts and non-specific binding
tubes.
2.3.2.4 Labelled Antigen
Antigen was labelled using the iodogen method (Fraker & Speck,
1978). lodogen (diphenyglycoturil) was coated onto the surface of the
reaction vessel and iodination affected by the addition of Na125l and peptide
solution. The reaction was stopped by dilution with 0.05M sodium
phosphate and potassium iodide to the mixture.
Solutions
Tyr° SS-14 - Peninsula, 0.25mg/ml in 5mM phosphate buffer, pH 7.4
Na125l - Amersham (1 MS 30): 3.7GBq/ml
lodogen - 40pg/ml in dichloromethane
Phosphate buffer - 0.05M pH 7.4
Kl - 10pg/ml in aqueous 0.2% v/v TFA
Method:
50jlxI lodogen was evaporated to dryness under nitrogen in a
polypropylene reaction vessel. 5|ig Tyr° SS-14 (20pl of stock solution) and
10pil (1mCi) Na125l were added, mixed and allowed to react for 10 min.
Figure 2.1 Graph showing a typical computed standard dilution
curve for SS-14. The dilution curve of SS content of













The reaction was interrupted by addition of 200|il 0.05M phosphate buffer
and 500pl Kl solution. Labelled peptide was then separated from
unreacted iodide and peptide by HPLC (Harmar & Rosie, 1984). The
chromatography system comprised a two-channel minipump (Milton Roy
Co., Riviera Beach, Fl., USA) connected in series to a sample injection valve
with a 1ml loop (Rheodyne Berkeley, CA, USA) and a guard column holder
(Brownlee MPLC Cartridge system: Brownlee Labs, Santa Clara, CA, USA).
Usually, a 3cm x 0.46cm disposable column of cyanopropyl silica (Spheri 5
cyano: Brownlee Labs) was used, although in some cases a similar sized
column of C-|8 silica (RP-18 Spheri 5: Brownlee Labs) was used with
comparable results. The two channels were primed respectively with 0.2%
aqueous TFA (solvent A) and 0.2% TFA in methanol (solvent B). Following
equilibration of the column with solvent A, the iodination mixture was loaded
and eluted with a stepwise gradient of solvent B from 0%-100%. The flow
rate was 1 ml/min and six fractions of 1 ml were collected at each step in the
gradient. The elution profile of 125l-labelled Tyr° SS-14 which eluted in
60% methanol is shown in Figure 2.2. Fractions 16 and 17 were combined
in a further 2ml of 0.2% TFA in methanol and stored at -70°C prior to use for
RIA.
2.3.2.5 Second Antibody
Bound, labelled antigen was separated from unbound labelled
antigen by precipitation using donkey anti-rabbit gamma globulin (ARGG;
Scottish Antibody Production Unit, Carluke; SAPU). 10Opil ARGG in assay
buffer (1:10 dilution) was added and to reduce background binding 10Opil
normal rabbit serum (1:100 NRS; SAPU) was added.
Figure 2.2 Typical elution profile of 125l-labelled Tyr° SS-14 from
a 30 x 4.6mm cyanopropyl silica column with
increasing methanol concentration. Fractions 16 and




































Assay tubes received 1.5ml of assay buffer before centrifugation to
reduce slippage of the precipitate caused by the previous addition of Triton-
X-100 in the antiserum buffer.
2.3.2.7 Quality Control
Pools were added at the start and end of assays to serve as
indicators of intra assay consistency and for comparison between assays.
The pools were derived from previously assayed tissue samples and
contained 30pg/ml and 140pg/ml respectively. For larger assays, additional
pools were placed in the middle of the assay. The inter-assay CoV was <
20%, and intra-assay CoV was < 10%.
2.3.2.8 Cross-Reactivity
SS assay did not cross-react with CGRP (<0.1 %) or SP (<0.01 %) at
the highest concentrations tested. The anti-SS serum was reportedly
directed against the C-terminal or central portion of the SS-14 molecule as
SS-28 and SS-25 are equipotent in displacing [125l-Tyr°] SS-14 from the
antiserum (Harmar & Keen, 1986).
2.3.2.9 Assay Procedure
Day 1:
Samples in 2M acetic acid were evaporated to dryness in polystyrene
RIA tubes (Luckham) in a vacuum oven (45°C, 700mm Hg) and
resuspended in 240pl assay buffer. Duplicate samples of 10Opil were
prepared and 10Opil of antiserum in antiserum buffer was added to
unknowns, standards and residual binding tubes. Tubes for total counts
received no solution and those for non-specific binding were given 100pl
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assay buffer and 100jil antiserum buffers. The tubes were vortexed and
incubated at 4°C overnight (minimum 16h).
Day 2:
100ja.l of [125l] Tyr° SS-14 diluted in antiserum buffer containing
5000cpm was added, vortexed and incubated at 4°C for a minimum 16h.
Day 3:
100fj.l ARGG and NRS was added, vortexed and the assay tubes
incubated at 4°C overnight.
Day 4:
All tubes, except for the total counts tubes, received 1.5ml assay
buffer and were centrifuged at 1,720 x g for 45 mins at 4°C. The
supernatant was aspirated from the tube and the radioactivity remaining in
the pellet was determined by counting in a gamma counter for 3 min.
2.3.3 Radioimmunoassay for Substance P
2.3.3.1 Buffers
The standard assay buffer consisted of 0.05M Na2 HPO4,
0.05M KH2 PO4, 0.14M NaCI, 0.05% w/v NaN3, 0.1% w/v gelatin at pH 7.4.
2.3.3.2 Standard Curve
A stock solution of SP (Peninsula, 100pg/ml) in 0.2% aqueous TFA
was prepared and stored at -40°C. Aliquots of this stock solution were
evaporated to dryness, resuspended in assay buffer and a series of dilutions
of 25, 50, 100, 250, 500, 1000, 2000 and 5000pg/ml in 200pl volume
prepared in duplicate. The standard curve was constructed by an on-line
computer using a best fit linear regression programme and a log-logit
transformation. Unknowns were compared to the standard curve by the
computer and expressed in pg/ml (see Fig. 2.3).
Figure 2.3 Graph of a typical standard dilution curve of SP. The



















The antibody was raised in rabbit against SP conjugated to
succinylated bovine thyroglobulin (Harmar & Keen, 1976). Stock
antiserum was kept at -40°C and diluted 1:60000 in assay buffer. 100pl
was added to all assay tubes except the total counts and non-specific
binding tubes.
2.3.3.4 Labelled antigen
Tyr8 SP (Peninsula) was labelled using the iodogen method (Fraker
& Speck, 1978).
Solutions
Tyr8 SP - Peninsula, 500pg/ml in 0.5M Na2 PO4, pH 7.4
Na125l - Amersham 1 MS 30: 3.7 G.Bq/ml
lodogen - 40pg/ml in dichloromethane
Trifluoracetic acid - 0.2% aqueous
Method:
50pl of iodogen was evaporated to dryness under nitrogen in a
polypropylene reaction vessel. 5pg Tyr8 SP (10pl of stock solution) and
10(il (1mCi) Na125l were added, mixed and allowed to react for 10 min at
room temperature. The reaction was stopped by addition of 750|il, 0.2%
aqueous trifluoroacetic acid. Unreacted iodide and peptide was removed
by HPLC from the labelled peptide using FIPLC as described in the
iodination of SS-14 above. Briefly, the reaction mixture was loaded onto a
30mm x 4.6mm column of cyanopropyl silica and eluted with trifluoroacetic
acid containing increasing amounts of methanol. The elution profile is
shown in Fig 1.4; fractions 24 and 25 were pooled, diluted in a further 2ml of
0.2% TFA in methanol and stored at -70°C, prior to use for RIA.
Figure 2.4 Typical elution profile of 125l-labelled Tyr8 SP from a
30 x 4.6mm cyanopropyl silica column, with increasing
methanol concentration. Fractions 24 and 25 were
pooled, diluted in a further 2ml of 0.2% TFA in




















































Bound, labelled antigen was separated from unbound by
precipitation using ARGG. 500|il of assay buffer containing NRS (1:1000
dilution) and ARGG (1:100 dilution) were added to all tubes except the total
counts.
2.3.3.6 Quality Control
Pools were placed at the beginnings and ends of assays, and for
larger assays, pools were added to the middle of the assay. The pools
used were old standards and contained 70pg/ml and 800pg/ml respectively.
Interassay CoV was <20% and intra-assay CoV was <10%.
2.3.3.7 Cross-Reactivity
The assay did not cross-react with SS-14 (<0.02%) or CGRP (<0.1 %)
at the highest concentrations tested (see Fig. 2.3). The anti-SP antiserum
was reported to be specific for the C-terminal 5 amino acids of the SP
sequence. SP free acid, lacking the C-terminal carboxamide has negligible




Samples in acetic acid were evaporated to dryness as for the SS
assay and resuspended in assay buffer. 200(il aliquots of sample or
standard were added to 100pl of antiserum, the tube mixed and incubated
overnight at 4°C. Samples and standards were prepared in duplicate.
Tubes for total counts received no solution and those for non-specific
binding were given 300pl assay buffer.
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Day 2:
100(j.l of labelled antigen in assay buffer was added to all tubes, the
solutions mixed and incubated overnight at 4°C.
Day 3:
500jj.I of ARGG and NRS was added to all tubes except total counts,
the tubes were mixed and incubated overnight at 4°C.
Day 4:
All tubes except the total counts were centrifuged at 4°C for 30 min at
1720 x g and the supernatants aspirated to leave the precipitate. The
radioactivity in the pellet was counted for 3 min in a gamma counter.
2.3.4 RADIOIMMUNOASSAY FOR CGRP
2.3.4.1 Buffers
The standard assay buffer was 0.05M sodium phosphate, 0.05M
sodium EDTA, 0.3% w/v BSA.
2.3.4.2 Standard Curve
A stock solution of rat CGRP (Peninsula) in 0.1 M acetic acid
(200pg/ml) was prepared and stored at -40°C. From this stock, aliquots
were dried down and standards prepared in duplicate, of 25, 50, 100, 250,
500, 1000, 2500 and 5000pg/ml in 200pl assay buffer. A standard curve
was computed by the on-line computer, using a best fit linear regression
programme and a log-logit transformation. Unknowns were compared to
the standard curve by the computer and reported in pg/ml (see Fig. 2.5).
2.3.4.3 Primary Antibody
A commercial antiserum raised in rabbit against human CGRP was
purchased (Amersham International, UK) as a lyophilised powder and
stored at -40°C until required. Prior to use, the powder was resuspended in
Figure 2.5 Typical standard dilution curve of CGRP. The dilution













2ml assay buffer and further diluted to 1/ioth stock in assay buffer. 100|il
was added to each assay tube.
2.3.4.4 Labelled Antigen
Labelled human CGRP (2-[125l] iodohistidyl10 CGRP of specific
activity 74 TBq/mmol) was purchased from Amersham International in a
10pCi lyophilisate. This was reconstituted in "lOOpI distilled water and
diluted in assay buffer such that 100|il contained 5000cpm. 100pl was
added to each tube.
2.3.4.5 Second Antibody
Separation of bound label from unbound was facilitated by use of
ARGG (1:20 dilution) in assay buffer; 300pl was added to each tube. 300pl
of NRS (1:800 dilution) was also added.
2.3.4.6 Quality Control
For comparison between assays and monitoring of intra-assay
consistency pools were placed within the assay. Pools consisted of
aliquots of a stock solution of rat drg homogenised in 2M acetic acid and
contained 670pg/ml and 7400pg/ml, respectively. Interassay CoV was
< 20% and interassay CoV was < 10%.
2.3.4.7 Cross-Reactivity
The antiserum was raised against human CGRP and was reported to
cross-react only 30% with the rat sequence. At the highest concentrations




Samples in acetic acid were dried down as for the SS assay and
resuspended in assay buffer. 200jil aliquots of sample or standard were
added to 10Optl of antiserum. The tubes were mixed and incubated
overnight at 4°C.
Day 2:
100|il of labelled antigen in assay buffer was added, the solutions
mixed, and incubated overnight at 4°C.
Day 3:
300pl ARGG was added, followed by 300pl NRS. The tubes were
mixed and incubated overnight at 4°C.
Day 4:
All tubes, except the total counts, were centrifuged at 1,720 x g for 30
mins at 4°C and the supernatants aspirated to leave the precipitate. The
radioactivity contained in the precipitates was determined by counting in a
gamma counter for 3 min.
2.3.5 Radioimmunoassay for acth
2.3.5.1 Buffers
Stock buffer for ACTH assay consisted of 0.05M Na2HPC>4, 13mM
Na2 EDTA, 0.02% w/v NaN3 and 200KIU/ml of trasylol, pH 7.4-7.6
2.3.5.2 Standard Curve
A stock solution of human ACTH (Peninsula, 500p.g/ml) in 0.1 M acetic
acid was prepared and stored at -40°C. Aliquots of this stock were
evaporated to dryness and resuspended in stock buffer containing 3.5%
BSA. A standard curve was constructed from duplicates containing 5, 10,
20, 50, 100, 200, and 500pg/ml ACTH. The curve was computed by an on-










line computer using a best fitting linear regression programme and a log-
logit transformation (see Fig. 2.6).
2.3.5.3 Primary Antibody
The antiserum, raised against human ACTH1-24, was purchased as a
lyophilised powder (IgG Corporation, USA), reconstituted in 1ml of stock
buffer containing 1% v/v NRS (SAPU) and stored at -40°C. Before use, this
stock was further diluted in stock buffer and used at a final dilution of 1:6300.
The antiserum cross-reacted 100% with rat ACTH.
2.3.5.4 Labelled Antigen
lodinated human ACTH1.39 (3-[125l]iodotyrosyl25) was purchased
from Amersham International (UK) with specific activity 74TBq/mmol, and
diluted in stock buffer containing 0.1% Triton-X-100 such that 100pl
contained lOOOOcpm.
2.3.5.5 Secondary Antibody
The bound labelled antigen was separated from the unbound by
precipitation with ARGG. 100pl of a 1:5 dilution in stock buffer containing
0.1% Triton-X-100 was added to all tubes except total counts.
2.3.5.6 Quality Control
Pools of rat plasma samples were added to the beginning and end of
each assay for comparison between assays and as a measure of the
consistency of conditions within the assay. Pools consisted of previously





Plasma samples were aliquoted and made up to 100jil with stock
buffer containing 3.5% w/v BSA. 100pl antiserum was added and the tubes
incubated overnight at room temperature.
Day 2 (a.m.):
100pl labelled antigen in stock buffer containing 0.1% v/v Triton-X-
100 was added and incubated for 7 hours at room temperature.
Day 2 (p.m.):
100(il ARGG containing 0.1% v/v Triton-X-100 was added.
Day 3:
1,6ml of stock buffer was added to each tube (except total counts) and
the tubes centrifuged at 1,720 x g for 30 min at 4°C. The supernatant was
aspirated and the precipitate counted in a gamma counter.
2.3.6 Radioimmunoassay for corticosterone
2.3.6.1 Assay Buffer
The standard assay buffer contained 0.1 M disodium citrate: 0.2%
gelatin w/v at pH 4.0. This was produced using the following protocol.
21,0g of citric acid was dissolved in 200ml 1M NaOH and diluted to 11 with
distilled water. To 200mls of this solution gelatin (2g) and thimerosal (0.2g)
was added and dissolved with heating. Once dissolved, this was added to
the remainder of the citric acid solution and was called solution A. 558mls
of solution A was then added to 442mls of 0.1 M HCI to give the final buffer at
pH 4.0.
2.3.6.2 Standard Curve
Standards containing 0, 500, 1000, 2500, 5000, 10000, 20000 and
40000pg/ml corticosterone were prepared from a solution of corticosterone
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in ethanol, evaporated to dryness and reconstituted in charcoal-stripped
plasma. They were mixed and allowed to stand at room temperature for 30
min, and 5pl aliquots taken in duplicate. The stock solution and prepared
standards were stored at -40°C. The standard curve was constructed by an
on-line computer using a best fitting linear regression programme and a log-
logit transformation. Unknowns were compared automatically by the
computer to the standard curve (see Fig. 2.7).
2.3.6.3 Primary Antibody
The antiserum, raised in rabbit against Corticosterone-21-hemi-
succinate conjugated to BSA was a kind gift of A. Watts. The antiserum was
diluted 1:200 in assay buffer and 500pl added.
2.3.6.4 Labelled Antigen
[1,2,6,7-3H] corticosterone with specific activity 2.78 TBq/mol was
purchased from Amersham International (UK) and diluted in assay buffer
such that 10Opil contained "lOOOOcpm. 10Opil was added to each tube.
2.3.6.5 Second Antibody
The bound labelled antigen was precipitated using ARGG. 500pl of
assay buffer containing 1:100 dilution of ARGG and 1:1000 dilution of NRS
was added and incubated overnight at 4°C.
2.3.6.6 Preparation of Samples for Counting
After incubation for at least 16h, the assay tubes were centrifuged at
1720g for 45 min and the supernatant aspirated, leaving the pellet. The
pellet was reconstituted in 1ml of 1mM HCI, the solution transferred to
counting vials and allowed to stand for 4h. Scintillant was added to each

































vial (4.5mls Aquasafe, Packard) and the radioactivity determined in a p
counter by counting for 10 mins.
2.3.6.7 Quality Control
Rat plasma sample pools containing 50ng/ml and 250ng/ml B were
added to the start and end of each assay.
2.3.6.8 Assay Procedure
Day 1:
lOOOOcpm of [1,2,6,7-3H] corticosterone in 100(il assay buffer, and
500pl of 1:200 dilution in assay buffer of antiserum was added to 5p!
plasma, mixed and incubated overnight at 4°C.
Day 2:
500|il of assay buffer containing ARGG and NRS was added, the
tubes mixed and incubated overnight at 4°C.
Day 3:
Tubes were centrifuged at 1720g at 4°C for 45 min and the
supernatant aspirated. The pellet was reconstituted in 1 ml of 1 mM HCI and
transferred to a counting vial. After standing for 4h, 4.5ml aquasafe
scintillant (Packard) was added and tubes were counted for 10 min in a p
counter.
2.3.7 Radioimmunoassay for testosterone
2.3.7.1 Buffers
The standard assay buffer consisted of 0.05M Na2HPC>4, 0.05M
KH2PO4, 0.14M NaCI, 0.05% v/v NaN3, 0.1% w/v gelatin, pH 7.4.
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2.3.7.2 Standard Curve
Aliquots of a stock solution of testosterone (100pg/ml in ethanol,
Sigma, UK) were evaporated to dryness and reconstituted in assay buffer.
Standards containing 50, 100, 200, 500, 1000, 2000 and 5000pg/ml
testosterone in 100pl assay buffer were prepared in duplicate. The
standard curve was constructed by an on-line computer using a best fit
linear regression programme and a log-logit transformation. Unknowns
were compared with the standard curve automatically by the computer (see
Fig. 2.8).
2.3.7.3 Primary Antibody
Antiserum raised in rabbit against Testosterone 19-carboxymethyl
ether conjugated to BSA was purchased from Radioimmunoassay Systems
Laboratories Inc. (USA) and used at a dilution of 1:800,000 in assay buffer.
2.3.7.4 Labelled Antigen
[1,2,6,7-3H] testosterone (Amersham, International UK) with specific
activity 3.63 TBq/mmol was used and diluted in assay buffer. 100pl,
containing 5000cpm was added to each assay tube.
2.3.7.5 Second Antibody
Bound labelled antigen was separated from unbound by precipitation
with ARGG. 500pl of a solution containing ARGG (1:10 dilution) and NRS
(1:100 dilution) in assay buffer was used.
The precipitate was pelleted by centrifugation at 2370 x g for 30 min
and the supernatant aspirated to leave the pellet. The pellet was
reconstituted in 1 ml of 1 mM HCI transferred to a counting vial and left to
stand for 30 min. To this, 4.5ml of aquasafe scintillant (Packard) was
added, and samples counted for 5 min in a p counter.


























Rat plasma sample pools containing 0.8ng/ml, 1.8ng/ml and 6ng/ml
testosterone were placed at the beginning and end of the assay.
2.3.7.7 Assay Procedure
Day 1:
20pl of plasma samples were extracted twice in 1ml of diethyl ether.
The aqueous phase was evaporated to dryness and reconstituted in 10Opil
assay buffer. 500(il of a 1:800000 dilution of antiserum in assay buffer and
5000cpm of [1,2,6,7-3H] testosterone in 10Optl assay buffer was added,
mixed and incubated overnight at 4°C.
Day 2:
500|il of assay buffer containing ARGG and NRS was added, the
tubes vortexed and incubated at 4°C for 16h.
Day 3:
The assay tubes were centrifuged at 1720g for 30 min, the
supernatant aspirated off and the pellet redissolved in 1ml of 1mM HCI and
the solution transferred to scintillation vials. After standing for 30 min,
4.5mls aquasafe scintillant (Packard) were added and the vials counted in a
P counter for 5 min.
CHAPTER 3
THE EFFECT OF ADRENALECTOMY AND CORTICOSTEROIDS ON SP, SS
AND CGRP CONTENT OF DRG OF RAT
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3.1 INTRODUCTION
Adrenal steroids are synthesised from cholesterol in the zona
reticularis of the adrenal gland. In the rat corticosterone (B) forms the major
component and is transported to target tissues in the blood bound to
transcortin. Corticosteroids bind to one of two types of intracellular receptor:
(i) the Type I receptor (K<j ~0.5nM for B) which binds aldosterone and B with
equal affinity but both with much greater affinity than dexamethasone (DEX),
and (ii) the Type II receptor (Kd ~2.5-5nM for B) which binds DEX with
greater affinity than aldosterone or B (Reul & de Kloet, 1985). However,
circulating levels of B are much greater than aldosterone, yet binding studies
using [3H]-B and [3H]-aldosterone indicate that in some tissues (e.g., kidney,
parotid gland and colon), the physiological ligand for type I receptors is
aldosterone (Sheppard & Funder, 1982). Given the equal affinity of type I
receptors for B and aldosterone in the presence of excess B, some
additional mechanism must operate to allow selective mineralocorticoid
action. There is considerable evidence to suggest that in mineralocorticoid
target tissues the presence of the enzyme 11-p hydroxysteroid
dehydrogenase serves to limit the access of B to type I receptors (Edwards
et al., 1988; Funder et al., 1988). The 11-(3 steroid metabolite produced by
the enzyme has been shown to have considerably lower affinity for both
Type I and Type II receptors (Funder et al., 1988) and inhibition of enzyme
activity enhances the in vivo uptake of B in the rat kidney (Funder et al.,
1988; Edwards et al., 1988). Using in situ hybridisation histochemistry, in
collaboration with Dr. J. Seckl, I have previously demonstrated the presence
of mRNA for both types of receptor in drg (Seckl et al., unpublished
observations).
Plasma corticosteroid concentration is regulated in a negative
feedback loop involving adrenocorticotrophin (ACTH), corticotrophin
releasing factor (CRF) and arginine vasopressin (AVP). Stimuli promoting
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the secretion of corticosterone elicit release of CRF from the hypothalamus
which, in turn, mediates the secretion of ACTH from the anterior pituitary
gland. AVP potentiates the release of ACTH by CRF. ACTH stimulates
synthesis and secretion of corticosteroid by the adrenal cortex, and this then
acts to inhibit the secretion of ACTH (see Williams & Foster, 1985).
Following adrenalectomy (ADX) both AVP peptide content and mRNA
in the paraventricular nucleus (PVN) are increased, and in the
suprachiasmatic nucleus (SCN) peptide and message content are
decreased (see McEwen et al., 1986). In the parvocellular population of the
PVN, AVP is colocalised with CRF peptide which is also increased following
ADX. CRF is also colocalised with enkephalin and neurotensin in the PVN,
but the immunostaining for these peptides does not change following ADX.
DEX reverses the effects of ADX on CRF in the PVN of long term
adrenalectomised rats, but mineralocorticoids are ineffective. CRF receptor
numbers also decrease in the anterior pituitary (AP) following ADX, but are
unchanged in the cortex and limbic system (Wynn et al., 1984; Sawchenko
et al., 1984).
In the adrenal cortex, ACTH binds to specific, high affinity,
membrane-bound receptors to increase intracellular c-AMP and activate a
number of c-AMP-dependent protein kinases. Following binding of ACTH to
its receptor in the adrenal cortex, a rapid increase in the biosynthesis of
pregnenolone (an intermediate in the biosynthesis of B) from cholesterol
precursor occurs, which subsequently leads to increased biosynthesis of B.
In addition to these acute effects of ACTH, chronic treatment of adrenal cells
with ACTH leads to increased synthesis of steroidogenic enzymes which
also enhances corticosteroid biosynthesis (see Simpson & Waterman,
1983).
ACTH is a product of the proopiomelanocortin (POMC) gene which in
the AP also encodes (5-endorphin; in the intermediate lobe, tissue specific
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splicing of the primary transcript produces mRNA encoding a melanocyte
stimulating hormone, corticotropin-like intermediate lobe peptide, y-
lipotropin and (3- endorphin. Following bilateral ADX, there is a rapid and
substantial rise in plasma ACTH, which is accompanied some 6-8 hours
later by stimulation of transcription of POMC mRNA in cells of the AP. This
lag in stimulation results in an initial depletion of pituitary ACTH peptide
content, but subsequently, some 10 days later a new steady state is
achieved in which pituitary ACTH is elevated 3-5 fold greater than in sham-
operated animals. In addition, the percentage of AP cells immunoreactive
for ACTH doubles, pituitary POMC mRNA levels are increased 2-3 fold and
plasma ACTH levels are considerably increased following chronic bilateral
ADX (Dallman et al., 1987).
Glucocorticoids have been found to regulate other neuropeptides.
Thus, immunostaining for angiotensinogen, the precursor of angiotensin I
and II, found in the preoptic area (POA), AP, periaqueductal grey matter and
area postrema is decreased following ADX (Wallis & Printz, 1980).
Following ADX and colchicine treatment of rats, angiotensin II
immunoreactivity is enhanced in the same population of parvocellular
neurons that contain CRF (Lind et al., 1984). In the hippocampus, VIP
immunoreactivity is decreased following ADX; this effect is reversed by DEX
and B (Rotsztejnet et al., 1980). Finally, in rat striatum the expression of
preproenkephalin mRNA is decreased following ADX (Chao & McEwen,
1990) and PPT mRNA expression is increased (Chao & McEwen, 1991).
Regulation of SS and CGRP by glucocorticoids has been investigated
in vitro, in a variety of cell lines. In the rat 44-2C cell line (derived from
thyroid C cells) SS content is elevated but CGRP specific mRNA is
significantly reduced by DEX (Zeytin & Delellis 1987; Zeytin et al., 1987). In
contrast, administration of DEX potently inhibits SS production in TT cells
(human medullary thyroid carcinoma cells; Cote et al., 1986), but increases
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production of CGRP-specific mRNA (Cote & Gagel, 1986). In the CNS, ADX
does not alter SS content of the hypothalamus, cortex, striatum or
hippocampus, however SS binding is decreased in hypothalamus,
hippocampus and striatum, but not cerebral cortex following ADX (Rodriguez
et al., 1988).
In the introduction to this thesis, I have discussed neuropeptides in
the drg and their putative role in the transmission of pain and neurogenic
inflammation, processes which can both be influenced by corticosteroids. It
is not known if the analgesic and anti-inflammatory actions of glucocorticoids
involve regulation of SP, SS or CGRP in the drg, however, corticosteroids
have been found to regulate axonal transport of SP and SS in the sensory
vagus nerve (MacLean, 1987). As a measure of neuropeptide transport the
vagus nerve of male rats was ligated unilaterally and 24 hours later the
neuropeptide content of 3mm sections of nerve on either side of the ligation
determined by RIA. It was found that daily administration of ACTH for 14
days significantly reduced SP accumulation in the nerve proximal to the site
of ligation compared to untreated controls. No difference in SP content of
the unligated nerve between ACTH treated and untreated animals was
found. However, administration of B over the same time period reduced the
accumulation of SP proximal to the ligation. In contrast, ADX increased
both SP transport in the ligated nerve and SP content of unligated nerve by
approximately 20%. SS transport was also regulated by corticosteroids;
following administration of B to supraphysiological levels over two weeks
axonal transport of SS increased, but administration of supraphysiological
amounts of ACTH or ADX was without effect on SS transport.
A direct relationship between SP axonal transport and SP synthesis
in the vagus nerve has been demonstrated previously using studies of
ligation and 35S methionine incorporation into SP, subsequently identified
by HPLC and immunoprecipitation (MacLean, 1987a; MacLean & Lewis,
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1984). Consequently, the observation of increased SP axonal transport
following ADX probably reflects an increase in SP synthesis in the ganglion.
In addition, whilst SS axonal transport in the vagus is unaltered following
ADX, supraphysiological levels of B increases axonal transport of SS and
thus, there would appear to be a reciprocal regulation of SS and SP by
corticosteroids in the vagus.
Given the presence of mRNA for both types of corticosteroid receptors
in the drg, and the role of these steroids in the regulation of neuropeptide
gene expression, biosynthesis and transport, I have examined the role of
corticosteroids in the regulation of neuropeptide content of the drg.
3.2 METHODS
Ham Wistar rats (male, 200g) were adrenalectomised or sham
operated under halothane anaesthesia using the two step method described
previously (Chapter 2). Animals were allowed to recover and five, ten or
thirty days after ADX, were killed by rapid decapitation, and trunk blood
samples collected on ice for determination of plasma B and ACTH by RIA
(see Chapter 2). Drg from cervical level C4, C5, C6 and C7 were collected
and SP, SS or CGRP content determined by RIA as described (Chapter 2).
Experiments investigating the time course of any effects of ADX on
neuropeptide content of cervical drg, and the role of glucocorticoids and
mineralocorticoids in these actions were performed.
To examine the time course, animals were adrenalectomised or sham
operated and implanted subcutaneously with 200mg pellets of wax or
containing 50% B (Sigma, UK)/cholesterol (Sigma, UK); pellets were
inserted under halothane anaesthesia subdermally in the scruff of the neck,
and replaced after fifteen days. Five, ten and thirty days after surgery,
animals were killed by rapid decapitation, drg dissected and SP and SS
content determined. Contents were expressed in pg/ganglion and given as
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mean ± S.E.M. Results were analysed by ANOVA followed by Duncan's
Multiple Range Test for post hoc comparison.
Having established the optimum period over which to examine the
effects of ADX on neuropeptides, the role of mineralocorticoids and
glucocorticoids were examined using B (Sigma, UK), DEX (Sigma, UK) and
the specific antiglucocorticoid RU38486 (Roussel, France). Animals were
adrenalectomised or sham operated, and received daily s.c. injection of DEX
(0.2mg/kg), B (2.5mg/kg) or RU38486 (10mg/kg) in sesame oil vehicle.
Sham operated controls and one group of adrenalectomised animals
received daily s.c. injection of vehicle. Ten days after surgery, animals were
killed and plasma samples and drg collected as previously. Mean SP, SS
and CGRP contents (pg/ganglion) of C4, C5, C6 and C7 drg, were
determined by RIA, results pooled, and expressed as a percentage of that of
sham operated controls. Results were analysed as above.
3.3 RESULTS
3.3.1 Time Course
The plasma B and ACTH concentrations following sham operation,
ADX or pellet replacement are given in Table 3.1. Plasma B of animals
following ADX was below the limit of sensitivity of the assay (< 2.9ng/ml) and
pellet replacement increased this to approximately one quarter that of sham-
operated controls. ADX elevated plasma ACTH compared with sham-
operated animals and pellet replacement partially reversed this increase in
plasma ACTH.
Mean SS content of cervical drg was significantly decreased five, ten
and thirty days following ADX compared with sham operated controls (Fig.
3.1a). B administration in the form of subcutaneous pellet implant partially
reversed the effects of ADX over the thirty day period. SS content was not
evenly distributed over the four ganglia studied; SS content (Fig 3.2a) was
Table 3.1 Plasma B (ng/ml) and ACTH (pg/ml) of animals





Corticosterone 227.1 ± 26.8 <2.9 57.4 ±9.8
(ng/ml)
Plasma ACTH
(pg/ml) 230.5 ± 104.2 1114.5 ± 125.7 844.7 ± 339.5
Figure 3.1 Mean SS (a) and SP (b) content (pg/drg) of drg from C4
to C7 following sham operation, ADX for five, ten or
thirty days (ADX 5, ADX 10, ADX 30) or pellet
replacement of B following ADX (B-REP)
*p < 0;05, ** p < 0.01, c.f. sham operated control
(ANOVA, post-hoc Duncan's Multiple Range test)
MEANSSCONTE T (pg/ganglion) N>-P*CT>00
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Figure 3.2 Distribution of SP (a) and SS (b) content (pg/drg) in drg
from C4 to C7, and the SP content following sham
operation, ADX for five, ten or thirty days (ADX 5, ADX




greatest in C4 compared with C5, C6 or C7. Thirty days after ADX the
differential distribution of SS was no longer present: B replacement over the
same period restored the distribution to that of controls.
SP content (Fig. 3.1b) was significantly increased five and ten days
following ADX compared to sham operated animals. However, this
increase in SP content was not sustained, and thirty days after ADX, SP
content was no longer significantly different from that of sham operated
controls. SP content of drg from adrenalectomised animals receiving B was
not significantly different from that of sham operated controls over the 30 day
period. SP content (Fig. 3.2b) was least in C4 and C5 and greatest in C7.
This distribution of SP was maintained five, ten and thirty days following
ADX.
3.3.2 Replacement Studies
As was expected, plasma B (Table 3.2) of adrenalectomised animals
was greatly decreased (below the limit of sensitivity of the assay, < 2.9ng/ml)
and plasma ACTH was increased compared with sham-operated animals.
DEX replacement did not alter the effects of ADX on plasma B, but
suppressed plasma ACTH below that of controls. Daily s.c. injection of B
only slightly increased plasma B above that of adrenalectomised animals
receiving no treatment and did not reverse the increase of plasma ACTH.
Treatment of intact animals with RU38486 did not significantly alter plasma B
but suppressed plasma ACTH below that of controls.
As in the previous experiment, 10 days following ADX, SP and CGRP
content (Fig. 3.3a,c) of cervical drg was significantly increased compared to
sham operated controls, SS content (Fig. 3.3b) was decreased. In contrast,
SP and SS content of drg from adrenalectomised animals treated with DEX
was not significantly different from controls. Similarly, DEX treatment
Table 3.2 Plasma B (ng/ml) and ACTH (pg/ml) of animals
following ADX, ADX and administration of DEX or B or


































Figure 3.3 Mean SP (a), SS (b) and CGRP (c) content of drg (% of
sham operated controls) following ADX, ADX and daily
treatment with DEX or B or treatment of intact animals
with RU38486
*p < 0.05, **p < 0.01, c.f. sham operated control
(ANOVA, Duncan's Multiple Range Test)
N/D not determined




reversed the effects of ADX on drg CGRP content and further suppressed
CGRP content significantly below that of controls.
In contrast to DEX treatment and the results of the previous
experiment the method of B replacement used in this experiment did not
reverse the effects of ADX on SP content or SS content. B replacement did
however reverse the effects of ADX on CGRP content of drg but did not
suppress CGRP content below that of controls. RU38486, the glucocorticoid
antagonist administered to intact animals by daily s.c. injection was without
effect on SP or CGRP content of cervical drg.
3.4 DISCUSSION
In the experiments described above, I have demonstrated the
regulation of neuropeptides in drg by glucocorticoids. SS content
decreased, but SP and CGRP content increased five and ten days following
ADX. Thirty days after ADX, whilst SS content remained suppressed, SP
content was no longer significantly different from that of sham operated
controls. B replacement by subcutaneous pellet implant reversed the
effects of ADX on both SS and SP content, restoring peptide contents to
control levels. Similarly, DEX given subcutaneously in oil reversed the
effects of ADX on SP and SS content and suppressed CGRP content below
that of controls. CGRP content of adrenalectomised animals was restored to
control levels following s.c. injection of B, but in contrast to pellet
replacement of B, injection did not reverse the effects of ADX on SP or SS
content . RU38486 a specific glucocorticoid antagonist was administered
by s.c. injection to intact animals but was without effect on neuropeptide
content of drg by this route of administration. I have also described
differential distributions of neuropeptide content of the 4 drg (C4-C7); these
results have been further investigated and are discussed fully in Chapter 7.
The SP gradient did not change following ADX, but the gradient of SS was
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abolished 30 days after ADX, and this was restored by replacement of B in
the form of s.c. pellet implantation.
As the adrenal gland is the sole site of synthesis of corticosteroids,
following ADX endogenous corticosteroid will be completely removed from
the animal. The success of ADX was gauged from the absence of B in the
plasma and upon inspection, the absence of adrenal fragments in cadavers.
Further evidence of the removal of corticosteroids following ADX was
indicated by the increase in plasma ACTH which resulted from the removal
of the negative feedback of B on ACTH biosynthesis and secretion.
DEX (9a-fluoro-16a-methyl-prednisolone) has a long half-life in the
body and some specificity for Type II receptors, although at a high dose is
active at both Type I and Type II receptors. In my method of administration,
daily s.c. injection will maintain pharmacologically active levels of DEX
between doses. Thus, Type II receptors will be occupied continuously, and
there may be some occupation of Type I receptors. DEX injection reversed
the effects of ADX on SP content of cervical drg, similarly SS content was
restored to sham levels after DEX. CGRP content of cervical drg was
suppressed significantly below that of sham operated controls. These
results suggest that corticosteroid regulation of SS, SP and CGRP is
mediated by Type II receptors. That CGRP content was suppressed below
that of controls suggests that CGRP was more sensitive to steroid regulation
than SP or SS.
In the current study two paradigms were used for B replacement. In
the first, a pellet containing 50% B in a 50% cholesterol mixture was inserted
subcutaneously, and thus provided a constant moderate dose of B (Dallman
et al., 1989). Thus, in this model, Type I, and to a lesser extent, Type II
receptors were likely to be occupied throughout the period of the
experiment. I have described in the Introduction to this Chapter, the
relationship between plasma ACTH and B, which reciprocally regulate each
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other in a negative feedback loop. Before considering the plasma B of
animals it should be noted that animals were killed in the morning and thus,
given the circadian nature of B secretion, plasma B would be expected to be
near a minimum. However, plasma B may be elevated as whilst great care
was exercised to minimise the stress on animals prior to decapitation,
handling and transfer of animals from the animal house to the laboratory
prior to sacrifice may have resulted in a stress induced release of B from
intact animals. Consequently it may be that the measured plasma B of
intact animals was higher at the time of sacrifice than it was for the previous
period of the experiment. Thus, whilst the measured plasma B level of
pellet replaced animals was approximately one quarter that of sham-
operated animals it may be that the model was in fact more effective at
replacement of plasma B than is immediately apparent from these figures.
I have found that pellet replacement of B reversed, but not fully, the
effects of ADX on SS and SP content of cervical drg, and thus this model of
replacement appears not to completely mimic the intact animal. The plasma
ACTH levels of replaced animals, whilst variable, also indicates that
replacement was incomplete; compared with sham-operated controls, the
plasma ACTH of replaced animals was elevated (by 3-4 fold), but less than
that of ADX animals (5-fold greater than sham).
The second model of replacement of B involved daily s.c. injections of
B in oil. In this model, animals will experience a rapid rise in plasma B
which will be metabolised between injections, thus given that the injections
were administered daily at approximately 4.30 p.m., this model mimics the
endogenous circadian rhythm in plasma B. However, as B is rapidly
metabolised, the plasma B will approach zero before the second injection is
administered. Consequently, when initially injected Type I and Type II
receptors will be transiently occupied. However, due to rapid metabolism of
B, it is presumed that for the majority of the period plasma B will be at a level
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such that only Type I receptors will be occupied, and for some time before
the next injection only a proportion of these receptors will bind B. Thus, the
animal will only transiently be replaced.
That measured plasma B was extremely low, was to be expected
given that animals were killed in the morning some 16 or 20 hours after the
last injection of B. Thus, the plasma B, given in Table II, which was just
above the limit of sensitivity of the assay was effectively the end point and is
of little use in considering the active dose of B achieved in this model.
However, this method of B replacement was ineffective in preventing the
increase in plasma ACTH following ADX and thus did not effectively mimic
the endogenous suppression of B on ACTH biosynthesis and secretion.
Furthermore, this method of replacement did not reverse the effects of ADX
on SS or SP. However, whilst the effects of ADX on SS or SP were not
reversed by daily s.c. injection of B, the CGRP content of drg in this treatment
group were not significantly different from sham operated controls. These
results suggest CGRP might be more sensitive to corticosteroid regulation
than SP or SS. The results of the experiments using DEX treatment also
suggested CGRP was more sensitive than SP or SS.
RU38486 (11 6-(4-dimethylaminophenyl)-17B-hydroxy-17a-propyl-l-
vinyl) estra-4,9,dien-3-one; Mifepristone) is a potent antiglucocorticoid with,
in addition, antiprogestin activity. It is an antagonist at both the
progesterone and glucocorticoid receptors and has 3-fold greater affinity
than DEX at the Type II receptor (Agarwal, 1984). In ADX animals,
RU38486 has been found to inhibit glucocorticoid induction of tryptophan
pyrolase, tyrosine transaminase as well as stimulation of gluconeogenesis
(Agarwal et al., 1987). Clinically, the antiprogestin activity of RU38486
allows its use as an abortifacient, and it is also proving useful in the
treatment of Cushing's syndrome, but as yet, has been found to possess no
agonist activity at the Type II receptor.
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In the model of administration used, daily s.c. injection in oil,
RU38486 did not significantly alter neuropeptide content compared with
sham operated animals. Two conclusions are possible from this
experiment: (i) Type II receptors are not important in corticosteroid
regulation of neuropeptides in drg or, (ii) my route of administration of
RU38486 failed to produce pharmacologically useful doses in the animal.
The action of DEX to reverse the effects of ADX argues against the assertion
that Type II receptors are not involved in the regulation of neuropeptides in
the drg. Consideration of plasma ACTH levels in animals receiving
RU38486 compared with sham operated controls indicates that RU38486
suppressed plasma ACTH. This finding is contrary to the expected outcome
of using a glucocorticoid antagonist in intact animals, as this would tend to
inhibit glucocorticoid suppression of ACTH synthesis and secretion and
consequently lead to an increase in plasma ACTH. From the evidnce
available it is not clear why in this experiment administration of RU38486
resulted in this apparent anomaly. However, RU38486 is normally
administered orally by gavage or in drinking water and it may be that my
route of administration was not suitable. I conclude that my method of
administration was not appropriate for RU38486.
In the vagus nerve following ADX, axonal transport of SP, but not SS,
was increased and, in contrast, following administration of
supraphysiological amounts of B, axonal transport of SS, but not SP, was
increased (MacLean, 1987). Using studies of ligation and 35S methionine
incorporation, a direct relationship between axonal transport of SP and
synthesis of SP in the vagus nerve has been demonstrated (MacLean,
1987a; MacLean & Lewis, 1984). It is possible, therefore, that increased
transport of SP in the vagus following ADX reflects or is supported by
increased synthesis of SP and thus SP in the sensory vagus and drg would
appear to be similarly regulated by corticosteroids. The reciprocal
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regulation by corticosteroids of SP and SS transport in the vagus nerve is
also in agreement with my finding that SP and SS content of drg changed in
opposite directions following ADX.
The rat 44-2C cell line (derived from thyroid cells) has also been used
to study glucocorticoid regulation of neuropeptides. Thus, following culture
in the presence of DEX, SS content is elevated and mRNA encoding CGRP
is significantly reduced (Zeytin & Delellis, 1987; Zeytin et al., 1987). My
findings in the drg, that DEX reversed the reduction of SS content and
increase in CGRP content following ADX are consistent with studies in the
44-2C cell line. In contrast, in the TT cell line (derived from human
medullary thyroid carcinoma cells) DEX treatment reduces SS production,
indicating glucocorticoid regulation of SS differs in this cell line. In the
CNS, SS content of the hypothalamus, cortex, striatum and hippocampus is
not changed following ADX, but SS binding is reduced in the hypothalamus,
hippocampus and striatum but not cerebral cortex (Rodriguez et al, 1988).
SS binding is also reduced on pituitary cells in culture following
administration of glucocorticoids (Schonbrun, 1982). In rat striatum, PPT
mRNA is regulated by glucocorticoids such that PPT mRNA content is
reduced five days following ADX compared with animals receiving B
replacement following ADX (Chao & McEwen, 1991).
In the current study RIA was used to examine the neuropeptide
content of drg following ADX; whilst this technique measures total peptide
content it provides no insight into the regulation of neuropeptides within
individual cells. The distribution of neuropeptides in the drg was described
in the introduction to this thesis (Chapter 1) and it is apparent that whilst
there is co-localisation of the three neuropeptides under study, discrete
populations may also exist (notably of SP and SS). The question therefore
arises as to the proportion of the population of peptidergic cells that respond
to steroids with a change in neuropeptide content. It may be that the
relatively modest changes in neuropeptide content detected by RIA in this
study underlies a far greater change in a subset of the population of
peptidergic cells that is masked by a larger population of unresponsive cells.
Use of the semi-quantitative technique of immunohistochemistry for the three
neuropeptides would allow determination of the specific subpopulation of
neurons, perhaps delineated on the basis of cell diameter which might be
responding to glucocorticoids. Alternatively it may be that the changes in
neuropeptides occurs in only those populations of cells colocalising the
peptides under study; the availability of a number of immunohistochemical
techniques whereby one can visualise more than one peptide in a single
tissue would be of use in resolving these questions.
Whilst I have found a reduction in SS content and an increase in SP
and CGRP content following ADX, there is no indication from this study as to
the mechanisms responsible for these changes. In the drg neuropeptides
such as SP, CGRP and SS are synthesised in the cell body and transported
in axons or nerve roots centrally or peripherally. Thus, an increase in
peptide content might reflect reduced axoplasmic transport of the peptide
from the drg, and this would be demonstrated using the ligation methods of
MacLean described in the introduction to this chapter. Alternatively,
increased peptide content might reflect an increase in the synthetic rate of
peptide which might be shown by incorporation of radiolabeled amino acids
into immunoreactive peptide (Harmar & Keen, 1982). The obverse of the
above argument would apply for a reduction in peptide content. Finally, the
peptide content could be altered as a consequence of a change in the
degradation of peptide in the cell body.
Peptide synthesis can also be regulated by actions of agents on the
genome or mRNA. If the availability of mRNA encoding neuropeptides is
raised and translation and processing mechanisms are not limiting, the
peptide biosynthesis will also be increased and reflected in an increase in
94
neuropeptide content of the drg, all other factors remaining constant.
Increases in the availability of specific mRNAs for translation can arise
through a number of mechanisms. In the cell body, there is a continual
turnover of mRNA and thus a reduction in degradation or increase in
synthesis of mRNA will increase availability of mRNA for transcription. It
would, therefore, be interesting to examine the content of mRNA encoding
SP, SS or CGRP of drg following ADX to determine if the effects on
neuropeptide content are mediated at the level of mRNA. This experiment
might be conducted using of northern blots, nuclease protection assays or
in-situ hybridization employing specific cDNA probes for the three
neuropeptide mRNAs.
The use of nuclease protection assays might be particularly
appropriate, as the technique not only provides information regarding mRNA
content (as would be obtained from the Northern Blot) but can also reveal
any alterations in the pattern of splicing of the primary transcript. The
splicing of the mRNA encoding the three peptides and the other possible
products that the mRNA can yield was described in the introduction to this
thesis (Chapter 1). The splicing patterns of mRNA are of interest as it has
been demonstrated previously in ovine thyroid C-cells that NGF can alter the
splicing of the calcitonin/CGRP gene primary transcript to produce CGRP
rather than calcitonin, the product in untreated cells. Examination of the
mRNA content by in-situ hybridization would also provide information not
gained by the use of the other two techniques. In addition to being semi¬
quantitative, in-situ hybridization would also reveal the population of ceils
expressing neuropeptide genes that were regulated by ADX.
Whilst I have demonstrated that following ADX, SP and CGRP
contents are increased and SS content of drg decreased and that these
effects are reversed by corticosteroids, the results do not establish the site of
action of corticosteroids in the regulation of neuropeptides in the drg. It may
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be that corticosteroids act at some distant site and influence release of a
mediator in the form of a hormone or paracrine factor which subsequently
regulates neuropeptides in the drg. Alternatively, the mRNA encoding both
Type I and Type II receptors has been localised in neurons of the drg by in
situ hybridisation (Seckl et al., unpublished observations) and thus the
glucocorticoids may act directly on the drg. An experiment to determine if
indeed corticosteroids do act directly at the drg, (although this does not, by
itself, obviate additional secondary actions) would be to examine steroid
regulation of neuropeptides in dissociated primary cultures of drg in defined
medium. This experiment has been performed and is described in
Chapter 6.
Neuropeptides in the drg, including SP, SS and CGRP have been
implicated in the transmission of pain to the dorsal horn and in inflammatory
processes (see Chapter 1). Clinically, glucocorticoids are used as anti¬
inflammatory agents in a variety of conditions including rheumatoid arthritis.
It is generally accepted that glucocorticoids influence the immune system
and act generally to inhibit the body's natural response to tissue injury (see
Chapter 1). It may be, in the light of my results, that in addition they also in
part act on the drg to regulate availability of neuropeptides in peripheral and
central terminals, and thus influence neurogenic inflammatory processes
and transmission of nociceptive information. A commonly used model of
inflammatory disease is the adjuvant arthritic rat, and in Chapter 5, I have
investigated the role of the neuropeptides SP, SS and CGRP in the drg in
this model. In addition, I have also determined the effects of manipulation of
corticosteroids on indices of inflammation and neuropeptides in the drg.
In conclusion, I have shown that the neuropeptides SS, SP and
CGRP were not evenly distributed in drg from the cervical region of the rat.
ADX reduced the mean content of SS, but increased SP, and CGRP and this
change in the neuropeptides was reversed by pellet replacement of
corticosterone or daily injection of DEX. These results suggest that
corticosteroids differentially regulate SS, SP and CGRP content of cervical
drg in the adult rat, and that this action may be mediated by glucocorticoids,
through Type II receptors.
CHAPTER 4
ANDROGENS DO NOT REGULATE SP, SS OR CGRP CONTENT OF ORG
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4.1 INTRODUCTION
Testosterone (T) is the major steroid produced and secreted by the
testes in the normal adult male. T is carried in the bloodstream to target
tissues where, being lipid soluble, it crosses the plasma membrane and
binds to the androgen receptor, a soluble intracellular protein of some 110-
120Kda present in the cytosol, (Johnson et al., 1987). Subsequently, the
hormone-receptor complex acquires a greater affinity for chromatin and
binds to specific areas of the genome to influence gene transcription
(Ostrowski et al., 1982; Heynes et al., 1977; Mainwaring et al., 1974). In
addition, a number of metabolites of T are biologically active in target
tissues. Thus, T can be converted by the intracellular enzyme 5a reductase,
present in target tissues, to its more active congener 5a dihydrotestosterone
(5a DHT) which also binds to the androgen receptor to influence gene
transcription (Bruchovsky & Wilson, 1968; Denef et al., 1973; Denef et al.,
1974). Oestradiol is another active metabolite of T formed by the action of
aromatase (Ball & Knopper, 1980) and oestrogens, acting again at the level
of the genome in a hormone-receptor complex, mimic the differentiating
effects of T in some areas of the CNS (Nordeen et al., 1986; Gorski &
Wagner, 1965). Finally, in liver and bone marrow, T can be converted to 5(3
metabolites which effect androgen actions (see Bardin & Catterall, 1981;
Urabe et al., 1979).
Receptors for androgen and oestrogens have been localised to areas
of the rat brain using biochemical and autoradiographic techniques (see
McEwen, 1980). Androgen receptors are present throughout the CNS, but
are concentrated in the hypothalamus, septum, preoptic area and amygdala,
and recognise both T and the metabolite 5a DHT. Whilst oestrogen
receptors are found in high concentration in anterior pituitary and to a lesser
extent in the basomedial hypothalamus, preoptic area, corticomedial
amygdala and mesencephalic gray matter of the rat, a necessary
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prerequisite for their mediation of androgen action is the presence of
aromatase activity . Aromatase activity is in high concentration in the
amygdala, and to a lesser degree, in the preoptic area and hypothalamus,
but is absent from the pituitary. This differential distribution of aromatase
activity is shown by the fact that following injection of [3H]-testosterone
oestrogen receptors in the amygdala, hypothalamus and preoptic area, but
not the pituitary are labelled with [3H]-oestradiol. Thus, the ability of a tissue
to aromatise oestrogen appears to be the limiting factor in oestrogen-
mediated effects of T; in contrast 5a reductase activity is present throughout
the CNS (see McEwen, 1980).
Sexually dimorphic patterns of sexual behaviour and gonadatrophin
secretion in adults results from the presence or absence of androgen (or its
metabolites) during the perinatal period (see Beyer & Feder, 1987). In
areas of the CNS concerned with the control of reproductive processes
including areas of the hypothalamus, medial preoptic area, amygdala,
septum and some cells in the brain stem and spinal cord, sex related
differences in a variety of morphological parameters such as size of nuclei in
neuronal groups, number of neurons, neuronal volume, extent of dendrite
elaboration and branching, number of dendritic spines, morphology and
localisation of synapses and cell nuclear volume and structure are apparent.
In the limbic regions, sex differences in the pattern of connectivity between
areas related to reproductive function have also been identified. Perinatal
castration of genetic (XY) males demasculinises and feminises those areas
of the brain underlying sexual behaviour and feminises the brain-pituitary
axis such that female patterns of gonadotrophin secretion are apparent in
adulthood. Conversely, injection of androgen into genetic (XX) females
masculinises and defeminises these same reproductive processes. Thus,
sex steroids, including androgens, have important actions on the brain
during ontogeny (see Beyer & Feder, 1987).
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Patterns of neuropeptide distribution in certain regions of the CNS
and pituitary gland have also been found to be sexually dimorphic. Thus, in
the lateral septum and lateral habenula, more fibres immunoreactive for
vasopressin are seen in male than female rats and the normal development
of this sex difference is dependent on the presence of gonadal steroids
during the first two weeks of life (De Vries et al., 1985, 1986). In adult rats,
the pattern of vasopressin innervation is also regulated by gonadal steroids;
thus, nearly all vasopressin fibres disappear following castration, and this is
reversed by treatment with T (De Vries et al., 1984). This innervation
probably arises from the bed nucleus of the stria terminalis (De Vries, 1983)
and a sharp decrease in the number of vasopressin containing cell bodies
occurs in this area following castration of adult rats; this is reversed by
treatment with T (Van Leeuwen & Caffe 1985).
Androgens also regulate release of gonadotrophins from the pituitary
gland. Thus, immediately (24h) following castration of adult male rats,
serum FSH is markedly increased, serum LH is also increased; no increase
in pituitary FSH or LH content is detectable. A second rise in serum LH, but
not FSH, occurs 7 days following castration and is accompanied by a rise in
pituitary LH content (Badger et al., 1978). Both T and 5aDHT suppress
pituitary LH, but not FSH content of intact animals and oestradiolsuppresses
both pituitary FSH and LH content below that of vehicle treated controls
(Arslan et al., 1989). Expression of the genes encoding the a subunit of
gonadotrophins and the (3-FSH and LH subunits is also regulated by
androgens. Androgens suppress expression of the a-subunit and the (3 LH
but not FSH subunits, whereas oestrogen administration uniformly inhibits
expression of all three of the gonadotrophin subunit genes in castrates of
both sexes (Gharib et al., 1987; Wierman et al., 1988).
In addition to regulating expression of the gonadotrophins, androgens
and androgen metabolites also regulate the gonadotrophin releasing
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hormone LHRH. Following castration of sexually mature rhesus macaques
the LHRH content of the infundibular nucleus, median eminence, ventral
medial nucleus, and lateral hypothalamus, are significantly reduced (Roselli
et al., 1987) and these effects can be reversed by administration of either T
or oestradiol (Roselli & Resko, 1990). Similar results have been found in
rats (Kalra et al., 1984), in which, following castration, the proLHRH
(precursor peptide of LHRH) content of the basal hypothalamus and preoptic
area is reduced in a T reversible manner (Roselli et al., 1990). Expression
of the LHRH gene is also regulated by T; thus, in the hypothalamus, LHRH
mRNA content is markedly reduced following castration in a T reversible
manner (Park et al., 1988). Given the role of LHRH in the regulation of FSH
and LH it may be that some of the actions of T on these two peptides are
mediated by LHRH.
In the central and medial amygdaloid nucleus of the rat a reduction
both in the number of SP immunoreactive fibres, and their SP content, has
been shown following castration, suggesting a trophic role of T on SP
neurons in this nucleus (Dees & Kozlowski, 1984). Gonadal steroids,
including T and oestradiol, are also implicated in the regulation of the
development of SP immunoreactivity in the anterior pituitary of neonatal rat
(Yoshikawa & Hong, 1983). However, short-term (8 day) castration of adult
male rats does not significantly change SP levels in this area (Coslovsky et
al., 1985; DePalatais et al., 1985), although p and y preprotachykinin mRNA
is increased (Brown et al., 1990).
SS is also under the control of T; in the median eminence, castration
results in a T reversible reduction in the amount of SS, both the peptide
content and the extent of peptide distribution is reduced (Gross, 1980).
Interestingly, in the nearby organum vasculosum of the lamina terminalas,
SS peptide is unchanged following castration. SS mRNA levels have also
been found to be regulated by gonadal steroids in some (Baldino et al.,
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1988; Chowen & Breed, 1989), but not all (Werner et al., 1988) areas of the
CNS.
In the spinal nucleus of the bulbocavernosus (SNB), motorneurons
innervating perineal striated muscles concerned with copulatory behaviour
accumulate radioactive T or 5aDHT, but not oestradiol (Breedlove & Arnold,
1980). In adult males the nucleus is found in the lumbar spinal cord, but in
females is diminished or absent; its presence dependent not on genetic sex,
but the action of androgens (Breedlove & Arnold, 1980). Castration of
young male rats reduces the number of CGRP-immunoreactive neurons in
the SNB in a T reversible manner (Popper & Micevyh, 1989). Given the role
of T in regulating neuropeptides including SS, SP and CGRP in a variety of
tissues it may be that T regulates the neuropeptide content of drg. This
possibility has been investigated in the rat by examining the SP, SS and
CGRP content of drg ten days following castration or castration plus T
replacement.
4.2 METHODS
Adult male Ham Wistar rats (200g) were anaesthetised under
halothane and castrated or sham operated as described previously (Chapter
2). Castrated animals were split into two groups of eight and implanted
subcutaneously with 30mm silastic capsules either empty or containing
crystalline T (Sigma, UK). Sham operated animals received empty silastic
capsules. Animals were allowed to recover and 10 days after surgery, killed
by rapid decapitation, trunk blood samples collected on ice and plasma
testosterone determined by RIA. Drg from cervical levels C4, C5, C6 and
C7 were removed and the SP, SS and CGRP contents determined by RIA
(Chapter 2). Results were analysed by ANOVA.
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4.3 RESULTS
Following castration, plasma T concentration (Table 4.1) was below
the limit of detection for the assay under the conditions used (< 0.1ng/ml).
SP, SS and CGRP content of cervical drg following castration was
unchanged compared with sham operated controls (Fig. 4.1). The model of
T administration used in this study resulted in plasma T of replaced animals
13-fold greater than in sham operated controls. In animals treated with
supraphysiological T, the SP, SS or CGRP content of drg was not
significantly different from that of controls or from that of castrates.
4.4 DISCUSSION
No change in SP, SS or CGRP content of drg was detected following
either castration or administration of supraphysiological levels of T.
Previously, as discussed in the introduction to this chapter SP, SS and
CGRP gene expression and peptide biosynthesis have been found to be
regulated by T or its metabolites. It is possible that my chosen period of
castration (10 days) did not allow sufficient time for a putative, required
series of biochemical events to occur (e.g., degradation or synthesis of
peptide stores) before changes in peptide content are detected. This
however, is unlikely, as changes in SP in the central and medial amygdaloid
nucleus are seen as early as four days following castration (Dees &
Kozlowski, 1984).
That neuropeptides are regulated by T in some but not all areas of the
CNS, suggests that the biochemical apparatus pre-requisite for T action may
not be present in all areas of the CNS. I have discussed in the Introduction
to this chapter that T can act on tissues either directly or following
metabolism to 5a DHT by binding to an androgen receptor. Alternatively T
may first be converted to oestrogen by aromatase and act on tissues via the
oestrogen receptor. Indirect actions of T can also be mediated by T
Table 4.1 Plasma T (ng/ml) of animals following castration, sham








Testosterone 2.2 ±0.8 <0.1 29.2 ±7.1
(ng/ml)
Figure 4.1 SP (a), SS (b), and CGRP (c) contents (pg/ganglion) of
cervical drg following castration (CAST), sham
operation or castration and administration of
supraphysiological T (T-REP). Values are mean of





regulation of an intermediate factor e.g., T modulation of LHRH regulation of
FSH and LH (see Introduction). Thus, for a direct action of T or its
metabolites, the presence of androgen receptor and/or oestrogen receptor
and associated T metabolising enzymes is an absolute requirement,
although their absence does not obviate a transynaptic or some other
secondary phenomenon. It is not known if these receptors and enzymes
are present in drg of the adult male rat.
In conclusion, T does not regulate SP, SS or CGRP content of
cervical drg in adult male rat.
CHAPTER 5
ROLE OF NEUROPEPTIDES SP, SS AND CGRP IN RAT ADJUVANT




Numerous animal models of inflammatory disease have been
developed employing a variety of mediators including collagen, carageenin
and adjuvant (see Sokoloff, 1984; Magilavy, 1990). Adjuvant arthritis, a
chronic, non-infectious polyarthritis was developed largely by Pearson and
colleagues (1956) and occurs in certain strains of rats, following intraplantar
injection of Freund's complete adjuvant (FCA). Adjuvant disease is evoked
by injection of bacterial peptidoglycans contained in water-in-oil emulsions,
usually derived from mycobacteria, but peptidoglycan from nocardia,
corynebacteria and other gram positive organisms are also effective (Hadler
& Granovetter, 1978). A number of mechanisms have been suggested to
account for the adjuvant function of these bacterial fractions. Current
opinion holds that the adjuvant stimulates an immune response in T and B
cells and macrophages, however N-acetylmuramyl-L-alanyl-D-isoglutamine
is a non-antigenic synthetic analogue which is both arthritogenic and an
adjuvant (Kohashi et al., 1982). Thus, it may be that the presence of D
isomers, as well as the usual L-isomer of amino acids in peptidoglycans,
may represent a catabolic problem for macrophages, although not all
peptidoglycans have adjuvant activity. It has been suggested that the use of
an oil in water emulsion reflects the importance of the physico-chemical
properties of the peptidoglycans in conferring adjuvant activity, but
streptococcal peptidoglycans produce adjuvant like lesions without prior
emulsification. Finally, CP-20961 a synthetic fat-soluble, non-immunogenic
non-peptidoglycan compound also induces an arthritis in rats comparable to
that of adjuvant disease (Chang et al., 1980). Despite the fact that the
mechanisms mediating adjuvant arthritis remain elusive it has become
widely employed as a model of inflammatory disease.
Adjuvant disease (Rosenthale & Capetola, 1982) is a painful systemic
disorder affecting almost exclusively the distal portions of the extremities:
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the carpals and tarsals and portions of the paws beyond them. Following
injection of isotopically labelled mycobacteria into the tail base
(polyarthritis), radioactivity is found in many parts of the body, with only a
small proportion in the hind paws (Glenn et al., 1977). Initially, an acute,
periarthritis, characterised by inflammation of periarticular tissues and
tendon sheaths occurs following a lag period. The synovial spaces are
infiltrated with predominately lymphocytes, monocytes and macrophages,
although some polymorphonuclear leukocytes are also found.
Subsequently, hyperplasia of synovial lining cells, and proliferation of
granulation tissue occur, and later subchondral bone and cartilage
destruction ensue accompanied by florid production of new bone in the
adjacent periosteum. Residual ankylosis and exophytic bone remain after
the inflammatory process recedes (see Sokoloff, 1984). It is also possible to
produce a more localised inflammation (monoarthritis) by injection of FCA
into particular tissues. In such animals, a similar inflammatory process
occurs to that found in joints of polyarthritic animals, but the inflammatory
processes are localised to the injected area.
Thus, conditions similar to those encountered clinically in RA are
manifest following injection of FCA into the tail base or peri-articular tissue of
rats. A number of studies have examined the role of neuropeptides in the
aetiology of adjuvant disease employing both polyarthritic and monoarthritic
animals. Weihe and colleagues (1988) used immunohistochemistry to
investigate changes in neuropeptides of lumbosacral spinal cord and drg in
a polyarthritis and hind paw monoarthritis. In lumbosacral dorsal horn of
polyarthritic animals a moderate increase in staining for SP and CGRP
immunoreactive fibres in laminae I, II and V was noted, compared with
untreated controls. A similar moderate intensification of CGRP and SP
immunoreactivity in the dorsal horn on the ipsilateral compared to the
contralateral side of monoarthritic animals was also observed, and
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immunostaining for CGRP in cells of the drg was more intense; no increase
in the number of SP and CGRP producing cells was noted. Interestingly, in
the inflamed joint, SP and CGRP immunoreactivity was elevated compared
with untreated controls. The increase in CGRP immunoreactivity was
particularly pronounced, accompanied by apparent sprouting of fibres within
the epidermis, subepidermal regions and in the vicinity of subepidermal
venules. CGRP immunoreactive fibres were also found associated with
mast cells and immunocompetent cells and in areas of infiltrated immune
cells.
Treatment with capsaicin, an irritant extracted from peppers, depletes
neuropeptides including SP. Capsaicin treatment has also been shown to
reduce the inflammatory response to adjuvant (Colpaert et al., 1983). In
studies of capsaicin-evoked neuropeptide release from dorsal slices of
lumbar spinal cord.from adjuvant arthritic rats inoculated in both hind paws
with FCA, release of CGRP was significantly enhanced compared with
controls (Nanayama et al., 1989). CGRP content was also increased in
lumbosacral drg (Kuraishi et al., 1989) of arthritic rats, and immunisation of
rats against CGRP reduces the inflammatory response to innoculation with
adjuvant (Louis et al., 1990).
A role for SP in the pathology of adjuvant arthritis has been
suggested from a number of studies. In the lumbar ventral spinal cord of
polyarthritic animals, Chery-Croze et al. (1985) reported the SP
concentration to be reduced, but no change in dorsal cord SP content was
reported. In contrast, Lembeck et al. (1981) reported a significant increase
in SP content of dorsal cord from L4-L5. More recently, spontaneous
release of SP into the spinal cord was found to be enhanced in polyarthritic
rats over controls. Furthermore, passive movement of inflamed joints
potentiated spontaneous release of SP but in control animals, no increase
in SP release was apparent following passive movement, suggesting that
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SP was directly involved in the transmission to the dorsal horn of pain,
produced by the movement (Oku et al., 1987a). Supporting the role of SP in
inflammation, it has been shown that the density of innervation by SP-
containing primary afferents is correlated with the severity of arthritis that
joint develops. Thus, in the adjuvant rat model, severely arthritic joints
(tarsals) have a more dense SPergic innervation than more mildly arthritic
joints (knees) (Levine et al., 1984). In addition, infusion of SP into the
inflamed joint potentiated the arthritis and SP antagonists ameliorated the
inflammation. Lembeck (1981) reported SP to be increased in drg, but not
significantly, following induction of polyarthritis. Recently, Satoh (1990) and
Ohno (1990) have reported increased SP, CGRP and SS content of drg in
adjuvant and carageenin models of inflammatory disease.
Given the role of neuropeptides in pain and inflammation, and the
previously described regulation of neuropeptides by glucocorticoids
(Chapter 3), I have investigated the changes in SP, SS and CGRP content of
drg of adjuvant-induced arthritic rats and examined the effect of ADX and
glucocorticoids on the progression of inflammation and neuropeptide
content of drg.
5.2 METHODS
Under halothane anaesthesia, Ham Wistar rats (male, 300g) were
injected subdermally around the left carpal joint with either Freund's
complete adjuvant (FCA; Sigma, UK) or incomplete adjuvant (ICA; Sigma,
UK). Two subdermal injections each of 0.05ml were made at different
locations around the carpal joint of the forepaw and the animals allowed to
recover. To assess the progress of the inflammation, the body weight and
the circumference of the carpal joints were recorded for the duration of the
experiments. A small tape measure was placed around the joint and the
circumference determined.
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In a preliminary experiment (Experiment 1), Ham Wistar rats (male,
250-300g) were divided into two groups (n = 5) and one group received FCA
as described; the second group received ICA and served as controls.
Twenty-two days following injection, the animals were killed by decapitation,
drg on ipsilateral and contralateral sides dissected from level C4 to C7 and
frozen on dry ice. The pooled drg were subsequently homogenised in 2M
acetic acid and SS, SP and CGRP content determined by RIA; results were
expressed in pg/ganglion. For comparison between treatments an unpaired
t-test was used, and for comparison between ipsilateral and contralateral
sides, a paired t-test was used.
A second experiment (Experiment 2) was performed to chart more
accurately the drg in which peptide contents changed. In this second
experiment, three groups (n = 5) of Ham Wistar rats (male, 250-300g)
received FCA, ICA or no treatment. Fifteen days after induction of adjuvant
arthritis, the animals were killed by decapitation, and trunk blood samples
collected in order that plasma B and ACTH contents could be measured by
RIA. On ipsilateral and contralateral sides of the spinal cord, drg were
dissected and collected in pairs from level C2 to T6. The tissues were
prepared for RIA and SP, SS and CGRP contents determined as described
previously and expressed in pg/ganglion. For comparison between
treatment groups, ANOVA was used with Duncan's multiple range test. For
comparison between ipsilateral and contralateral sides, repeated measures
ANOVA, followed by Scheffe's F-test was used.
A third and final experiment (Experiment 3) was concerned with the
effects of ADX and glucocorticoids on adjuvant-induced inflammation and
neuropeptide changes. Ham Wistar rats (male, 250-300g) were divided into
two groups. One group (n = 7) received injection of ICA around the carpal
joint; the remaining animals were injected with FCA. Ten days following
injection of FCA, animals in this group were subdivided into a further five
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groups. Some animals were bilaterally adrenalectomised (n = 10), using a
single step procedure, or sham operated (n = 7). A further two groups of
animals were orally administered DEX (0.2mg/kg; n = 7) or RU38486
(10mg/kg; n = 7) in saline, respectively. The drugs were given daily in 0.9%
saline, 0.2% ethanol by gavage (0.4ml/100g) until the experiment was
terminated. The remaining group of animals given FCA received no further
treatment. The experiment was terminated 20 days after the peri-articular
injection of FCA or ICA. Animals were killed by decapitation and plasma
samples collected and frozen for determination of B and ACTFI content. Drg
from the ipsilateral and contralateral sides were dissected in pairs between
level C2 and T6, frozen on dry ice, and stored at -20°C. The tissues were
subsequently homogenised in 2M acetic acid, SP and CGRP content
determined by RIA and expressed in pg/ganglion. Statistics were used as
described for experiment 2.
5.3 RESULTS
5.3.1 Experiment 1
Animals were injected unilaterally with FCA and sacrificed 22 days
later. SP, SS and CGRP content of pooled drg from ipsilateral and
contralateral sides, of level C4 to C7, were determined.
Body Weight
It is apparent that in this experiment, a slight difference in the body
weight of the two groups existed from the start. Animals receiving FCA lost
some weight compared with those receiving ICA immediately following
injection, but this did not reach significance (Fig 5.1., ANOVA). There was
no difference in the rate of weight gain between the two groups
Carpal joint Circumference
Injection of FCA or ICA produced significant swelling of the ipsilateral
carpal joint compared with the contralateral carpal joint (Fig. 5.2b) between
Figure 5.1 The body weight (gm) of animals following peri-articular
















Figure 5.2 The circumference (cm) of the ipsilateral (a) and
contralateral (b) carpal joints of rats after injection of
FCA or ICA. Values are mean with S.E.M. to bar.
There was significantly more inflammation in the
forepaw of animals following injection of FCA
compared with ICA
(*p < 0.05, ** p < 0.01, c.f. ipsilateral joint of ICA treated
















day 1 and 22 (p < 0.01; ANOVA, Scheffe's F-test). This swelling was more
pronounced in the FCA-treated animals than those in the ICA group.
Neuropeptide Contents
There was no significant difference between the SS, SP or CGRP
content of ipsilateral and contralateral drg of animals injected with ICA
(Fig. 5.3). Following injection of FCA, no significant difference in the SS
content was detected; whilst the CGRP content did tend to be greater, this
did not reach significance. In contrast, the SP content of ipsilateral drg was
significantly greater than that of contralateral drg. There was a tendency for
SP content of contralateral drg to be lower in FCA-treated animals compared
with ICA-injected animals; this difference did not, however, reach
significance (unpaired t-test).
5.3.2 Experiment 2
In order to more accurately define the drg in which neuropeptide
changes occurred, adjuvant arthritis was induced and animals sacrificed 15
days later. SP, SS and CGRP content of pairs of drg, from ipsilateral and
contralateral sides, at level C2/3, C4/5, C6/7, T1/2, T3/4 and T5/6 were
determined.
Body weight
There was no significant difference in the body weight of the three
groups at any time during the experiment (Fig. 5.4) .
Carpal joint circumference
In ICA and FCA injected animals, the ipsilateral carpal joint was
significantly swollen one day after injection compared with the untreated
animals; this swelling persisted for the duration of the experiment
(Fig. 5.5a). FCA injection produced a significantly more pronounced and
prolonged inflammation than ICA. No significant difference in the
Figure 5.3 SS (a), SP (b) and CGRP (c) contents (pg/ganglion) of
pooled drg collected from ipsilateral and contralateral
level C4 to C7 of animals 22 days following unilateral
injection of FCA or ICA. Values given are mean with
S.E.M. to bar



























Figure 5.4 The body weight (gm) of animals following no treatment
(N/T) or subdermal injection of FCA or ICA to the left








Figure 5.5 The circumference (cm) of the ipsilateral (a) and
contralateral (b) carpal joint of animals after receiving
no treatment (N/T) or peri-articular injection of FCA or
ICA. Values are mean with S.E.M. to bar
(**p < 0.01, c.f. ipsilateral joint of untreated animals,





circumference of the contralateral carpal joint between any of the groups
was detected throughout the experiment (Fig. 5.5b).
Plasma Data
There was no significant difference in plasma B between ICA-treated
animals and those receiving no treatment (Table 5.1). However, plasma B
was significantly greater 15 days following injection of FCA compared with
ICA injected animals or animals receiving no treatment. No significant
difference in plasma ACTH was detected between the three groups.
Neuropeptide Contents
In untreated animals, SS content (Fig. 5.6) of drg from contralateral
and ipsilateral sides was greatest at C2/3 and least in drg from C6/7 and
T5/6. This distribution did not change 15 days following peri-articular
injection of ICA or FCA. There was no significant difference in SS content of
ipsilateral drg compared with the contralateral side in any of the three
treatment groups (ANOVA).
In untreated animals, SP content (Fig. 5.7) of contralateral and
ipsilateral drg was greatest in drg from level C6/7, and decreased rostrally
and caudally. Fifteen days following subdermal injection of ICA or FCA, the
SP content of both contralateral and ipsilateral drg was similarly distributed
to that of untreated animals. There were no significant differences between
the SP content of drg from ICA, FCA or untreated animals at any of the levels
studied, either on the ipsilateral or contralateral side (ANOVA), and within
each group the SP content of ipsilateral drg did not differ significantly from
that of contralateral drg, although SP content of ipsilateral C6/7 drg of FCA
treated animals did tend to be greater than the contralateral.
On the contralateral and ipsilateral sides of untreated animals CGRP
content (Fig. 5.8) was greater in cervical than thoracic drg. The distribution
of CGRP in drg from both ipsilateral and contralateral sides in either FCA- or
ICA-treated animals was similar to that in untreated animals. CGRP content
Table 5.1 Plasma B (ng/ml) and ACTH (pg/ml) of untreated
animals and animals 15 days following injection of FCA
or ICA. Values given are mean ± S.E.M.




Plasma Corticosterone 286.9 ± 53.2 105.5 ± 22.0** 133.6 ±31.1*
(ng/ml)
Plasma ACTH 119.0 ±56.0 63.6 ± 6.0 166.9 ±94
(pg/ml)
Figure 5.6 SS content (pg/ganglion) of drg collected in pairs C2/3,
C4/5, C6/7, T1/2, T3/4 and T5/6 from ipsilateral and
contralateral sides of untreated animals (a) and
animals 15 days following subdermal injection of ICA






















Figure 5.7 SP content (pg/ganglion) of drg collected in pairs C2/3,
C4/5, C6/7, T1/2, T3/4 and T5/6 of ipsilateral and
contralateral sides of untreated animals (a) and
animals 15 days following subdermal injection of ICA
(b) or FCA (c). Values are mean with S.E.M. to bar
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Figure 5.8 CGRP content (pg/ganglion) of drg collected in pairs
C2/3, C4/5, C6/7, T1/2, T3/4 and T5/6 of ipsilateral and
contralateral sides of untreated animals (a) and
animals 15 days following subdermal injection of ICA
(b) or FCA (c). Values are mean with S.E.M. to bar
(*p < 0.05, **p < 0.01, c.f. contralateral side, ANOVA,
Scheffe's F-test)
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Figure 5.9a Body weight (gm) of animals following subdermal
injection of FCA or ICA. Values are mean with S.E.M.
to bar
Figure 5.9b Body weight (gm) of animals following subdermal
injection of FCA and either adrenalectomy or sham
operation. Values are mean with S.E.M. to bar
Figure 5.9c Body weight (gm) of animals following subdermal
injection of FCA, and subdermal injection of FCA with
daily dose of RU486 or DEX. Values are mean with
S.E.M. to bar
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Figure 5.10 The circumference (cm) of the ipsilateral (a) and
contralateral (b) carpal joint of rats following injection of
FCA or ICA. Values are mean with S.E.M. to bar
(*p < 0.05, **p < 0.01, c.f. ICA injection, ANOVA,
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Table 5.2 Plasma B (ng/ml) and ACTH (pg/ml) of animals in each
of the six treatment groups; plasma samples were
collected at the termination of the experiment. Values












































of ipsilateral C6/7 drg in FCA-treated animals was significantly (p < 0.01;
ANOVA, Duncan's Multiple Range Test) greater than that in untreated or
ICA-injected animals and was significantly greater than that of the
contralateral side of the same animals. Similarly, the CGRP content of
ipsilateral T1/2 drg of ICA-injected animals was significantly greater (p <
0.05) than the CGRP content of drg from the same area in untreated or FCA-
treated animals and was also significantly greater than that in the
contralateral side of the same animals.
5.3.3. Experiment 3
Animals were administered adjuvant and 10 days later, animals were
adrenalectomised or sham operated or daily treatment with DEX or
RU38486 commenced. A further 10 days later, animals were sacrificed and
SP and CGRP content of pairs of drg from C2/3 to T5/6 of ipsilateral and
contralateral sides determined.
Effects of FCA and ICA
There was no significant difference (ANOVA) in the body weights of
FCA- or ICA-treated animals at any time during the experiment (Fig. 5.9a).
As in previous experiments, injection of either ICA or FCA produced a
pronounced swelling of the ipsilateral carpal joint (Fig. 5.10a), which was
significantly greater in the FCA treated group. Whilst plasma B and ACTFI of
FCA-treated animals (Table 5.2) tended to be greater than that of ICA-
treated animals, this difference did not reach significance (unpaired t-test).
The SP content of drg from C2/3 to T5/6 of FCA- and ICA-treated
animals is given in Fig. 5.11. The distribution of SP was broadly similar to
that found previously in Experiment 2. Comparing the SP content of drg
from C2/3 to T5/6 between the two treatment groups, no significant
difference in SP content in any of the areas studied was noted (ANOVA).
Figure 5.11 SP content (pg/ganglion) of drg collected in pairs C2/3,
C4/5, C6.7, T1/2, T3/4 and T5/6 from ipsilateral and
contralateral sides of animals injection with ICA (a) or,
FCA (b). Values are mean with S.E.M. to bar
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Similarly, in both the ICA- and FCA-treated groups, no significant difference
between ipsilateral and contralateral SP content was found.
The distribution of CGRP content (Fig. 5.12) of drg from level C2/3 to
T5/6 of FCA or ICA treated animals was similar to that found previously in
Experiment 2. Comparing the CGRP content of drg from C2/3 to T5/6
between the two groups, no significant difference in the content of the two
groups was noted (ANOVA). Similarly, but in contrast to Experiment 2, no
significant difference in CGRP content of ipsilateral compared with
contralateral drg was found in either ICA or FCA treated animals.
Effects of ADX or Sham operation on FCA-injected animals
The body weight of adrenalectomised animals was not significantly
different from that of sham operated controls throughout the duration of the
experiment (ANOVA, Fig. 5.9b); whilst both treatments did tend to inhibit the
weight gain found in FCA- or ICA-treated animals, this was not significant.
As expected, following ADX, plasma B (Table 5.2) was below the limit of
sensitivity of the assay, but sham operation did not alter plasma B compared
with unoperated animals (FCA-treated group). Similarly, as expected
following ADX, plasma ACTH increased above that of sham operated
animals (Table 5.2). For the initial 10 days of the experiment prior to ADX,
no significant difference in the circumference of the ipsilateral carpal joint
between the two groups was noted (Fig. 5.13). Following ADX (on day 10),
the circumference of the ipsilateral forepaw of animals in this group was
significantly greater than that of sham operated controls.
No significant difference in the SP content of drg from level C2/3-T5/6
was apparent between sham operated (Fig. 5.14a) or adrenalectomised
animals (Fig. 5.14b; ANOVA). Similarly, the SP content of ipsilateral drg in
either the sham operated or adrenalectomised animals did not differ
significantly from that of the contralateral at any level studied (ANOVA).
Figure 5.12 CGRP content (pg/ganglion) of drg collected in pairs
C2/3, C4/5, C6/7, T1/2, T3/4 and T5/6 from ipsilateral
and contralateral sides of animals injected with ICA (a)




















Figure 5.13 The circumference (cm) of the ipsilateral (a) and
contralateral (b) carpal joint of rats following subdermal
injection of FCA and either sham operation or ADX.
Values are mean with S.E.M. to bar






































Figure 5.14 SP content (pg/ganglion) of drg collected in pairs C2/3,
C4/5, C6/7, T1/2, T3/4 and T5/6 from ipsilateral and
contralateral sides animals injected with FCA and sham
operated (a) or, adrenalectomised (b). Values are
mean with S.E.M. to bar
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Following ADX, CGRP content (Fig. 5.15) of ipsilateral C6/7 drg was
significantly greater than that of sham operated animals (p < 0.01; ANOVA,
Duncan's multiple range test), and of contralateral C6/7 drg. Similarly, in
area T1/2, the CGRP content of ipsilateral drg of adrenalectomised animals
was significantly greater than the contralateral side and that of sham
operated controls (p < 0.01).
Effects of DEX on FCA-injected animals
Treatment of animals with DEX from day 10 to day 20 produced a
significant fall in body weight (Fig. 5.9c) compared with FCA-treated controls.
Treatment of animals with DEX suppressed plasma B below the limit of
detection of the assay and significantly below that of FCA-treated controls
and reduced plasma ACTH significantly below that of FCA-treated controls
(Table 5.2). Up until day 10 (the commencement of DEX treatment), no
significant difference between the circumference of the ipsilateral carpal joint
of the two FCA-treated groups was detected (Fig. 5.16). Following DEX
treatment, the circumference of the ipsilateral carpal joint fell compared to
that of the FCA-treated controls (day 12 - day 18). Thus, DEX treatment
ameliorated the inflammation caused by FCA, such that by day 18 the
ipsilateral forepaw circumference was not significantly different from that at
day 0.
Whilst DEX treatment tended to reduce SP content of drg from all
areas compared to animals receiving FCA alone, this was not significant
(ANOVA, Fig. 5.17). The SP content of ipsilateral C6/7 drg from
DEX-treated animals, was significantly greater than that of the contralateral.
No other differences between ipsilateral and contralateral SP contents were
detected.
The CGRP content of drg from DEX-treated animals, tended in all
areas to be less than that of animals receiving FCA alone, but again, this
was not significant (ANOVA; Fig. 5.18). Similarly, comparison of the CGRP
Lr
Figure 5.15 CGRP content (pg/ganglion) of drg collected in pairs
C2/3, C4/5, C6/7, T1/2, T3/4 and T5/6 from ipsilateral
and contralateral sides of animals injected with FCA
and sham operated (a) or, adrenalectomised (b).
Values are mean with S.E.M. to bar
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Figure 5.16 The circumference (cm) of the ipsilateral (a) and
contralateral (b) carpal joint of rats receiving FCA
injection and vehicle, DEX or RU38486. Values are
mean with S.E.M. to bar




Figure 5.17 SP content (pg/ganglion) of drg collected in pairs C2/3,
C4/5, C6/7, T1/2, T3/4, and T5/6 from ipsilateral and
contralateral sides of animals injected with FCA and
administered DEX (a) or RU38486 (b) from days 10 to
20. Values are mean with S.E.M. to bar
(*p < 0.05; ANOVA, Scheffe's F-test)
ADJUVANT + DEXAMETHASONE F'q- 5.17a
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Figure 5.18 CGRP content (pg/ganglion) of drg in pairs C2/3, C4/5,
C6/7, T1.2, T3.4 and T5/6 from ipsilateral and
contralateral sides of animals injected with FCA and
administered DEX (a) RU38486 (b) from days 10 to 20.
Values are mean with S.E.M. to bar
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content of ipsilateral drg with contralateral drg in DEX-treated animals
revealed no significant difference between the two sides (ANOVA).
Effects of RU38486 on FCA-injected animals
The body weight of animals treated with RU38486 did not differ
significantly (ANOVA) from that of the FCA control group at any point during
the experiment (Fig. 5.9c). Compared with FCA treated control animals,
RU38486 treatment did not significantly alter plasma B or ACTH, although
ACTH did tend to be lower (Table 5.2, unpaired t-test). In both the FCA
controls and the RU38486-treated animals, the circumference of the
ipsilateral carpal joint was significantly (p < 0.01, ANOVA, Scheffe's F-test)
greater than the contralateral from day 2 until the end of the experiment
(Fig. 5.16). Treatment of FCA-injected animals with RU38486 from day 10
until the end of the experiment did not significantly alter the circumference of
the ipsilateral carpal joint compared with FCA controls.
Compared with the SP content of drg from FCA-treated animals,
RU38486 did not produce a significant change in any of the areas studied
(ANOVA Fig. 5.17).
CGRP content of ipsilateral C6/7 drg of RU38486 treated animals was
significantly (p < 0.05; ANOVA, Duncan's multiple range test) greater than
that of FCA-treated controls (Fig. 5.18). Comparing drg from the two sides
of RU38486-treated animals, no significant difference between ipsilateral
and contralateral CGRP contents was apparent; although CGRP content of
ipsilateral C6/7 drg tended to be greater than contralateral, this was not
significant.
5.4 DISCUSSION
In the present study, I have investigated, using RIA, the neuropeptide
content of drg following induction of monoarticular adjuvant arthritis in the
left carpal joint of the rat. Injection of FCA or ICA resulted in an acute
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inflammation of the ipsilateral joint over the first four days. In the carpal joint
of the FCA injected animals, this initial acute inflammation was more severe
and a period of secondary inflammation was apparent between 12 and 18
days after injection (Fig. 5.2a.). I have shown that 15 (Fig. 5.5a.) but not 20
days (Fig. 5.10a.) following induction of FCA evoked inflammation there was
an increase in CGRP content of dry from level C6/7 of the ipsilateral side, but
that no significant change in SP and SS content was detectable, although
SP content did tend to be greater on the ipsilateral side. Whilst DEX
suppressed the inflammation (Fig. 5.16a.), ADX exacerbated and extended
the duration of the swelling of the affected joint to day 20 (Fig. 5.13a.), at
which point the CGRP content of ipsilateral C6/7 drg (Fig. 5.14b.) was
elevated. The CGRP content of the ipsilateral T1/2 drg of ADX animals was
also significantly greater.
The evidence from other studies implicating neuropeptides in the
pathology of adjuvant arthritis has been discussed in the Introduction.
Weike and colleagues (1988) described increased immunostaining for SP
and CGRP in the dorsal horn and in peripheral inflamed tissues a
proliferation of immunoreactive fibres was noted. Release of CGRP into the
spinal cord of adjuvant arthritic rats inoculated in both hind paws, is
significantly enhanced compared with controls (Nanayama et al., 1989) and
CGRP content of lumbosacral drg of arthritic rats is also elevated (Kuraishi et
al., 1989) . Consequently, my own finding of increased CGRP in ipsilateral
drg at C6/7 is in agreement with previous findings implicating CGRP in the
inflammatory process and it may be that the increased content reflects
elevated biosynthesis of CGRP to supply the reported proliferation of
CGRPergic peripheral terminals and increased release of CGRP in the
dorsal horn.
SP has also been implicated in the pathology of adjuvant arthritis
from a number of studies, including that of Weihe (1988) described above.
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Oku et al. (1987) reported that spontaneous release of SP into the spinal
cord was enhanced in polyarthritic rats over controls and passive movement
of inflamed joints, likely to cause pain, potentiated spontaneous release of
SP. The suggestion that SP is directly involved in the transmission to the
dorsal horn of pain produced by the movement is supported by the finding
that in control animals, no increase in SP release was apparent following
passive movement. Supporting the role of SP in inflammation, it has been
shown that in the adjuvant rat model, severely arthritic joints (ankles) have a
more dense SPergic innervation than more mildly arthritic joints (knees)
(Levine et al., 1984). In addition, infusion of SP agonists or SP antagonists
into the inflamed joint respectively potentiated and ameliorated the
inflammation. In my own experiments I found a moderate but not significant
increase in the SP content of drg. Lembeck and colleagues (1981) have
reported a similar moderate, but not significant, rise in SP content of drg
following induction of adjuvant arthritis, and Weihe et al. (1988) suggested
that the changes in CGRP staining in the periphery and drg were more
pronounced than those for SP. This does not, however, preclude a role of
SP in adjuvant arthritis in peripheral tissues or the dorsal horn. It is possible
that whilst the storage of SP is not enhanced in drg, the synthesis may be
increased to supply the extra peptide requirement suggested by the results
described above.
Recently, in contrast to mine and others results, Satoh (1990) and
Ohno (1990) have reported increased SP, CGRP and SS content of drg in
adjuvant and carageenin models of inflammation. It is possible that the
model of arthritis used in this study produces a less severe inflammation of
the joint, that does not involve SP or SS. Kuraishi et al. (1989) reported an
increase in paw circumference of approximately 100% in contrast to the 50%
increase found in this study. In that study, a higher dose of adjuvant was
used to induce arthritis, and it is possible that in the less severe, low dose
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model used here, the inflammation is not sufficiently pronounced to produce
changes in SP content of drg. Interestingly, Kuraishi and colleagues
(1989), using the same methodology as Ohno (1990), report a reduction in
the withdrawal threshold of arthritic rats in the Randall-Silleto test. In the
current study, while the adjuvant arthritis produce a relatively mild
inflammation and erythema, the lesion did not appear painful, as the animals
did not lose weight compared with untreated controls, groomed normally,
and bore weight on the affected limb. Thus, it may be that SP is only
important in painful inflammatory conditions. This suggests that CGRP is
involved in mild inflammatory processes and SP is involved only in more
severe, possibly painful inflammatory processes.
Whilst the origin of the sensory innervation of the carpal joint in the rat
is not known, the changes in neuropeptides following localised, unilateral
inflammation of this joint were restricted to ipsilateral C6/7 drg. The
specificity of these changes suggests that principally C6/7 (and possibly
T1/2) drg innervate the area of inflammation, and that changes in
neuropeptide contents are due to local inflammatory processes and do not
arise from systemic consequences of adjuvant arthritis. The sensory
innervation of the carpal joint might be established by using one of the many
retrogradely transported markers, such as true blue. Following intra¬
articular injection, this label is taken up by nerve terminals and retrogradely
transported to the cell bodies. It is easily visualised in innervating drg using
fluorescence microscopy.
My finding that ADX prolonged the inflammation and was associated
with elevated CGRP content of ipsilateral C6/7 and T1/2 drg, and DEX
suppressed the inflammation affirms the clinical use of glucocorticoids in the
treatment of inflammatory disorders. The mechanisms by which
glucocorticoids produce their anti-inflammatory activity have been discussed
in the introduction to this Thesis (Chapter 1) and were shown to be complex,
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varied and poorly understood. The results of my own study infer that a
component of glucocorticoid anti-inflammatory activity might be to limit the
availability of CGRP, a potent vasodilator (Brain et al., 1985) at peripheral
terminals of primary afferents. Capsaicin destroys primarily C afferent fibres
including SP and CGRP containing nerves and it has been shown that
neonatal capsaicin treatments attenuates the oedema occurring in adjuvant
arthritis (Levine et al, 1986). These findings support my contention that
reducing the availability of neuropeptide in the periphery is anti¬
inflammatory, and my findings in Chapter 3 that glucocorticoids down-
regulate CGRP content of drg supports the suggestion that this may be a part
of their anti-inflammatory actions.
It should, however, be noted that the time course of the adjuvant
evoked inflammation in the current series of experiments was variable. In
the experiment investigating the role of glucocorticoids (Experiment 3), there
was no significant difference in CGRP content of ipsilateral C6/7 drg
compared with that of contralateral C6/7 drg of the FCA control group, in
contrast to Experiment 2. Furthermore, in these animals, the inflammation
was receding at the time the neuropeptide contents were determined. This
does not alter the interpretation of the effects of ADX, which clearly
exacerbated the inflammation and increased ipsilateral CGRP content.
Flowever, whilst DEX treatment equally clearly reduced the inflammation, it
cannot be determined from the present results if this was also associated
with a reduction in CGRP content of ipsilateral C6/7 drg. In future
experiments, this question may be addressed if animals are killed at the time
when the inflammation in FCA control animals is at a peak.
In contrast to the effects of ADX to prolong inflammation and elevate
ipsilateral C6/7 drg CGRP content, RU38486, the Type II corticosteroid
receptor antagonist, did not change the progress of the inflammation
compared with FCA-injected controls. Furthermore, whilst the ipsilateral
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C6/7 CGRP content of RU38486-treated animals tended to be greater than
that of the contralateral, this was not significant It is likely that the dose of
RU38486 used in this study was insufficient to block the action of
endogenous glucocorticoids. Evidence for this comes from the finding that
whilst following ADX, plasma ACTH rose over 4-fold, plasma ACTH of
RU38486-administered animals was slightly lower than FCA-treated
controls. It is suggested that at the doses used in this study, RU38486
produced only incomplete antagonism of the anti-inflammatory actions of
endogenous glucocorticoids.
The present results give no indication as to the mechanisms
underlying the changes in CGRP content of drg in adjuvant arthritis. As
discussed in the introduction to this thesis (Chapter 1), CGRP is contained in
a large proportion of the cells of the drg, in both the large light and small
dark populations. Whilst Weihe et al. (1988) reported that immunostaining
for CGRP and SP was enhanced in cells of the drg, and there was no
expansion of the immunoreactive populations, they did not report if this was
in the total population, or a subset thereof. Given the effect of capsaicin,
which destroys primarily C-fibres (principally, small dark cells), in reducing
oedema in adjuvant arthritic rats (Levine et al., 1986), it would be of interest
to establish if solely this population of CGRP containing cells showed
enhanced immunoreactivity. This might be determined using
immunohistochemistry, which would also allow investigation of the response
in those cells co-localising SP and CGRP. The use of consecutive sections
stained for SP or CGRP immunoreactivity, or double labelling techniques,
would be useful in such a study.
In the drg, neuropeptides are synthesised in the soma and
transported in vesicles to the peripheral or central terminals, although some
peptide is degraded in the soma. Consequently, an increase in peptide
content of the drg may reflect reduced axoplasmic transport from the drg,
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increased synthetic rate, or reduced degradation rate. Whilst the evidence
of other authors (Weihe et al., 1988) would suggest that the transport of
CGRP and SP must be elevated to supply the expanded ramifications of the
peripheral and central terminals, this might be established in studies using
ligation of peripheral nerve (MacLean 1987; MacLean & Lewis 1984; see
Introduction to Chapter 3).
Given the chronic nature of adjuvant evoked inflammation, it is
possible that the CGRP content was increased through elevated gene
transcription, mRNA translation or reduced mRNA degradation. Whilst this
is of interest in itself, it may also be of relevance in considering the actions of
glucocorticoids as they act principally, if not exclusively, on the genome to
influence transcription (see Chapter 1). This question might be examined
by use of a Northern blot or nuclease protection assay for CGRP mRNA.
Both techniques would also indicate if a or (3 CGRP or both species was
involved in the pathology of adjuvant inflammation. In situ hybridisation,
using probes specific for either a or (3 CGRP mRNA would also be useful in
investigating the cell population involved in the response to adjuvant
innoculation.
In conclusion, I have demonstrated, using an adjuvant model of
rheumatoid arthritis, increased CGRP content of drg but not of SP and SS
during inflammatory processes. I have further shown that DEX reduced the
inflammation whilst ADX prolonged the duration of inflammation and this
was associated with an increase in the CGRP content of C6/7 and T1/2 drg.
I speculate that part of the anti-inflammatory action of glucocorticoids might
be to regulate the availability of CGRP at primary afferent terminals in the
periphery.
CHAPTER 6
GLUCOCORTICOID REGULATION OF SP AND CGRP IN VITRO:
DISSOCIATED PRIMARY CULTURE OF ADULT RAT DRG
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6.1 INTRODUCTION
Harrison (1907) was the first to culture nervous tissue; a fragment of
frog neural tube placed in a drop of clotted lymph on a coverslip which was
inverted and sealed over a depression slide. With suitable aseptic
precautions, cultures could be maintained for up to four weeks and the
development of nerves observed. For culture of avian and mammalian
tissue, the lymph was replaced by plasma and embryo extract provided the
nourishment required which, in the frog, is contained within the embryonic
cells themselves. Further developments included culture of sympathetic
ganglia explants on chick embryo intestinal wall placed in saline solutions
and the use of cerebrospinal fluid as a medium for mammalian cerebral
cortex. In general, however, cultured avian or mammalian tissue underwent
a characteristic granular degeneration within one or two weeks (see Murray,
1965).
From these initial experiments, technical developments in the
composition of the medium and nature of supplements, the substrate to
which cultures attached and the vessels in which they were grown improved
the viability of cells and produced cultures which more closely resembled
tissues in vivo. Noteworthy amongst these developments was the addition
of foetal or placental serum to media and the addition of glucose
supplement to the medium. Reduction of toxic trace elements in reagents
used to produce media, and use of collagen-coated coverslips to allow cells
to adhere, rather than be held stationary in plasma clots further enhanced
survival of neuronal cultures (see Murray, 1965; Nelson, 1975).
Whilst initial studies were concerned with tissue explants held in
plasma clots, Nakai (1956) produced cultures of dissociated chick embryo
drg by digestion with proteinase followed by gentle trituration. The resulting
cell suspension, contained in a balanced salt solution, was added to an
equal amount of chick embryo extract alone or supplemented with human
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placental serum or bovine serum. This mixture was then clotted using
heparinised cockerel plasma and placed in a Maximow slide preparation.
Incubated at 37°C, the cultures could be maintained for up to 19 days. A
number of improvements in this technique followed; the development of
chemically defined media, sufficient to maintain neurons in culture when
supplemented with foetal calf serum was of particular significance (Scott et
al., 1969). The use of collagen substrata and a rigorous study of the
digestion agents (Banks et al., 1970) also enhanced the survival of
dissociated cultures.
Whilst the vast majority of early studies used embryonic or early post
natal tissue for culture, initially there were relatively few reports of successful
culture of adult neurons. Adult human sympathetic ganglia (Murray & Stout,
1974,1975) adult rat sympathetic ganglia (Silberstein et al., 1971, 1972),
adult frog drg (Padjen et al., 1975) and adult frog sympathetic ganglia (Hill &
Burnstock, 1975) were notable exceptions but it was not until 1977 that the
first report of dissociated culture of mammalian (mouse) adult drg appeared
(Scott, 1977). In this technique, drg were 'softened' in 0.25% collagenase
before being split open with microforceps and triturated in a firepolished
pipette. The cells were cultured on collagen-coated coverslips in CMRL-
1415 medium supplemented with 10% foetal calf serum. A variety of media
have since been used to maintain dissociated cultures of drg but the
medium used in this study is based on that of Lindsay (1988).
In these early experiments, no attempt was made to reduce the
numbers of non-neuronal cells. However, non neuronal cells are mitotically
active and consequently, with time tend to multiply and cover the culture
plate, compromising the survival of neurons. Furthermore, the presence of
non-neuronal cells complicates interpretation of experiments utilizing
cultures of drg neurons as it is now known that such cells produce growth
factors, including NGF which are important in supporting the survival and/or
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stimulating outgrowth of neurites from both neonatal and adult drg neurons
(Varon et al., 1974; Wrathall, 1982; Roufa et al., 1983). Interestingly, it has
also been claimed that non-neuronal cells regulate SS content of cultured
sensory neurons (Mudge, 1981). Initially, methods for purifying neurons
from non-neuronal cells in drg preparations were based on that employed in
the purification of chick embryo cortical cells (Varon et al., 1969).
Suspension of drg were plated for approximately three hours onto layers of
glass beads, to which the non-neuronal cells preferentially adhered. The
supernatant containing purified neurons was then removed and plated on to
culture dishes. With this method, an increase in the percentage of neurons
from 40% to 80% was achieved (Okun, 1972). Another technique relied on
the differential sedimentation of the two cell types under centrifugation, in
which neurons were gently pelleted leaving the smaller non-neuronal cells
and connective tissue debris in the supernatant (Lodin et al., 1970; Miller et
al., 1970). Passing drg suspensions through Percoll gradients also proved
useful (Goldenberg & De Boni, 1983). In the current study, non-neuronal
cell numbers were reduced using a method based on that described by
Lindsay (1988). This technique relies on a combination of cleaning drg of
connective tissue to reduce initial non-neuronal cell contamination,
preferential adherence of non-neuronal cells to a polyornithine substrate
(McCarthy & Partlow, 1976) and differential sedimentation of the two cell
types.
Whilst the pre-plating procedure reduces the non-neuronal cell
population a certain proportion of such cells remain following plating onto
laminin. Given that such cells are mitotically active and tend to proliferate in
culture it is desirable to inhibit their multiplication by inclusion in the medium
of a mitotic inhibitor. Typically, in previous studies the chemotherapeutic
agent cytosine arabinoside (Ara-C), a structural analogue of 2'-
deoxycytidine was included for such a purpose (Lindsay, 1988; Lindsay et
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al., 1989). Despite extensive study, the precise mechanism of action of Ara-
C is not clear (Calebresi & Parks, 1985), although it has been found to
inhibit DNA strand elongation following phosphorylation to an active
intermediate that substitutes for dCTP (Kufe & Major, 1982). However,
when used clinically in the treatment of leukaemia patients occasionally
suffer from a cerebellar toxicity syndrome in which Purkinje cells die, despite
the fact that such cells are not mitotically active (Sylvester et al., 1987;
Winkelman & Hines, 1983).
Such observations have led to a re-evaluation of the use of Ara-C as
a mitotic inhibitor in the culture of neuronal cells. Wallace and Johnson
(1989) have recently reported that Ara-C produces a dose dependent
inhibition of potassium and insulin stimulated survival of postmitotic (E8)
chick ciliary ganglion neurons and the NGF stimulated survival of postmitotic
chick drg neurons. This cytotoxic effect of Ara-C was blocked by 2'-
deoxycytidine, but this factor did not of itself enhance survival. Furthermore,
it has been demonstrated that the morphological and temporal
characteristics of neuronal death following NGF deprivation or Ara-C
treatment on post mitotic rat sympathetic neurons were indistinguishable
(Martin et al., 1990). Other means of producing neuronal cell death such as
ultraviolet irradiation and ricin toxin did not share these characteristics.
Thus, there is now some doubt as to the wisdom of using Ara-C as an
antimitotic agent in the preparation and maintenance of non-neuronal cell
free cultures. On consideration of the evidence indicating the dubious
suitability of Ara-C as an antimitotic agent I used an alternative method for
the control of non-neuronal cell proliferation.
Kao & Prokop (1977) have shown that a number of proline analogues
are incorporated into protein during procollagen biosynthesis in fibroblasts.
Furthermore, they demonstrated that culture of fibroblasts in the presence of
cis-4-hydroxyproline (cis 4-OH) markedly reduced their growth rate. Whilst
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the mechanism of action of this agent is not clear it is thought that it prevents
deposition of triple helical collagen at the cell surface, possibly inhibiting
adhesion of cells to the substratum. Thus inclusion of cis 4-OH proline in
the culture medium would appear to offer an expeditious, non-toxic method
of controlling fibroblast growth in cultures of drg. Observations of my own
cultures suggests that it also prevents generalised proliferation of non-
neuronal cells although this has not been quantified.
The major advantage of primary cultures of adult drg over embryonic
or post natal cultures is that NGF or other growth factors are not required for
cell survival. Lindsay (1988) has demonstrated using cultures of single
cells, in the absence of non-neuronal cells, that drg neurons can survive in
fully defined medium (i.e., F.14 supplemented with insulin, transferrin,
selenium, progesterone and putrescine) for up to seven days in culture.
Whilst NGF and BDNF were not required for neuronal survival, they did
enhance neurite formation and NGF has been found to regulate SP and
CGRP gene expression and peptide content (Lindsay et al., 1989; Lindsay
& Harmar, 1989). The SS content of drg in culture rapidly falls to low levels
and is not maintained in the presence of NGF or other growth factors
(A. J. Harmar personal communication) and thus it is not currently practical
to study regulation of drg SS in the the dissociated culture system.
However, the adult rat drg primary culture system offers the opportunity to
examine regulation of SP and CGRP in a fully defined medium.
In the current study, I have developed primary culture of adult rat drg
and used this system to investigate adrenal steroid regulation of SP and
CGRP content of drg. Previously, in collaboration, I have demonstrated,
using in situ hybridisation histochemistry, the presence of mRNA for Type I
and Type II corticosteroid receptors in drg (J. Seckl et al, unpublished
observations). Furthermore, I have demonstrated that SP and CGRP
content of drg increased following ADX and that this was reversed by
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administration of glucocorticoids. However, there was no indication from
these in vivo experiments of the site of action of glucocorticoids; directly at
the drg or by some other, secondary intermediate. One way of resolving
this question is to examine the role of glucocorticoids in regulation of SP
and CGRP in purified culture of neurons.
6.2 METHODS
Between four and six Cob Wistar rats (male, 200g) were killed by
decapitation, drg dissected free and dissociated cultures of drg enriched for
neurons prepared as described previously (Chapter 2). Cells were plated
onto 35mm four well plates coated with laminin at a density of 3000-5000
cells/well (constant within each experiment). Medium containing antibiotics
was supplemented with either 4% USG or the defined serum supplement
ITS+ containing insulin, transferrin, selenium and fatty acids; cis 4-OH
proline (200|ig/ml) was added to inhibit non-neuronal cell proliferation.
Medium was changed on day 1 and every 2 days thereafter and samples
were extracted from each well separately in 80(il 2M acetic acid and stored
at -70°C before RIA for SP or CGRP.
A number of experiments were performed to investigate the action of
corticosteroids on neuropeptide content of drg. Experiments were carried
out over 3 or 5 days and samples were extracted on days 0,1,3 and 5. The
effect of forskolin (10|iM), B (lOOpg/ml), DEX (10|iM) and NGF (25ng/ml) on
SP and CGRP content of drg in medium supplemented with either ITS+ or
USG was initially studied. Subsequently, the effect of dexamethasone and




6.3.1 Effect of NGF
In the absence of NGF, SP and CGRP contents of drg grown in
medium containing USG or ITS+ fell over 5 days from the time of plating.
NGF administration maintained the SP and CGRP contents of drg in media
supplemented with USG or ITS+ compared with untreated controls over the
same period (Fig. 6.1a,b).
6.3.2 Effect of forskolin
As in previous studies, SP and CGRP contents of drg decreased over
the 3 days from the time of plating when grown in either USG or ITS.
Forskolin administration over the same period produced a significant
increase in both SP (Fig. 6.2a) and CGRP (Fig. 6.2b) content of drg grown in
medium supplemented with either USG or ITS when compared with the
untreated controls.
6.3.3 Effect of Dex and B
In the absence of NGF, SP and CGRP content of cultures fell rapidly
from the time of plating; concomitant administration of DEX (Fig. 6.3a,b) or B
(Fig. 6.4a,b) did not influence this reduction. Fig. 6.5a,b shows the effect of
DEX and B on SP and CGRP content of drg grown in ITS+ supplemented
medium in the presence of NGF. SP content fell slightly from the time of
plating, but concomitant administration of DEX or B significantly reduced the
SP content over the same period. CGRP content increased from the time of
plating, and administration of DEX or B significantly reduced CGRP content.
6.4 DISCUSSION
As found by previous authors, I have shown that NGF is required in
order to maintain SP and CGRP content of drg in culture. Administration of
Figure 6.1 The effect of NGF (25ng/ml) on SP (a) and CGRP (b)
content (pg/well) of neuron enriched cultures of drg
grown in medium supplemented with ITS+ or USG
(4%).











Figure 6.2 The effect of forskolin (FK; 10pM) on SP (a) and CGRP
(b) content (pg/wel!) of neuron enriched cultures of drg
grown in medium supplemented with ITS+ or USG
(4%).
Values are mean with S.E.M. to bar (n = 8)
CGRPCONTENT (pg/well)
SPCONTENT (pg/well)
Figure 6.3 The effect of DEX (10|iM) on the SP (a) and CGRP (b)
content (pg/well) of neuron enriched cultures of drg
grown in medium containing ITS+ or USG (4%).
Values are mean with S.E.M. to bar (n = 8)
CGRPONTENT (pg/well)
SPCONTENT (pg/well)
Figure 6.4 The effect of B (100|ig/ml) on SP (a) and CGRP (b)
content (pg/well) of neuron enriched cultures of drg
grown in medium containing ITS+ or USG (4%).
Values are mean with S.E.M. to bar (n = 8)
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Figure 6.5 The effect of DEX (10pM) or B (100(j.g/ml) on SP (a)
and CGRP (b) content (pg/well) of neuron enriched
cultures of drg grown in medium supplemented with
ITS+ and 25ng/ml NGF (n = 8)




DEX or B reduced NGF maintained SP and CGRP content, but of
themselves did not appear to influence the SP and CGRP content of
cultures. These results suggest that adrenal steroids regulate SP and
CGRP content of drg directly, possibly by antagonising the action of NGF.
Furthermore, I have found that forskolin, which activates adenylate cyclase
leading to increased c-AMP production, stimulated an increase in both SP
and CGRP content of cultured drg.
The finding that DEX and B reduced the SP and CGRP contents of
cultures grown in the presence of NGF is consistent with my observations in
vivo. Following ADX, SP and CGRP contents of drg were increased, and
this was prevented by administration of DEX or B (see Chapter 3). In other
tissues, glucocorticoids has also been shown to regulate neuropeptides.
DEX reduced SP content of rat neonatal superior cervical ganglia in
dissociated culture in the presence of NGF (Kessler et al., 1983). NGF
increased both SP and CGRP content of cultured neonatal rat vagal sensory
neurons, whilst B reduced SP but not CGRP content independently of NGF
(MacLean et al., 1989). In the clonal rat C-cell derived 44-2C cell line, DEX
significantly reduced the levels of CGRP-specific mRNA (and calcitonin
peptide and mRNA; Zeytin et al., 1987).
The PC12 cell line, derived from a rat phaeochromocytoma responds
to both NGF and glucocorticoids, and synthesises a number of
neuropeptides including neuropeptide Y (NPY) and neurotensin (NT). The
NPY content of PC12 cells grown in the presence of NGF increases, and this
is inhibited by concomitant administration of DEX (Sabol & Higuchi, 1990).
In contrast, intracellular content and synthesis of NT is substantially and
synergistically increased by the combined action of NGF and DEX (Tischler
et al., 1982, 1986). Further studies have demonstrated that these agents
act to increase mRNA encoding NT/neuromedin (Dobner et al., 1988).
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PC12 cells grown in the presence of glucocorticoids round up and
differentiate to a cell type with a phenotype resembling an endocrine
adrenal chromaffin cell, and cultures grown in the presence of NGF tend to
stop dividing, flatten down on to the substratum and extend neurites.
Similarly, in cultures of dissociated rat adrenal chromaffin cells, it is found
that NGF stimulates fibre outgrowth, and this is abolished by glucocorticoids
(Unsicker et al., 1978). Sympathetic neurons grown in dissociated culture
elaborate neurites in response to NGF, and this is inhibited, but not
completely abolished by administration of glucocorticoids. It is now
considered that glucocorticoids influence differentiation of the
sympathoadrenal lineage derived from neural crest precursors; thus, NGF
promotes development of such cells into noradrenergic neurons and
glucocorticoids stimulate the development of so-called 'SIF' (small intensely
fluorescent) cells (Landis & Patterson, 1981). It appears that the apparently
antagonistic link between the actions of NGF and glucocorticoids, whilst not
immutable, is a commonly encountered phenomenon, both in neuropeptide
regulation, and differentiation and development.
The glucocorticoid receptor contains a region, known as the DNA
binding domain (domain C, see Fig. 1.4), within which is found two zinc-
finger motifs. Such structures are thought to allow the ligand activated
receptor to bind, as a dimer to DNA in the 5' regulatory regions of genes.
Analysis of the sequence specificity of binding has allowed construction of a
15 mer base pair sequence which shows greatest specificity for binding of
the glucocorticoid receptor, the so-called glucocorticoid response element
(GRE(+)). It is thought that glucocorticoids produce their effects by binding
to this sequence to activate gene transcription (see Chapter 1 for full
description and references). Given that SP and CGRP content was reduced
by glucocorticoids, it may be that this was due to a direct action on a GRE(-)
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(see Chapter 1), the binding of glucocorticoids to which is thought to down-
regulate gene expression.
Sequence analysis of 800bp of the 5' flanking region of the rat PPT
gene and 1.8kb of 5' flanking sequence of the human calcitonin/a-CGRP
gene reveal no sequences with homology to the GRE(+) (Carter & Krause,
1990; Broad et al., 1989). Currently, no consensus sequence is available
for the GRE(-) and thus it is not known if such a region is contained within
the regulatory sequences of the SP or CGRP genes. Alternatively, it may be
that they are contained in regions not yet sequenced or glucocorticoids may
influence transcription by regulation of an unknown, trans-acting factor.
In the current study forskolin, an activator of adenylate cyclase was
found to mimic the effects of NGF on SP and CGRP content. A number of
other biochemical and transforming actions of NGF such as NGF induced
phosphorylation (Flalegoua & Patrick, 1980) and neurite formation
(Schubert et al., 1978) can also be mimicked by c-AMP analogues; although
qualitative differences are apparent in the effects of NGF and c-AMP
agonists. These differences in the actions of the two agents, the findings
that NGF does not activate adenylate cyclase (Race & Wagner, 1985) and c-
AMP antagonists do not block the neurotrophic effects of NGF (Rydel &
Greene, 1988) suggests that the actions of NGF may not be mediated solely
or directly by a c-AMP second messenger. Furthermore and most
convincingly it has been found that a PC12 clone, deficient in c-AMP
dependent protein kinase is still NGF responsive (Rydel & Greene, 1988).
Inositol phosphate second messengers and tyrosine phosphorylation have
also been implicated in the action of NGF and it appears that NGF actions
are probably mediated via more than one second messenger signal (see
Cho et al., 1989; Levi & Alema, 1991).
That forskolin mimicked the effects of NGF on SP and CGRP content,
suggests that the two peptides may be regulated at the level of the genome
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by the action of c-AMP second messenger on a c-AMP response element
(CRE). A similar finding, that forskolin mimics the effect of NGF on SP and
CGRP peptide content has been reported for rat neonatal vagal sensory
neurons in culture (MacLean et al., 1989). In this study, it was further shown
that forskolin also increased SP but not CGRP content of cultures in the
presence of maximal doses of NGF, indicating that other mechanisms or
ligands mediated by adenylate cyclase, may regulate SP content in this
tissue.
Cote et al. (1990) coupled the first 146bp of the 5' regulatory region of
the calcitonin/CGRP gene, to a human growth hormone reporter gene and
transfected this into TT cells (derived from a medullary thyroid carcinoma).
Studies demonstrated that expression of this construct was up-regulated by
cAMP mimetics. In another medullary thyroid carcinoma cell line (MTC
cells), secretion of calcitonin and expression of calcitonin mRNA was found
to be up-regulated by forskolin (Haller-Brem et al., 1988). Sequence
analysis of the regulatory regions of the human calcitonin/a-CGRP gene has
identified two potential CREs one with two inverted copies of the consensus
sequence and one with a single copy of the consensus sequence (Broad et
al., 1989). Whilst no studies are known of cAMP regulation of the tachykinin
gene, sequence analysis has identified two regions with homology to the
CRE consensus sequence (Carter & Krause, 1990). My findings suggest
that in drg, forskolin may stimulate production of cAMP possibly leading to
enhanced SP and CGRP gene transcription and synthesis, resulting in
increased peptide content. Interestingly, glucocorticoid inhibition of the
human glycoprotein hormone a subunit has been found to occur as a
consequence of the close proximity of a GRE(+) and a CRE. Negative
regulation of gene expression is thought to occur when glucocorticoid
receptors bind to the DNA and impair binding of transcription factors acting
through the CRE (Akerblom et al., 1988). Given the lack of GREs in the
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regulatory regions of the CGRP and tachykinin genes, it is not thought likely
that such a mechanism would account for my findings.
The SP and CGRP contents of NGF maintained cultures were
reduced significantly by DEX and B, both of which were used at a high dose,
DEX was more effective than B, suggesting this action could be mediated
via Type II receptors but, from this single dose observation, it is not possible
to state this conclusively. Previously, in collaboration with Dr. J.S. Seckl, I
have demonstrated, using in situ hybridisation, the mRNA for both Type I
and Type II receptors in the neurons of the drg. Thus, adrenal steroids may,
through either receptor, regulate neuropeptides in the drg. Further studies
utilising the recently developed Type II specific agonists and antagonists
would provide conclusive evidence as to the nature of the corticosteroid
effect. In further experiments, I would suggest that antagonism of DEX and
B suppression of SP and CGRP contents by the Type II specific antagonist
RU38486 and use of RU28362 (a Type II specific agonist) to mimic the
actions of DEX and B should provide sufficient evidence as to the nature of
the receptors mediating steroid inhibition.
The molecular mechanisms underlying the maintenance of SP and
CGRP contents of drg neurons in dissociated culture have been investigated
previously (Lindsay & Harmar, 1989). Following culture of dissociated
neurons in the absence of NGF, a fall in SP and CGRP peptide was
paralleled by a reduction in mRNA encoding the two peptides. It was further
demonstrated that NGF stimulated an increase in SP and CGRP peptide,
preceded by increased SP and CGRP mRNA content. It would be of
interest to extend the results of my current study by determining if
glucocorticoids reduce SP and CGRP peptide content by an action of the
transcription of the respective genes. As discussed earlier, this is of
particular interest, given the proposed mechanism of action of
glucocorticoids, to influence gene transcription. Whilst the Northern blot
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would allow determination of total mRNA for SP or CGRP, the production of
a number of PPT mRNAs and the role of mRNA splicing in the regulation of
CGRP mRNA expression suggests that a nuclease protection assay might
be more informative. Such a technique, if the appropriate probes are
available, allows assessment of changes in the splicing pattern of mRNA, in
addition to changes in the total mRNA content.
Nuclease protection assays provide information regarding splicing
but do not identify regulatory sequences in the 5' non-coding region of the
gene. Such sequences can be identified using constructs comprising the 5'
regulatory regions of genes and a reporter gene such as chloramphenicol
acetyltransferase (CAT; Seed & Sheen, 1988). These constructs can be
transfected into an appropriate cell line, site directed mutagenesis used to
delete or reconstruct specific sequences of the regulatory region to
determine their importance in control of reporter gene expression by
particular ligands. Preliminary studies of this nature, using PC12 cells
transfected with 1.8kbp of bovine PPT gene regulatory sequences (1.9kbp)
indicate that glucocorticoids do not influence gene transcription (C. Gilchrist,
personal communication). However, it may be that the sequences
responsible are not contained in the fragment transfected, or the PC12 cell
line may not be an appropriate model in which to study this phenomenon.
PC12 cells synthesise SP at very low levels, and it may be that they are
deficient in some unknown protein necessary for expression of the PPT
gene. It is possible that the recently developed ND cell lines (produced by
fusion of neonatal-rat drg and N18Tg2 mouse neuroblastoma cells) might
be more appropriate for such work. These cells are found to contain
relatively large amounts of SP and CGRP (and SS), a property of drg
neurons (Wood et al., 1990).
In previous experiments in vivo (Chapter 3), I have shown that ADX
increased SP and CGRP contents of drg and that this was reversed by DEX
administration. However, given the complexity of the whole animal, I was
not able to demonstrate that glucocorticoids have a direct effect on the drg.
The experiments described in this chapter confirm and extend my
observations in vivo. I have now shown that DEX and B both reduce the SP
and CGRP contents of dissociated drg grown in medium containing NGF.
Whilst the mRNA encoding both Type I and Type II receptors has been
localised in neurons of the drg using in situ hybridisation, the action of DEX
suggests that steroid action may be mediated by the Type II receptor,
although further studies are required to conclusively prove this assertion. In
conclusion, I would suggest that glucocorticoids act directly on drg neurons
to inhibit biosynthesis of SP and CGRP.
CHAPTER 7
THE DISTRIBUTION OF SP, SS AND CGRP CONTENT OF
DRG FROM LEVEL C1 TO L6 OF THE RAT
136
7.1 INTRODUCTION
In previous studies of drg from the cervical spinal column (C4-C7,
Chapter 3), I have shown that the neuropeptides SP, SS and CGRP are not
evenly distributed, but rather, SP and CGRP content was greatest in drg
from C7 and SS content was greatest in drg from C4. The distribution of
neuropeptides in sensory ganglia may be of importance in understanding
factors regulating the development of neural crest progenitor cells and the
functional significance of neuropeptide in sensory ganglia. In the following
chapter, a description of the distribution of SP, SS and CGRP in drg from
C1 to L6 is given.
7.2 METHODS
Six Ham Wistar rats (male, 200g) were killed by asphyxiation in CO2,
the dorsal surface of the spinal column exposed and laminectomy
performed to reveal the spinal cord from level C1 to L6 (see Chapter 2).
The spinal cord was carefully dissected free, leaving the drg in situ, which
were removed bilaterally in pairs from each level (C1 to L6) and rapidly
frozen on dry ice. After weighing, tissues were homogenised in 2M acetic
acid centrifuged at 16000g, for 10 min, and SP, SS and CGRP content of
the supernatants determined by RIA (Chapter 2).
7.3 RESULTS
Generally, wet weight (Fig. 7.1a) of drg was between 0.3mg and
0.5mg, but this increased in the cervical region between C4 and T1 to a
maximum at C7, and in the lumbar region between L3 and L6 to a
maximum at L5. The SP content of drg (Fig. 7.1b) was found to be
distributed similarly to wet weight; minima from C1 to C3 and T4 to T5. In
cervical drg, SP content increased progressively from C4 to a maximum at
C7. In the thoraco-lumbar region, between T8 and L3, SP content was
Figure 7.1 (a) Wet weight (mg) of drg from level C1 to L6
(b) Distribution of SP content (pg/ganglion) in drg from
C1 to L6

























































relatively uniform. Of the lumbar drg, L5 contained the greatest SP. CGRP
content of drg (Fig. 7.2a) from rostral regions increased moderately from C1
to C7 and subsequently decreased to T5. In thoraco-lumbar regions of the
spinal column, drg content of CGRP was generally greater than in more
rostral drg, and maximum in drg from L5. SS content (Fig. 7.2b) was
distributed in a markedly different pattern from the wet weight, SP and
CGRP content. SS content of drg from the cervical region of the spinal
column was greatest between C2 and C4. Between C4 and L1, SS
content was relatively constant and varied between a minimum at C7 and a
maximum at T1. In lumbar drg from L2 to L6, SS content was greatest in
drg from L2 and L6.
7.4 DISCUSSION
I have demonstrated, using RIA, that the neuropeptides SP, SS and
CGRP were not evenly distributed in drg from level C1 to L6. The wet
weight of drg was relatively uniform, except in the lumbar and cervical
enlargements. SP distribution paralleled drg wet weight, but CGRP was
found to be greatest in drg from the more caudal areas of the spinal column,
whereas SS content was greatest between C2 and C4 and least in C5, C6
and C7. Large amounts of SS were also found in drg from lumbar areas,
but elsewhere down the length of the spinal column, SS content was
relatively constant.
Little is known of the distribution of neuropeptides in drg from
different levels of the spinal cord. However, in rat, thoracic drg had the
highest CGRP content (Gibson et al., 1984b), consistent with this study.
Dynorphin content of rabbit drg was reported to be relatively uniform down
the length of the spinal column (Botticelli, 1981). In the spinal cord a
variety of neuropeptides including SP, CGRP (Gibson et al., 1984b), met-
enkephalin (Majane et al., 1983), neuropeptide Y (Gibson et al., 1984),
Figure 7.2 (a) CGRP content (pg/ganglion) of drg from C1 to L6
(b) SS content (pg/ganglion) of drg from C1 to L6
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avian pancreatic polypeptide (Hokfelt et al., 1981) and vasoactive intestinal
polypeptide (Gibson et al., 1984a; Anand et al., 1983), have been shown to
be in highest concentration in lumbo-sacral regions of a number of species
(Merighi et al., 1990).
The differential distributions of neuropeptides described here may be
a reflection of the cell types found in drg from various levels of the spinal
column. The neurons of the drg can be sub-divided into two histological
types based on their staining properties under the light (Hatai, 1902;
Lawson et al., 1974) and electron microscope (Duce & Keen, 1977) termed
large light or A, and small dark or B, type neurons (for a full description, see
Chapter 1); neuropeptides are found predominantly, although not
exclusively, in B-type neurons (Ju et al., 1987; Price, 1985, Tuscherer &
Seybold, 1985; Henken et al., 1988; Hokfelt et al., 1976). In studies of cat
drg, Rose (1990) has shown that rostral cervical drg (C1-C5) have
predominantly B type neurons (35-50|im in diameter) whereas 51-77% of
perikarya of drg from C6 to C8 are A type neurons (more than 50pm in
diameter). In thoracic drg (Larnicol, 1988), large diameter cells
predominate at the Ti level, but are in the minority at the T2-T4 level, where
medium diameter cells constitute the major class. The factors that regulate
cell diameter of neurons in the drg and produce these differences are
unknown, but it is likely that this differentiation occurs during development.
Drg arise from progenitor cells of the neural crest and undergo
natural cell death during development, where upon the size of the
remaining neuronal population of the drg is influenced by the extent of the
available target tissue ultimately innervated. Thus, in the chick embryo,
early removal of a limb bud results in hypoplasia of the corresponding drg
(Hamburger & Keefe, 1944) and, conversely, transplantation of a
supernumerary limb bud causes hyperplasia in adjacent drg (Hamburger,
1939; Hamburger & Levi-Montalcini, 1949). In the present study, drg
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innervating the forelimbs (C4 - C7) and hindlimbs (L4 - L6) had greatest wet
weight confirming the relationship between extent of peripheral target and
size of drg.
The peripheral target not only promotes neuronal cell survival, but
may also determine the function of the neurons that innervate that area
(Scott, 1986; Frank & Westerfield, 1982; Smith & Frank, 1987; Weiss,
1942; Miner, 1956; Baker & Jacobson, 1970). McMahon (1987) has
shown that redirection of nerves innervating skin to muscle reduces the
number of SP-containing fibres. Similarly, the number of SP fibres was
increased following redirection of muscle afferents to skin. It is thought that
target derived neurotrophic factor (NTFs) first postulated by Weiss and
others (Weiss, 1942; Sperry & Miner, 1949; Miner, 1956) may mediate the
influence of the periphery on drg. NTFs are retrogradely transported from
the periphery and chronic sciatic nerve section, crush, or inhibition of
retrograde transport from the periphery produces biochemical changes in
drg (Nielsch et al., 1987; Csillick & Knyihar-Csillick, 1982) including
changes in neuropeptides. A number of NTFs have been described
(Richardson, 1986; Riopelle & Cameron 1987; Richardson & Ebendal,
1982) including nerve growth factor (NGF), brain derived neurotrophic
factor (BDNF; Barde et al., 1982) and neurotrophin 3 (NT-3; Hohnetal.,
1990). NGF is a heteropentameric polypeptide synthesised in peripheral
tissues innervated by sensory neurons (Bandtlow, 1987), it is internalised in
nerve terminals and retrogradely transported by peripheral neurons
(Palmatier et al., 1984; Korsching & Thoenen, 1983) and administration of
NGF protects against the cell death seen following nerve injury or section
(Rich et al., 1987; Fitzgerald et al., 1985; Csillick, 1985). In vitro, NGF
elevates levels of SP and CGRP peptide and mRNA in primary culture of
adult drg (Lindsay & Harmar, 1989). Neurotrophic factors other than NGF
are also present in extracts of peripheral nerve (Richardson & Ebendal,
1983) and a variety of tissue extracts (Lindsay & Tarbitt, 1979; Lindsay &
Peters, 1984; Riopelle & Cameron, 1981; Hsu et al., 1984). Brain derived
neurotrophic factor (Barde et al., 1982), a peptide extracted from pig brain,
has been found to support survival of drg in vivo (Kalcheim, 1987) and in
culture (Lindsay et al., 1985; Hofer & Barde, 1988). Recently, Nawa &
Patterson (1990) have identified a number of factors from heart cell
conditioned medium that regulate neurotransmitter choice in sympathetic
neurons (Nawa & Sah, 1990). It is probable that a variety of factors
released from peripheral and central target areas regulate peptide content
of drg at different levels of the spinal column.
In conclusion, I have demonstrated that SP, SS and CGRP were not
evenly distributed in drg down the length of the spinal column. I suggest





In this thesis, I have presented results suggesting that adrenal
steroids regulate the SP, SS and CGRP content of drg in vivo In vitro,
glucocorticoids reduced SP and CGRP content of drg neurons cultured in
the presence of NGF, suggesting that glucocorticoids exert a direct effect
upon neuropeptide synthesis in drg neurons, possibly mediated by the Type
II corticosteroid receptor. Using an adjuvant model of inflammatory disease,
I have further demonstrated that CGRP and, possibly SP, in the drg may be
important in inflammatory processes, and that glucocorticoid regulation of
neuropeptides in the drg may contribute to their effectiveness as anti¬
inflammatory agents. In this chapter, I now propose a model of chronic
inflammation, in which NGF regulates the involvement of sensory neurons
and neuropeptides, and further suggest, that in such a model,
glucocorticoids can act at a variety of sites to reduce inflammation and pain.
A key mediator in the development of adjuvant arthritis, and possibly
of human rheumatoid arthritis (RA) is thought to be the cytokine interleukin 1
(IL-1; di Giovine & Duff, 1990). IL-1 is present in the synovial fluid of
patients suffering RA (Nouri et al., 1984; Marshall et al., 1990) and its
concentration is correlated with the severity of inflammation (Rooney et al.,
1989; Eastgate et al., 1988). In the synovial fluid, IL-1 is produced by
synovial cells, infiltrating leukocytes and activated macrophages (Gery &
Waksman, 1972) and chronic infusion of IL-1 enhances development of
arthritis in spontaneously arthritic MR/lpr mice (Henderson et al., 1988;
Horn, 1990) and development of collagen induced arthritis (Horn, 1988). If
administered intra-articularly, IL-1 induces an acute, transient arthritis,
induces leukocyte infiltration and loss of articular cartilage similar to that
found in adjuvant arthritic rats (Pettipher et al., 1986; Henderson &
Pettipher, 1988) and exacerbates development of collagen induced arthritis
in mice (Horn, 1988). In culture, it has been found that IL-1 stimulates
chrondrocytes from healthy articular cartilage to secrete collagen degrading
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enzymes (Stephenson et al., 1987), and stimulate synthesis of collagen
(Goldring, 1987). Cartilage removed from arthritic joints shows significantly
elevated basal release of these enzymes and is more sensitive to IL-1
stimulation (Shinmei, et al., 1988).
When applied to cultured fibroblasts, astrocytes or non-neuronal cells
of the sciatic nerve, IL-1 stimulates synthesis of NGF mRNA and peptide and
enhances stability of NGF mRNA (Lindholm et al., 1987, 1988; Spranger et
al., 1990). NGF is also synthesised in peripheral tissues (Bandtlow et al.,
1987; Heumann, 1984), where it is thought to regulate sensory neuron
survival in development (see Thoenen & Barde, 1980) and phenotype in
adult rats (Fitzgerald et al., 1985). In vitro NGF stimulates neurite extension
of drg neurons (Lindsay, 1988) and as I, and others (Lindsay & Harmar,
1989), have shown, maintains SP and CGRP mRNA and peptide levels.
Weihe (1988) has shown that following induction of adjuvant arthritis, there
is an increased ramification of SP and CGRP containing nerve terminals in
peripheral tissues and moderately enhanced SP and CGRP content in drg
innervating the inflamed areas. It may be that during the development of
inflammation, IL-1 released from infiltrating leukocytes and macrophages
and synovial cells stimulates local enhanced synthesis and release of NGF
from the surrounding tissues. The elevated levels of NGF might, in turn,
lead to the ramification of nerve fibres within the inflamed tissues and an up-
regulation of SP and CGRP content of drg.
Thus, in the proposed scheme, sensory neuropeptides, including SP
and CGRP, in the drg, which are implicated in the pathology of chronic
inflammatory states, are up-regulated by NGF released from inflamed
tissues. In this model, glucocorticoids might act at one of a number of sites
to inhibit inflammatory processes. NGF biosynthesis can be reduced by a
direct action of glucocorticoids in a variety of tissues in culture (Siminoski et
al., 1986; Wion et al., 1986; Houlgatte et al., 1989; Lindholm et al., 1990),
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and a similar process may occur in inflamed tissues. In PC12 cells
glucocorticoids reduce the levels of NGF receptor which may inhibit the
action of NGF (Tocco et al., 1988). Glucocorticoids also inhibit release of IL-
1 from macrophages (Snyder & Unanue, 1982), which would reduce IL-1
stimulation of NGF. As a consequence of these actions of glucocorticoids,
NGF-mediated up-regulation of SP and CGRP in the drg and proliferation of
peptidergic terminals in inflamed peripheral tissues would be attenuated.
Furthermore, as low doses of SP have been reported to stimulate IL-1
production by monocytes (Lotz et al., 1988; Laurenzi et al., 1990) and
P388D1 cells (Kimball et al., 1988), a reduction of SP might act to further
reduce IL-1 stimulated synthesis of NGF. Finally, I have shown that
glucocorticoids can act directly on the drg to reduce both SP and CGRP,
resulting in a further reduction in pro-inflammatory drive. The model is
summarised in Fig. 8.1.
Thus, whilst glucocorticoid anti-inflammatory activity is undoubtedly
complex and varied (see Chapter 1), it is possible that some of the anti¬
inflammatory activity is mediate by an inhibition of the processes elucidated
above. In conclusion, I have demonstrated that in a rat model of
inflammatory disease, the neuropeptides CGRP, and possibly SP, are
increased in the drg . Furthermore, I have shown that glucocorticoids
reduce the inflammation and attenuate the increase in CGRP content. In
intact animals, I have shown that glucocorticoids also reduce SP and CGRP
content, but increase SS content of drg. In vitro, I have shown that this is a
direct effect of glucocorticoids on the drg, probably mediated via the Type II
receptor. Finally, I have suggested that glucocorticoids may produce some
of their anti-inflammatory effects through direct and indirect actions on the
neuropeptides in drg.
Figure 8.1 Schematic diagram of a possible model for the
involvement of sensory neurons and neuropeptides in
the development of inflammatory pathologies. The
diagram also shows sites at which glucocorticoids
(GLUC) might act to inhibit this process and thereby
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